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Abstract
Obstructive lung diseases such as chronic-obstructive-lung-disease (COPD), bronchiectasis,
and asthma are characterized by airflow obstruction. They affect over six million Canadians
costing the economy $12 billion/year. Despite decades of research, therapies that modify
obstructive-lung-disease progression and control are lacking because patient diagnosis,
monitoring, and response to therapy are currently made using airflow measurements that may
conceal the independent contributions of underlying pathologies. One goal of obstructivelung-disease research is to develop ways to identify patients with specific underlying
pathological phenotypes to improve patient care and outcomes.

Thoracic computed-

tomography (CT) and magnetic-resonance-imaging (MRI) provide ways to regionally identify
the underlying pathologies associated with obstructive-lung-disease, and offer quantitative
biomarkers of obstructive-lung-disease (e.g. lung-density, airway dimensions, ventilation
abnormalities, and lung microstructure). As the first step to identify patients with specific
underlying pathological phenotypes, it is important to understand the physiological and clinical
consequences of these imaging derived measurements. Accordingly, our objective was to
evaluate lung structure and function using multi-nuclear pulmonary MRI in aging and
obstructive-lung-disease to provide a better understanding of MR-derived biomarkers. In older
never-smokers, the majority of subjects had 3He MR ventilation abnormalities that were not
responsive to bronchodilation.

3

He ventilation abnormalities were related to airflow

obstruction and airways resistance, but not occupational exposure or exercise limitation. We
then developed and evaluated ultra-short-echo-time MRI in COPD subjects with and without
bronchiectasis. This work demonstrated that ultra-short-echo-time MR-derived measurements
were reproducible and significantly related to CT tissue-density measurements. In the COPD
subjects with bronchiectasis, ultra-short-echo-time signal-intensity was related to airway
measurements.

In COPD subjects without bronchiectasis, ultra-short-echo-time signal-

intensity was related to the severity of emphysema. Finally, based on the ultra-short-echo-time
MR biomarkers developed in patients with COPD and bronchiectasis, patients that share some
of the airway and inflammatory features common in asthmatics, we produced ultra-short-echotime MR measurements in asthma. These measurements not only provided similar information
as CT, but also information about regional ventilation deficits. These results demonstrated that

ultra-short-echo-time MR biomarkers may reflect ventilation heterogeneity and/or gastrapping in asthma. These important findings indicate that multi-nuclear pulmonary MRI has
the potential to quantitatively evaluate the different pathologies of obstructive-lung-disease.
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CHAPTER 1

1

INTRODUCTION

Obstructive Lung Diseases are chronic and heterogeneous diseases characterized by the
obstruction of the airways resulting from inflammatory processes. Chronic obstructive
pulmonary disease (COPD) and asthma are the most common obstructive lung diseases.
COPD is characterized by persistent airflow limitation that is usually progressive and
associated with an enhanced response of the lungs due to noxious particles or gases,1
whereas asthma is a chronic inflammatory disorder characterized by airway hyperresponsiveness and inflammation.2

1.1

The Burden of Obstructive Lung Disease

According to the World Health Organization’s estimates, 300 million people suffer from
obstructive lung disease (i.e. chronic obstructive pulmonary disease [COPD]: n=64
million3 and asthma: n=235 million4). All respiratory diseases including asthma and
COPD accounted for the 4th leading cause of death worldwide (Figure 1-1).5 However,
looking at all diseases individually, COPD was the 3rd leading cause of death worldwide
(n=3.1 million), behind ischaemic heart disease (n=7.4 million) and stroke (n=6.7 million),
but just above lower respiratory infections (n=3.0 million). Unfortunately, asthma also
accounted for 386,318 deaths.

Figure 1-1 Proportion of deaths due to respiratory disease
1

Above: Number of disease specific deaths. Below: Left-Top five leading causes of death.
Right-proportion of causes of death due to respiratory diseases: 1) COPD (n= 3,104,330),
2) Other respiratory diseases (n=551,425), and, 3) Asthma (n=386,318).
In 2014, Statistics Canada reported that over 3 million people were affected by COPD
(n=804,043) and asthma (n=2,448,817).6 Obstructive lung disease also accounted for the
most number of hospitalizations, surpassing the number of hospitalizations due to angina,
heart failure, and diabetes in 2007 (as shown in Figure 1-2). Although, COPD accounted
for the number one reason for hospitalizations (and remained the leading cause of
emergency department visits in 2014), asthma was the most common cause of
hospitalizations among children.7-9

Figure 1-2 Repeat Hospitalizations by Condition at First Admission
This graph shows the number of patients (outside Quebec) with a single hospitalization,
one repeat hospitalization, and two or more repeat hospitalizations by Ambulatory Care
Sensitive Condition at first admission. Adapted from the Canadian Institute for Health
Information’s (CIHI) publication.10
In Ontario, from the years 2002 to 2011, 722,494 individuals were identified as having
COPD. The prevalence rate for COPD in Southwestern Ontario was significantly higher
than the provincial average of 103 per 1000 population aged 35 years and older.11 In 2015,
asthma statistics reported by the Ontario Asthma Surveillance Information System, and
data provided by the Institute for Clinical Evaluative Sciences demonstrated that there were
about 2 million individuals living with asthma in Ontario.12,13 In terms of healthcare
2

service use, in Southwestern Ontario, from 2003-2013 the average emergency department
visit rate was greater than 2.4 per 1000 asthma prevalence.14 Evidently, obstructive lung
disease is a health and economic challenge in Ontario. To give some perspective, in 2011
the total projected expenses for the Government of Ontario was $124 billion and the direct
and indirect costs for COPD and asthma were over $5 billion.15
Despite these alarming statistics, therapies that modify obstructive lung disease outcomes
are still lacking and perhaps it is because of our reliance on pulmonary function test
measurements.1 While these measurements provide a reproducible and easy method to
evaluate lung function, they can hide the different underlying components of obstructive
lung disease and do not provide any regional information. Accordingly, one goal of
obstructive lung disease research is to develop methods to identify obstructive lung disease
patients with specific underlying pathological phenotypes with the hope that this will
improve patient care and outcomes.
Pulmonary magnetic resonance imaging (MRI), with and without the use of inhaled
contrast agents, is an emerging technique that not only provides a way to quantify lung
structure and function in-vivo, but also provides spatial information. However, before these
methods can be translated to clinic, a strong understanding of the different MR imaging
biomarkers is needed, more specifically, their clinical consequences and structural
determinants. Equipped with such knowledge, there is potential to use these measurements
to phenotype patients with obstructive lung disease to better guide and individualize
therapies. This thesis focuses on the development and application of novel quantitative
measurements of lung structure and function derived from hyperpolarized noble gas MRI
and non-contrast enhanced ultra-short echo time (UTE) MRI. These measurements were
evaluated in older never-smokers and subjects with obstructive lung disease (COPD and
asthma). In order to validate and understand imaging biomarkers aimed at quantifying lung
function in obstructive lung disease, imaging measurements must first be understood in
healthy lung aging. These measurements can then be extended to evaluate lung function
in the context of obstructive lung disease, and more specifically, COPD and asthma.
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In this Chapter, the relevant background knowledge necessary to understand and motivate
the original research presented in Chapters 2 to 4 will be summarized. It will begin with a
general overview of the respiratory system’s structural and functional responsibilities while
addressing the current understanding of normal lung aging (1.2). The pathophysiology and
underlying disease mechanisms of obstructive lung disease (i.e. COPD and asthma) will
be addressed next (1.3) and followed by the standard clinical measurements of obstructive
lung disease (1.4). The benefits and limitations of currently available imaging methods
will then be discussed with respect to imaging biomarkers and the different
pathophysiology they probe (1.5). Novel multi-nuclear MRI methods for pulmonary
imaging will then be discussed (1.6). Finally, the specific hypotheses and objectives of
this thesis will be introduced (1.7).

1.2

Lung Structure and Function

The respiratory system is responsible for the exchange of oxygen and carbon dioxide
between the cells of the body and the external environment. In humans, the respiratory
system includes the oral and nasal cavities, two lungs, the conducting airways, the chest
wall structures, diaphragm, and the central nervous system responsible for controlling the
muscles of respiration.16 The primary function of this system is to move oxygen from the
environment into the blood and to move carbon dioxide out of the blood and back into the
environment. The oxygen is used for cellular metabolism and the carbon dioxide waste
that is produced by cellular metabolism is eliminated.

This process is called “gas

exchange”.16 This section will begin with a discussion on the process by which air moves
from the environment into our body through the conducting and respiratory zones.

1.2.1

The Airways: Conducting and Respiratory Zones

The conducting zone is responsible for leading air from the external environment to the
exchange surface of the lung. During inspiration, air enters the upper respiratory tract
through the oral or nasal cavities and passes through the pharynx, larynx, and then into the
trachea. The trachea is a hollow tube held open by cartilage rings and extends down into
the thorax where it branches into the primary bronchi.17 Each bronchus feeds into the left
and right lung. Within the lung, the bronchi continue to divide while progressively
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decreasing in diameter (Figure 1-3). Similar to the trachea, the bronchi are supported by
cartilage. The smallest bronchi branch to become bronchioles, which are small collapsible
airways with smooth muscle walls. The bronchioles are histologically different from the
bronchi because they are not supported by cartilage.
As shown in Figure 1-3, the last seven generations of the airway tree make up the
respiratory zone.16 The respiratory zone contains air passages with alveoli which facilitate
gas exchange. The bronchioles continue to branch until the respiratory bronchioles form a
transition between the airways and the exchange epithelium of the lung. The diameter of
the bronchioles decreases progressively the further they are from the trachea and
consequently their number and the total cross section increases.16,17 The respiratory zone
makes up most of the volume in the lung, accounting for 2.5 to 3 liters at rest.
The upper airways and bronchi are involved in conditioning the air before it reaches the
alveoli. There are three main components to air conditioning: the air is heated to body
temperature, water vapour is added to ensure the air reaches 100% humidity, and foreign
material is filtered out.17 The air entering the human body needs to be heated to body
temperature (37°C) and moistened to ensure that the core body temperature does not
change and the cold air does not damage or dry out the alveoli. The air is heated and
moistened by the water evaporating from the mucosal lining of the airways. The trachea
and bronchi are lined with ciliated epithelium. A sticky layer of mucus floats over cilia to
trap particles larger than 2μm. The cilia beat upward to move mucus toward the pharynx
and once the mucus reaches the pharynx, it can be expectorated or swallowed.17
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Figure 1-3 Schematic of the human airways
Generations 0 to 16 make up the conducting zone and the last 7 make up the respiratory
zone. The conducting zone is responsible for guiding air into the gas exchanging regions
of the lung. The respiratory zone is where gas exchange occurs. Adapted from West, JB,
Respiratory Physiology: The Essentials, Ninth Edition.16

1.2.2

The Alveoli: Site of Gas Exchange

The alveoli line the respiratory bronchioles, alveolar ducts, and alveolar sacs, thus making
up the majority of lung tissue. The average adult lung has 480 million alveoli18 with each
alveolus being about 1/3mm in diameter.16 Their main function is to exchange gas between
themselves and the blood via simple diffusion (i.e. from high partial pressure to low partial
pressure). Two cells make up the epithelium of the alveoli (Type I: thin alveolar cells to
allow for gas diffusion, and, Type II: thicker alveolar cells that produce surfactant to aid
the lungs in expanding). The walls of the alveoli are thin (approximately 0.2μm)19 without
any muscle and surrounded by capillaries to ensure rapid gas exchange. The surface area
of the alveoli in contact with capillaries is approximately 70m2.20
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1.2.3

Ventilation and Diffusion

Ventilation is the bulk flow exchange of air between the environment and the alveoli.17
During a normal breath, about 500mL of air is inspired (at a rate of 1L/s) and the volume
of the thoracic cavity increases while the pressure decreases, thus drawing air in. The
mechanism for this is partly due to the diaphragm contracting and descending and the
intercostal muscles raising the ribs and increasing the cross-sectional area of the thorax.17
The rate and force of inspiration and expiration depends on the respiratory system
compliance. Compliance is the change in volume relative to the change in pressure. Once
air reaches the terminal bronchioles, the air is drawn in by bulk flow (i.e. due to a pressure
gradient). Finally, when air is in the respiratory bronchioles, the forward velocity of the
air decreases and the mechanism of ventilation becomes diffusion.
Expiration is a passive process during quiet breathing. The average healthy adult exhales
500mL of air at 15 breaths/min—meaning that each minute 7500mL of air has been
exhaled. This is known as total ventilation.16 The amount of air that is inhaled is slightly
more than what is exhaled because more oxygen is taken in than carbon dioxide is given
out. It should also be noted that not all of the 500mL of gas that is inhaled reaches the
alveoli. About 150mL of the 500mL of gas that is inhaled comprises “dead space” and is
the same volume as that of the conducting airways. The volume of new gas that enters the
respiratory zone each minute is thus 5250mL and this is called alveolar ventilation.16
Once air has entered the alveoli from the atmosphere, the gas is transferred across the
blood-gas barrier by a process called diffusion. The process of diffusion through tissues
can be described by Fick’s law: the rate of transfer of gas through a sheet of tissue is
proportional to the tissue area and the difference in gas partial pressure between the two
sides, and inversely proportional to the tissue thickness.21
The pulmonary arteries follow the airways as far as the terminal bronchioles and then
supply the capillary bed in the walls of the alveoli. The partial pressure of oxygen (PO2) in
a red blood cell entering a capillary is normally 40 mmHg and across the blood-gas barrier
the pressure increases to 100 mmHg.16 Blood takes in oxygen from the alveolar air space
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provided that the oxygen there is greater than in the blood. Oxygen then diffuses across
the alveolar walls into the blood down the concentration gradient.

1.3

Pathophysiology of Obstructive Lung Disease

Obstructive lung disease is characterized by persistent airflow limitation.

Increased

resistance to airflow can be caused by conditions inside the lumen, the airway wall, or the
peribronchial region (i.e. the region outside the airway). The airway lumen may be
partially occluded by excessive secretions (as in chronic bronchitis), acutely due to
pulmonary edema, or localized due to the inhalation of foreign particles. The airway wall
may be contracted due to the airway smooth muscle (as in asthma), or inflamed (as in
bronchitis and asthma). There may be hyperinflation due to gas-trapping (i.e. abnormal
retention of air) caused by mucus plugging of the segmental, subsegmental, and smaller
conducting airways. In the peribronchial region, the lung parenchyma may become
destroyed (i.e. emphysema), the bronchus may become compressed locally by an enlarged
lymph node, and peribronchial edema could case narrowing. Before addressing the
pathophysiology of obstructive lung disease, the physiology of aging will be briefly
discussed.

1.3.1

The Aging Lung

Aging is a progressive phenomenon that occurs in each and every individual. In order to
appreciate and recognize obstructive lung disease, it is essential to understand the agerelated changes involving the lung in the absence of disease.

Physiological and

immunological changes with aging influence the presentation of disease, responses to
treatment, and possible complications.
Aging of the lung can be classified into a growth phase, maturation phase, a plateau phase,
and a decline phase. The major physiological changes of the aging lung during the decline
phase are: 1) loss of elastic recoil, 2) decrease of chest wall compliance, 3) change in the
shape and structure of the lung, and, 4) decrease in respiratory muscle strength.22
Similar to an elastic band, the lungs experience elastic recoil during inspiration and
expiration.

Elastic recoil is the rebound of the lungs after being stretched during
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inspiration. The lungs have elastic fibers (elastin), collagen, smooth muscle, pulmonary
blood, and bronchial mucus which all have elastic properties and contribute to elastic
recoil. As the lung increases in volume, the elastic recoil also increases. Although the
decrease in elastic recoil in the lung is not completely understood, some studies have
demonstrated that reduced elastic recoil and diffusing capacity of the lung (a measure of
the transfer of gas from the lungs to the surrounding blood vessels) is a result of stress
relaxation of elastin-fibers as evidenced by an apparent increase in thickness along with
the appearance of more loosely associated fibers.23 A disruption in collagen fibers leading
to an increase in intermolecular crosslinks has also been hypothesized to explain
diminished elastic recoil with age.24 Currently, there is limited and conflicting evidence to
support this theory.
The chest wall also stiffens with age leading to a decrease in chest wall compliance. This
is due to structural changes of the lung such as the decalcification of the ribs, calcification
of the costal cartilage, changes in rib-vertebral articulations, changes in the shape of the
chest, and narrowing of the intervertebral disk space.25 Other structural changes that
contribute to decreased chest wall compliance are kyphotic curvature of the spine and
deformation of the diaphragm leading to a reduction in its force generating capabilities.26
Taken together, all these structural changes lead to the decreased respiratory system
compliance which ultimately increase the work of breathing.
The fine structures of the lung also undergo changes with age. The degeneration of the
elastic fibers around the alveolar duct results in airspace enlargement which leads to a
reduction of airspace wall surface per unit volume of lung tissue.22,27 Reduction in
supporting tissue results in premature closure of small airways during normal breathing.
There is also calcification of bronchial cartilage. These changes result in an increase in
anatomic dead space, gas-trapping, and hyperinflation.28
Lastly, muscle strength and endurance decrease with age. The thoracic diaphragm, a sheet
of internal skeletal muscle extending across the bottom of the thoracic cavity, is the most
important respiratory muscle and plays a vital role in inspiration. Maximum inspiratory
pressure is an index of diaphragm muscle strength and is measured using a mechanical
9

pressure gauge with a closed valve at the mouth during an inspiration. A decline in this
measurement is indicative of impaired ventilation and impaired clearance of airway
secretions. Studies have demonstrated that maximum inspiratory pressure is higher in men
than in women and decreases with age.29,30 Reduced maximum inspiratory pressure and
decreased diaphragm muscle strength may be due to age-related muscle atrophy and
decrease in fast twitch muscle fibers that are responsible for generating higher peak
tensions. The age related changes to the lungs are reflected in clinical measurements of
lung function which will be discussed in Chapter 1.4.

1.3.2

Obstructive Lung Disease: Airways Disease in Asthma and COPD

Airway disease in obstructive lung disease (i.e. asthma and COPD) is characterized by an
inflammatory process of the airways that can lead to airflow limitation. Airflow limitation
is mostly reversible in asthma and is mostly irreversible in COPD. The natural progression
of asthma and COPD are different.

Asthma begins in childhood31,32 and has been

associated with allergic diathesis and environmental factors in modern affluent
countries.33,34 The onset of COPD is attributed to the total burden of toxic gases and
particles that a person inhales during his or her lifetime.35,36 The smoking of tobacco
products is the major risk factor for the development of COPD.37,38
Asthma
Asthma is a chronic disease confined to the airways characterized by airway hyperresponsiveness (i.e. increased responsiveness of the airways to stimuli), airway
inflammation and narrowing. Histopathological studies have demonstrated that asthma
affects the central and peripheral airways.39

This process involves cellular changes

(infiltration of inflammatory cells such as eosinophils and lymphocytes) and structural
changes (such as thickened airway walls). Figure 1-4 shows a bronchiole of a subject who
died during an asthma attack. There is a luminal occlusion caused by muscle constriction,
airway wall thickening, increased smooth muscle mass, and a marked inflammatory
response in the airway wall which is characterized by eosinophils.40
Airway inflammation is a multi-cellular process which involves eosinophils, CD4 Tlymphocytes, and mast cells. Eosinophils are the most striking cellular feature of asthma.
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Distribution of eosinophils varies between the small and large airways. In the small
airways, most eosinophils are in the outer section of the airway wall (between the smooth
muscle and the alveolar attachments). The increased density of eosinophils in the outer
airway promotes airway constriction by decreasing the tethering forces of the parenchyma
in the airway wall. In the larger airways, eosinophils are mostly located in the inner section
of the airway wall (between the smooth muscle and the basement membrane).41 The
increased density of eosinophils in the inner airway wall promotes constriction by
increasing the effect of bronchial smooth muscle shortening.
The structural changes that accompany asthmatic airways are increased smooth muscle
mass, mucous gland hypertrophy, and bronchial wall edema. These all lead to a thickened
airway wall which contribute to airflow limitation resulting from the increased airways
resistance. The increase in smooth muscle mass is induced by inflammatory mediators,
cytokines, and growth factors. Further enhancing this flow limitation is the increased
amount of mucous and inflammatory exudate. They not only block airways, but can
increase surface tension which can lead to airway closure. The excess production of
mucous is not only due to the hypertrophy of mucous glands, but also resultant of
hyperplasia of goblet cells.
Taken together, these cellular and structural changes of the airways can obstruct airflow in
the large and small airways, thus affecting ventilation or leading to an abnormal retention
of air at expiration (i.e. gas-trapping).
Chronic Obstructive Pulmonary Disease
In COPD, airways disease can present itself as chronic bronchitis. This is characterized by
airway inflammation and excessive mucous production. The inflammation associated with
chronic bronchitis is located in the epithelium of the central airways (airways with a
diameter larger than 4mm) and extends along the gland ducts into the mucous-producing
glands.42-44 There is hypertrophy of the mucous glands in the large bronchi and chronic
inflammation in the small airways. Excessive mucous is found in the airways and can
obstruct them.
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The major site of obstruction in COPD is found in the smaller conducting airways (less
than 2mm in diameter). The small airways are spread out between the fourth and 14th
generation of airway branching. The increase in the number of airways with respect to the
branching increases their total cross sectional area and decreases their resistance. In the
healthy lung, about three quarters of the total airway resistance is from the large airways
(i.e. diameter greater than 2mm) and the rest is from the small airways. The airways below
the larynx account for half of the total resistance measured at the mouth, and the smaller
conducting airways only account for 10–15% of total airway resistance. For this reason,
the smaller conducting airways are the lungs’ silent zone.45 This means that the disease
may accumulate for many years without being detected.
The structural and physiological components responsible for the increase in peripheral
airway (small conducting airway) resistance include: the destruction of alveolar support of
the peripheral airways,46 loss of elastic recoil in the parenchyma that support the airways,47
a decrease in the elastic force available to drive flow out of the lung,48 and structural
narrowing of the airway lumen because of inflammatory processes.49 Figure 1-4 shows a
representative small airway of a subject with COPD. The airway is inflamed with a
thickened wall in which the lumen is partly filled with an inflammatory exudate of mucous
and cells. Similar to asthma, these changes can lead to ventilation abnormalities and the
retention of air, i.e. gas-trapping.

Figure 1-4 Small airway pathology in health, asthma, and COPD
From left to right: Healthy: normal small airway, Asthma: luminal occlusion resulting from
muscle constriction, thickening of the airway wall, increased smooth muscle mass, and an
increased inflammatory process in the airway wall (mainly characterized by eosinophils),
COPD: inflamed airway with thickened wall in which lumen is partly filled with an
inflammatory exudate.
Adapted from Hogg JC, Lancet (2004)43 and Saetta M et al. Eur Respir J (2001).40
12

1.3.3

Obstructive Lung Disease: Emphysema

Emphysema is defined as “the enlargement of air spaces distal to the terminal bronchiole,
accompanied by the destruction of their walls and without obvious fibrosis.”50,51 This
destruction reduces the expiratory flow because of the reduced elastic recoil force available
to expire the air out of the lung. Figure 1-5 shows a typical appearance of histology of a
healthy subject and a subject with emphysema. The emphysematous lung has loss of
alveolar walls and the small airways are reduced in number in comparison to the healthy
subject.

Figure 1-5 Parenchymal pathology in healthy and COPD subject.
Adapted from Wood et al.
There are two major types of emphysema: centriacinar and panacinar. These classifications
are based on where the destruction occurs in the acinus. Centriacinar emphysema is more
prominent in smokers and is confined to the destruction of the central part of the lobule
and does not affect the peripheral alveolar ducts or alveoli. It initially affects the upper
lobes and spreads down the lung as the disease progresses. Panacinar emphysema affects
the entire lobule and is more common in the lower lobes.52
It is interesting to note that only 40% of smokers develop emphysema and only 15%
develop airflow limitation.43 Smokers who develop emphysema have an increased number
of macrophages, neutrophils, T-lymphocytes, and eosinophils in their lungs compared to
those smokers who do not develop emphysema.44,53-55

13

1.4

Clinical Measurements of Lung Function

There are several methods that can be used to evaluate lung function in patients with
obstructive lung disease. Here, two clinically available methods for testing lung function
are discussed: pulmonary function testing and cardiopulmonary exercise testing (CPET).
Pulmonary function testing is the first method of choice to evaluate lung function at a
physician’s clinic. These measurements are made at the mouth that provide global lung
function and lung volume measurements. These tests can be used to evaluate forced
expiration, lung volumes, diffusion, and airways resistance. CPET is another method that
can be used to test exercise responses that involve the respiratory, cardiovascular, skeletal
muscle, and neuropsychological systems that cannot be adequately reflected by evaluating
one organ system. The use of CPET stems from the fact that resting pulmonary and cardiac
testing cannot reliably predict exercise performance and functional capacity. Although
pulmonary function testing is more commonly used clinically, CPET should be considered
when specific questions remain unanswered.

1.4.1

Pulmonary Function Testing

Pulmonary function testing can be divided into spirometry, plethysmography, and single
breath carbon monoxide diffusing capacity. Spirometry measures the volume of air that is
inhaled or exhaled as a function of time. The primary signal measured using spirometry is
volume or flow. Plethysmography allows for the measurement of lung volumes (i.e. the
volume of air in the lungs).
Figure 1-6 shows a spirometer which is a mouthpiece attached to a small machine that
allows for the measurement of volume inhaled or exhaled. The plot beside the spirometer
is the volume of air inspired as a function of time. The two most important measurements
obtained from spirometry are the forced expiratory volume (FEV) and the forced vital
capacity (FVC). FEV1 is maximum volume of air expired in one second after a full
inspiration. FVC is the maximum volume of air that can be expired when the patient
exhales as forcefully and quickly as possible after a maximum inspiration.56
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Figure 1-6 Pulmonary Function Testing: Spirometry
Shown above is a hand held spirometer and a sample airflow curve measured by the
spirometer.
Figure 1-7 shows a plethysmograph which is an air-tight box that patients sit in to perform
lung function tests. The plot shown on the right is an example airflow curve of volume
inspired as a function of time. The main measurements obtained using plethysmography
are: functional residual capacity (FRC), residual volume (RV), tidal volume (VT),
inspiratory capacity (IC), vital capacity (VC), and total lung capacity (TLC).57 The FRC
is the volume of air present in the lung at the end of a passive expiration. The maximum
volume of gas that can be inspired from FRC is the IC. RV is the volume of air remaining
in the lung after a maximum expiration. The volume of gas displaced between passive and
inhalation and expiration during the respiratory cycle is the VT. The VC is the volume
change at the mouth between the positions of full inspiration and complete expiration.
Finally, TLC is the volume of gas in the lungs after a maximum inspiration.57

15

Figure 1-7 Pulmonary Function Testing: Plethysmography
Above: a whole body plethysmograph and a sample airflow curve used to determine lung
volumes.
The diffusing capacity of the lung for carbon monoxide (DLCO) can also be determined
using pulmonary function tests and provides an indirect measure of diffusion of gases
across the alveolar membrane into the blood.58 DLCO is measured when the subject exhales
to RV and then performs a maximum inhalation to TLC. The subject inhales a gas mixture
that contains a very low concentration of carbon monoxide (CO) (0.3%) and helium (10%)
with air. The subject then holds his/her breath for 8 seconds before exhalation. The
exhaled gas is collected and analyzed. The gas first exhaled is discarded as it represents
the anatomic dead space volume and is defined as the product of 2.2ml and the body weight
in kilograms. The remaining volume is analyzed by comparing the exhaled concentrations
of CO and helium to the inspired concentrations to determine the amount of CO diffusing
across the alveolar membrane. The capacity of the lung to exchange gas across the
alveolar-capillary interface is determined by its structural (e.g. lung gas volume, path
length for diffusion, thickness and area of the alveolar capillary membrane, etc.) and
functional (e.g. levels of ventilation, composition of the alveolar gas, diffusion
characteristics of the membrane, the concentration and binding properties of haemoglobin
in the alveolar capillaries, etc.) properties. Flow rates, lung volumes, and DLCO are
expressed as a percent of predicted value (%pred). These measurements are dependent on
age, sex, height, and ethnicity.59
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Aging
The underlying structural changes that occur in the aging lung lead to changes in lung
function, including dynamic flow rates, static lung volumes, and alveolar gas exchange
rates. The current understanding of lung function decline over age stems from work done
by Fletcher et al. in 1977. This work showed a continuous decline in FEV1 at a rate of
roughly 42 ml/year beginning between the ages of 25 and 30 (Figure 1-8).38 FVC has also
been shown to steadily decrease to approximately 75% of the corresponding peak-value.
Together, with the age-related changes in FEV1, this results in an overall decrease in the
FEV1/FVC ratio (approximately 70-75% of peak value) by the age of 70, as FEV1 declines
more rapidly than FVC. In terms of lung volumes, RV, RV/TLC, and FRC (due to
increased lung compliance) decrease, while TLC shows no change with age.26,28 The
increase in RV that occurs with age is likely due to the decreased strength of the expiratory
muscles and the tendency of the small airways to collapse. There is also an increase in
anatomic dead space that occurs during aging and this is thought to be due to calcification
of the bronchial cartilage.28 Finally, studies have also suggested that there is a decline in
DLCO with age, corrected for alveolar volume. The reported decrease in DLCO correlates
well with the decrease in internal surface area of the lung.60
It should be noted that although elderly subjects have sufficient lung function for their
normal day-to-day lives,61 these age-related changes increase the risk of breathlessness and
respiratory failure when compromised. And although the changes associated with aging
are histologically different from COPD-related changes to the lung parenchyma, they result
in similar changes in lung compliance and function. A consequence of the reduction in
supporting tissues (as mentioned above) around the airways is the tendency of the smaller
airways to collapse.
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Figure 1-8 Pulmonary function decline in aging in health and disease.
Plot of FEV1 over time in non-smokers and smokers not susceptible to smoke and smokers
that are susceptible to effects of smoking (with the risk of smokers developing airflow
obstruction being 25%62). Adapted from Fletcher et al.38
Obstructive Lung Disease
Most of the pulmonary function features of obstructive lung disease stem from the
pathologic features discussed above.

In asthma, especially during a lung attack,

measurements of expiratory flow are reduced (i.e. FEV1 and FEV1/FVC). The FVC is also
reduced because the airways prematurely close during forced expiration. Static lung
volumes are also increased (such as FRC and TLC) during asthma attacks. The increase
in RV is caused by premature airway closure during a full expiration which can be a result
of increased smooth muscle, edema, or inflammation of airways. This may be indicative
of gas-trapping.

In COPD, FEV1, FVC, and FEV1/FVC are all reduced.

These

measurements reflect airway obstruction, whether it is caused by excessive mucous in the
lumen, thickening of the airway wall by inflammation, or by the loss of radial traction.
FVC is reduced because the airways close prematurely during expiration at an abnormally
high lung volume and this can also increase RV. In patients with emphysema, TLC,
RV/TLC, and FRC are also increased resulting from the loss of elastic recoil. A decrease
in IC can be indicative of hyperinflation. A decline in DLCO is measured in patients with
COPD, reflective of the loss in alveolar surface area.63
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Pulmonary function test measurements remain the gold standard for the diagnosis and
monitoring treatment of obstructive lung disease. These measurements evaluate the lung
on a global basis and lack the ability to detect functional changes in the distal lung.45 These
measurements are also dependent on patient effort.56

1.4.2

Cardiopulmonary Exercise Testing

Cardiopulmonary exercise testing (CPET) is used to evaluate a combination of exercise
responses

involving

multiple

body

systems

(i.e.

respiratory,

cardiovascular,

neuropsychological, and skeletal muscle systems). CPET allows for the evaluation of
submaximal and peak exercise responses while providing an objective measurement of
functional capacity and impairment.64 Studies have shown that measurements of exercise
intolerance, functional capacity and impairment65 correlate better with overall health status
than resting lung function measurements.64 CPET can be performed using two methods
involving either a treadmill or a cycle ergometer. In addition to measuring respiratory gas
exchange (e.g. respiratory exchange ratio [RER]), oxygen uptake (VO2), carbon dioxide
output (VCO2), minute ventilation (VE), heart rate, and blood pressure can also be
evaluated. Two different types of gas analyzers can be used to determine the O2 and CO2
concentrations: a mass spectrometer (this is considered the “gold standard”) which
analyzes all gases (CO2, O2, N2), and separate mass spectroscopy analyzers for CO2 and
O2. Exercise testing in patients with obstructive lung disease is clinically useful in relating
symptoms

to

exercise

limitation,

especially

when

exertional

symptoms

are

disproportionate to resting pulmonary function test measurements.

1.5

Imaging Measurements of Lung Structure and Function

While pulmonary function testing and CPET measurements provide global measurements
of lung function, they do not expose underlying pathologies of lung disease, have been
shown to be poor predictors of mortality66 and are insensitive to disease onset, progression,
and treatment response.67 These limitations have motivated researchers to investigate
methods that provide biomarkers sensitive to regional structural and functional changes,
and sensitive to the heterogeneity of lung disease. Thoracic imaging is a potential method
that allows for the regional evaluation of obstructive lung disease and provides quantitative
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measurements of lung disease. Thus far, imaging methods such as chest x-ray, thoracic
computed tomography (CT), single photon emission computed tomography (SPECT), and
positron emission tomography (PET), have played a role in the visualization of pulmonary
structure and function in obstructive lung disease and will be discussed in this section.

1.5.1

Chest X-ray

The discovery of x-rays was made in 1895 by a German physicist, Wilhelm Rӧntgen.
Today, x-rays are widely used in for diagnostics because of the short acquisition time, low
cost, and low radiation dose. A typical dose associated with a chest radiograph is
approximately 0.01mSv68 which is less than a percent of the annual background radiation
(2-3mSv/year).68 Radiographs (or x-ray images) are shadows created when all or part of a
beam of x-rays are attenuated by part of the body. The x-rays that are not absorbed by the
body are absorbed by a detector and this results in a projection of the objects in the path of
the x-ray beam. Essentially, the resulting image is an overlap or superposition of all
structures in the path of the x-ray leading to a loss of depth information.
Image contrast is thus dependent on the mass attenuation coefficient of the tissue which
varies with photon energy, atomic number, and mass density of the absorbing material.
Thus, a bony structure, is highly attenuating (i.e. absorbs many x-rays) and appears white
on an x-ray image. On the other hand, a low attenuating structure, such as the lung, absorbs
fewer x-rays and thus appears black on a radiograph. Figure 1-9 shows a chest radiograph
of a healthy volunteer. The lungs appear dark and the ribs, scapula, and spine appear white,
which is consistent with the notion that bony structures attenuate x-rays more than soft
tissues such as the lung.
Radiographic abnormalities in patients with obstructive lung disease have previously been
studied. In asthma, the most common radiographic findings include: hyperinflation and
abnormalities of the airways.69,70 On a frontal radiograph, similar to what is shown in
Figure 1-9, hyperinflation is seen as an increase in the length of the lung, a depression of
the diaphragm, and a decrease in the transverse cardiac diameter. Airway abnormalities of
the large airways are also visible on a frontal radiograph, more specifically, bronchial wall
thickening. In patients with emphysema, a chest radiograph is mostly useful at detecting
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moderate-to-severe emphysema.52 The key features on a radiograph in a patient with
emphysema are hyperinflation and abnormalities of the small vessels.71 The radiographic
signs of hyperinflation in emphysema (Figure 1-9) are no different than what is observed
in asthma (i.e. elongated lung, depressed diaphragm, and change in the cardiac silhouette).
Radiographic findings in asthma, such as bronchial wall thickening have been shown to be
signs of an asthmatic exacerbation.72,73 Bronchial wall thickening in asthma has also been
qualitatively evaluated in asthma using chest radiographs and compared with healthy
controls.74 This work has demonstrated that wall thickening measured using chest x-rays
is greater in asthmatics than in healthy volunteers.74 In patients with COPD, as stated
before, only moderate-to-severe emphysema is detectable on radiographs. The limited
work that has been done in COPD using planar x-rays, has demonstrated that emphysema
severity (evaluated using chest x-rays) is related to pulmonary function test
measurements.75

Figure 1-9 Representative posterior-anterior chest radiograph of a healthy volunteer, an
asthmatic subject, and subject with COPD.
In asthma, the lungs appear hyperlucent, the diaphragm is flattened indicative of
hyperinflation, and more than six anterior ribs are in the mid-clavicular line at the lung
diaphragm level. In COPD, the lungs are hyperinflated (consistent with a flat diaphragm
and secondary to emphysema), the retrosternal airspace is enlarged, and the pulmonary
arteries are protruding (consistent with pulmonary hypertension).
Healthy case courtesy of Dr. Frank Gaillard, Radiopaedia.org, rID: 8090. Asthma case
courtesy of Dr. Ian Bickle, Radiopaedia.org, rID: 33470. COPD case courtesy of Dr. MaiLan Ho, Radiopaedia.org, rID: 6452.
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1.5.2

X-ray Computed Tomography

The limitations of a planar chest x-ray, including the loss of depth information and poor
contrast, for the evaluation of obstructive lung disease has been recognized for some while.
In the 1970s, radiography (the science of medical x-ray images) was revolutionized with
the introduction of x-ray CT. Over the past few years, CT has become the imaging
modality of choice for the lung because it provides subtle differences in lung parenchymal
density and eliminates the anatomical superposition present in chest x-rays.76,77
Furthermore, high resolution CT allows for the assessment of emphysema and airways
disease using quantitative indices.78
During a CT scan, a series of x-ray projections are collected from different regions of the
body. These projections are created by an x-ray source which is detected by a series of
detectors that lie opposite to one another. Each voxel in a CT image represents a relative
measurement of tissue density based on the attenuation coefficient of water:
Equation 1-1
𝜇𝑡𝑖𝑠𝑠𝑢𝑒 − 𝜇𝑤𝑎𝑡𝑒𝑟
𝐻𝑜𝑢𝑛𝑠𝑓𝑖𝑒𝑙𝑑 𝑈𝑛𝑖𝑡 = (
) 1000 [𝐻𝑈]
𝜇𝑤𝑎𝑡𝑒𝑟
where μwater and μtissue are the linear attenuation coefficients of water and tissue, respectively.
The Hounsfield Unit (HU) scale is a standard scale that represents densities within the
tissue being scanned. The scale is based off of water which has a Hounsfield value of 0HU.
Tissues or substances with higher densities have higher Hounsfield numbers compared to
those with lower densities. A soft tissue such as the liver would have a Hounsfield value
between 30-50HU, blood around 80HU, and bone around 1500-4000HU.79 A tissue with
low density such as the lung would have a Hounsfield value between -1000HU to -525HU.
The dose associated with a typical chest CT is approximately 7-8mSv.80 Depending on
where an individual lives, this is equivalent to about 4 years of natural background radiation
or 400 chest x-rays. It should be noted, low dose and ultra-low-dose CT acquisitions81 are
becoming achievable with new image reconstruction techniques where doses on the order
of 0.1mSv have been observed. These methods have yet to be implemented in clinic.82
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Airway Disease
Airway disease in patients with obstructive lung disease presents with varying diagnoses
and symptoms as discussed above. The key features of airways disease seen on CT include:
mosaic attenuation patterns, mucous plugging, atelectasis, bronchiectasis, and bronchial
wall thickening. The small airways (diameter less than 2mm) cannot be directly evaluated
using CT because of spatial resolution limitations. As a result the small airways, as shown
in Figure 1-10, in obstructive lung disease are reflected by gas-trapping, more specifically
the mosaic attenuation pattern. A typical mosaic pattern results when the distribution of
these areas of decreased attenuation is patchy, which is often the case in gas-trapping, and
when the surrounding normal lung areas show increased lung density resulting from
compensatory hyper-perfusion. Gas-trapping is best visualized on expiratory CT. The
extent of gas-trapping can be estimated using computerized and automated analysis. In
this analysis the CT density histogram of all Hounsfield unit values is evaluated using a
number of HU threshold to generate the relative area of the lung occupied by attenuation
values lower than specific threshold (e.g. relative area under -856HU [RA856] at full
expiration to evaluate gas-trapping83).
Large airway abnormalities, such as bronchiectasis and bronchial wall thickening, are
frequent findings in patients with obstructive lung disease. Bronchiectasis is reflected by
bronchial dilation where the diameter of the bronchus is approximately 1.5 times greater
than the corresponding artery. In Figure 1-10, the yellow arrows in the axial slice indicate
cylindrical bronchiectasis, whereas the arrows in the coronal view show a signet ring and
varicose bronchiectasis. Bronchial wall thickening appears like a donut, where the edge of
the airway wall is thicker and the centre contains air.
Airway dimensions can be quantified using CT and this is helpful in obstructive lung
disease to provide an understanding of bronchial inflammation and remodeling. Currently,
there is software available (e.g. Pulmonary Workstation V.2.0 [VIDA Diagnostics,
Coralville, Iowa, USA]) for the reconstruction of airways from volumetric datasets. These
software allow for the quantification of luminal diameter and wall thickness to the fifthsixth airway generation. Indices for evaluating airway dimensions include: bronchial
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luminal area (LA), bronchial wall thickness and area (or percent, where the wall area in
normalized to the outer wall area [WA%]), and total bronchial area.
In patients with asthma, CT bronchial wall thickness measurements are greater than healthy
controls84 and have been shown to be associated with airflow obstruction.85,86 Decreased
lung density has been shown to be related to pulmonary function test measurements of gastrapping (e.g. RV) and airflow obstruction (e.g. FEV1).87,88

Furthermore, CT

measurements of gas-trapping have been shown to be associated with increased number of
asthma related hospitalizations and intensive care unit visits.83
Airway wall measurements in patients with COPD have been associated with histology,89
frequency of exacerbation,90 and dyspnea.91 Wall area measurements have also been
shown to be correlated with the FEV1/FVC, and RV/TLC, but not DLCO.92 COPD patients
with a clinical diagnosis of chronic bronchitis have also been shown to have thicker airway
walls (measured using CT) than those without chronic bronchitis.93 Recent work showed
that quantitative CT measures of airway thickness in COPD patients were greater in those
with bronchodilator responsiveness.94

Figure 1-10 Axial and coronal x-ray CT images of representative subjects.
Subjects shown in health, with small airways disease, and large airways disease.
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Emphysema
The evaluation of emphysema using CT has been done for the past three decades. The
earliest studies evaluating emphysema noted the key feature of emphysema was the
decrease of lung density.95 Other radiological signs of emphysema include focal areas of
low attenuation, no definable wall, upper zone predominance, no obvious fibrosis, vascular
pruning and distortion, and bullae.96
The CT image is essentially a densitometric map of the lung, where each pixel corresponds
to a Hounsfield Unit value representing tissue density. The evaluation of emphysema has
evolved from visual scoring systems which are subject to high inter- and intra-user
variability97 to less biased quantitative methods. Emphysema can now be estimated using
computerized and automated analysis. In this analysis the CT density histogram of all
Hounsfield unit values is evaluated using a number of HU threshold to generate the relative
area of the lung occupied by attenuation values lower than specific threshold (Figure 111) and percentiles (e.g. relative area under -950HU [RA950] or the lowest 15th percentile
[HU15] at inspiration to evaluate emphysema). These values have been shown to correlate
well with manual radiologists' emphysema scores,98 pulmonary function test
measurements,99 and with histology.100 Limitations with single threshold methods include
the over or under-estimation of emphysema, where a lower threshold differentiates more
severe emphysematous regions101 disregarding regions with mild tissue destruction and a
higher threshold identifies mild emphysematous regions.102 Consequently, methods that
diverge from single threshold measurements have emerged. An example of this is an
automated evaluation of the CT density histogram using principal component analysis that
has been used to generate a principal component score based on each frequency–HU pair.
This measurement was strongly related to pulmonary function tests and expert radiologist
emphysema scores.103
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Figure 1-11 Representative CT images and corresponding frequency distribution of
radiodensity shown below for healthy and emphysematous lungs.
The regions below -950HU are shown in yellow.
Another commonly used measurement of emphysema is the percentage of lower
attenuation areas (LAA%). The LAA% expresses the emphysema volume as a proportion
of total lung volume measured by CT and has been shown to be associated with pulmonary
function test measurements,104 frequency of COPD exacerbations,90 and quality of life
scores.105
It should be noted that the use of CT for pulmonary applications, especially for serial and/or
longitudinal studies or pediatric applications, is limited due to the potential risks related to
radiation doses stemming from the ionizing x-ray radiation (the radiation that displaces
electrons from atoms or molecules and produces ions).106 However, thoracic x-ray CT
provides a wealth of structural pulmonary information, where each voxel in the resulting
CT image provides a physical unit of tissue density.
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1.5.3

Nuclear Medicine

In comparison to CT imaging methods that are based on the relative absorbance of x-rays,
nuclear medicine techniques utilise tracers that emit radiation. These methods involve
intravenous injection of radioisotopes to the pulmonary vasculature or inhalation to the
peripheral airspaces, thus giving functional images of ventilation and perfusion.
Single Photon Emission Computed Tomography
Three-dimensional SPECT has been clinically available for 30 years, having mainly been
used for myocardium, brain, and liver imaging. The technique has also been applied in
lung scintigraphy, especially for the assessment of pulmonary embolisms.

SPECT

radioisotopes emit a single gamma beam as they decay. Every point on the gamma camera
image corresponds to an entire line within the person being imaged. These projections can
be reassembled to provide three-dimensional information about the distribution of
radionuclides within the body. For pulmonary imaging, SPECT has been used to provide
information about pulmonary physiology, i.e. ventilation and perfusion.

Perfusion

scanning is typically performed using 99m-technecium labelled macro-aggregated albumin
(99mTc-MAA), which lodges in the pulmonary circulation after peripheral injection.
Ventilation scanning requires the inhalation of gaseous radioisotopes (e.g. 81mKr and 133Xe)
and the gas distributes throughout the whole lung, and the differences in its regional
distribution reflect differences in regional ventilation. These isotopes have been used to
produce both perfusion107 and ventilation108,109 maps in subjects with obstructive lung
disease. These studies have quantified perfusion defects and ventilation defects as the
extent that is not perfused or ventilated, respectively.
In patients with asthma, the disease heterogeneity has been established using SPECT
imaging.110

Changes

in

regional

perfusion

and

ventilation

during

bronchoconstriction,111,112 bronchodilation,113 exercise,114 antigen challenge,115 and
histamine inhalation116 have been evaluated in asthmatics using 99mTc-MAA and 81mKr. In
patients with COPD, previous work has investigated the effects of baseline lobar perfusion
on outcomes following endobronchial valve placement.107 This study demonstrated that
pulmonary function test measurements did not change pre- and post-endobronchial valve
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placement. However, the patients with high baseline perfusion had significant shifts in
perfusion with endobronchial valve placement, in comparison to patients with low baseline
perfusion.

Although SPECT has been used to assess the severity of airflow limitation in

subjects with COPD,117,118 intrabullous ventilation in patients with emphysema,119 and
ventilation-perfusion mismatch in COPD subjects,120,121 it is limited by the risk of
cumulative radiation exposure for longitudinal monitoring and offers poor spatial
resolution. As a result so far there have been no published studies using SPECT to assess
treatment responses aimed at improving ventilation patterns in asthma or COPD.
Positron Emission Tomography
PET utilises radioisotopes that emit positrons as they decay through the process of beta
decay. As the positron is ejected from the nucleus and encounters an electron, these
particles annihilate resulting in two photons emitted at approximately 180 degrees. These
photons are detected at or very near the same time and are considered to be “coincident”
and the location of the source particle can therefore be determined geometrically from the
coincident beams—being located on the straight line between the two detectors. Flourine18 (18F) is the most commonly used radioisotope in PET and when it is bound to
fluorodeoxyglucose (FDG) it can be taken up by metabolically active tissue. In COPD,
18

F-FDG has been used to assess inflammation. Studies have highlighted the challenges

of quantifying inflammation given the variability of lung density in diseased patients.122
For example, visually, a patient with emphysema would unlikely show an increased signal
even when there is a high degree of inflammation, simply because there is so little tissue
in each image voxel. However, the finding that COPD patients have greater

18

F-FDG

uptake than healthy controls,122,123 paves the road for future work that may assess treatment
response with 18F-FDG uptake as an endpoint. Regional ventilation has also been assessed
using PET by using the

13

N isotope.124 This marker is injected and enters the lung via

pulmonary arterial circulation. Due to its low tissue solubility, the 13N diffuses across the
alveolar membrane and allows for the measurement of ventilation and perfusion. As such,
unventilated lung regions, termed ventilation defects, retain the tracer due to gas-trapping
whereas the tracer is quickly washed out of ventilated lung regions.
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In patients with asthma, 18F-FDG PET has been used to evaluate inflammation125 and 13N
PET has been used to evaluate bronchoconstriction.126 Studies have evaluated perfusion
and ventilation using

13

N PET as a vascular biomarker in COPD, demonstrating that

perfusion is significantly heterogeneous in COPD patients compared to healthy
volunteers127 and this may suggest that regional changes in pulmonary blood flow may
precede lung parenchymal changes in COPD. Ventilation-perfusion ratios have also been
assessed in COPD patients, where emphysema dominant COPD patients had higher
ventilation-perfusion ratios compared to COPD patients with airways disease.128
PET has evolved over the years to allow for the measurement of ventilation and perfusion
in patients with lung disease. However, the limitations that accompany PET include the
need for a cyclotron for the production of isotopes, for short term repeated studies time is
required for the radioisotope to decay enough to avoid signal contamination, cumulative
radiation exposure limits longitudinal monitoring of patients, and low spatial resolution
(due to physical effects) does not allow imaging of individual gas exchange units.

1.6

Pulmonary Magnetic Resonance Imaging

Unlike x-ray and nuclear imaging methods, magnetic resonance imaging (MRI) uses
radiofrequency (RF) waves to manipulate nuclear spins (typically of hydrogen atoms) to
generate images. The MRI signal is generated from the protons in water molecules and
unfortunately, the lung contains only 800g of tissue which is distributed over 4-6L.129 The
resulting signal-intensity of the lung is low compared to the rest of the body. Although
pulmonary MRI remains clinically challenging due to the unique characteristics of lung
tissue, in the last several decades, MRI using hyperpolarized noble gases and conventional
methods has revolutionized the field of pulmonary imaging. There have been a series of
new technologies developed to qualitatively and quantitatively evaluate lung
abnormalities.

These techniques provide unique biomarkers and insights into the

pathophysiology of obstructive pulmonary diseases. Before these biomarkers can be used
in clinic, their structural determinants and clinical consequences must first be better
understood.
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1.6.1

Inhaled Noble Gas Magnetic Resonance Imaging

The development of inhaled gas contrast MRI has allowed for the visualization of lung
function and structure. The first lung ventilation images acquired using hyperpolarized
129

Xe were captured in 1994.130 Shortly after the first lung ventilation images were

acquired using 129Xe MRI, the field shifted towards hyperpolarized 3He. The main reason
for this stems from the inherent properties of these two gases. The gyromagnetic ratio of
129

Xe (𝞬=-11.8MHz/T) is three times smaller than that of 3He (𝞬=-32.3MHz/T) and the

achievable polarization of

129

Xe is lower (129Xe: 8-25%; 3He: 30-40%)131—which

consequently leads to a lower signal-to-noise ratio. With improvements in hardware,
however, similar signal-to-noise ratio is becoming more attainable.132
Unlike clinically available MR methods, hyperpolarized inhaled gas MRI requires
specialized equipment and personnel to prepare and image the gas. This is because both
129

Xe and 3He have low spin density in the gaseous state. The spin densities of these gases

are typically about four orders of magnitude less than the density of protons in water.133
Since MR signal is determined by the difference in the number of spins aligned in either
direction, the most ideal case to produce signal would involve spins being aligned
completely in one direction (i.e. 100% polarized). In practice, not all spins will align in
one direction and this is determined by the Boltzmann distribution, therefore, there is a
reduction in the polarization which is proportional to the signal. The polarization of dilute
gases like 3He and 129Xe is not sufficient for imaging and results in a very low signal for
in-vivo imaging. Angular momentum can be added to the system to align all nuclear spins
in one direction and overcome the lack of polarization.
Classically, hyperpolarization involves the addition of angular momentum to the system.
Optical pumping and spin exchange are typically used to polarize the gas. A circularly
polarized laser serves as the carrier of the angular momentum. This laser (where the
wavelength of laser photons matches the electronic orbital transmission of the alkali atom)
is used to excite the electrons of an alkali metal (e.g. rubidium). The angular momentum
that the electrons obtain from the laser is transferred to the noble gas nuclei through
collisions. Once there is enough rubidium vapour (at temperatures >>40°C which is the
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melting point of rubidium) for the gas to interact with, the temperature has a minimal effect
on the spin exchange. It should be noted, that the pressure is well controlled in this system.
This method increases the nuclear polarization of the unpaired nuclear proton in these
atoms up to five orders of magnitude compared to thermal polarization.134 This increase
in polarization is needed to compensate for the low density of noble gas nuclei within the
lung (compared to the protons from the lung tissue) and provides ventilation images with
resolution on the order of millimetres. The polarization for 3He and 129Xe lasts up to days
if there are no external sources of relaxation (such as oxygen, magnetic field gradients, and
surface-to-volume relaxation).131
Ventilation Imaging
Hyperpolarized noble gas MRI using 3He and 129Xe provides a method to visualize those
regions of the lung that are ventilated and those that are not. This type of imaging is based
on the spin density of the hyperpolarized gas. In a healthy young subject, as shown in cyan
in Figure 1-12, the hyperpolarized gas is distributed homogeneously in the lung. In older
never-smokers or patients with obstructive lung disease (Figure 1-12), the distribution of
the hyperpolarized gas is more heterogeneous. There are apparent regions of signal void
known as ventilation defects. These regions of signal void can be quantified as the
ventilation defect percent (VDP) by normalizing the ventilation defect volume (VDV) to
the thoracic cavity volume (TCV).135 The imaging biomarker, VDP, has been shown to be
reproducible,136 related to lung function,137 and sensitive to disease severity and treatment
response.138,139

Figure 1-12 Representative coronal centre slice of healthy young and older never-smokers
and patients with OLD.
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Hyperpolarized 3He MRI gas distribution (in cyan) registered to the 1H MRI of the thorax
(in grey-scale). Unlike the representative healthy young never-smoker, the older neversmoker and obstructive lung disease subjects have visually obvious ventilation defects.
Studies using ventilation MR imaging have revealed that COPD and asthma are regionally
heterogeneous diseases140,141 and that there are significant ventilation improvements posttherapy even in the absence of pulmonary function test measurement improvements.138 As
can be seen in Figure 1-12, the distribution of ventilation defects varies for those subjects
who are older never-smokers or have asthma or COPD. Although the aged subject and
subjects with obstructive lung disease have ventilation defects, they are distributed in
different patterns. This suggests that there are different looks to ventilation patterns in
obstructive lung disease patients and this information could potentially be used for
phenotyping. But before these biomarkers can be used for phenotyping, as stated before,
their structural determinants and clinical consequences need to be better understood.
In order to better understand the clinical consequences of this imaging biomarker in
patients with obstructive lung disease, studies have evaluated aging,142 asthma,139,143-145
and patients with COPD.138,140,146 Ventilation defects have been shown to correlate with
age.142 The clinical consequences of ventilation defects in aging have yet to be determined.
In asthma, ventilation defects have been shown to be related to worse airflow obstruction,
greater airways resistance, and airway inflammation.145 Ventilation defects in severe
asthmatics have also been reported to be related to asthma control.147 In COPD, ventilation
defects have been shown to represent a mixed airways disease-emphysema phenotype148
and have been shown to be correlated with COPD exacerbations.146
Collectively, these studies suggest that in obstructive lung disease the biomarker VDP is
related to airways disease and emphysema, these defects are heterogeneously distributed,
and are responsive to therapy.

Hyperpolarized noble gas MRI for evaluating lung

ventilation has thus become an accepted tool for visualizing lung function. With the
increased costs related to noble gas ventilation MR imaging, the field’s future transition
appears to be geared towards non-contrast enhanced MR methods, such as proton MRI.
However, obstructive lung disease has yet to be evaluated using these more clinically
available approaches. Although it can be hypothesized that the knowledge gained from
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pulmonary non-contrast enhanced MRI studies will be complementary, direct comparisons
with noble gas MRI are required.
Diffusion Weighted Imaging
In addition to the visualization of gas distribution, there is the potential to evaluate lung
microstructure using hyperpolarized noble gas MRI. 3He is a highly diffusive gas due to
its low atomic weight (self-diffusion coefficient of 2cm2/s at 37°C).131 The diffusion
coefficient can be measured using diffusion-weighted MR methods that are sensitive to the
gas’ self-diffusion based on the random Brownian motion of the atoms, as opposed to
transmembrane gas diffusion. The 3He apparent diffusion coefficient (ADC) reflects
diffusion of the gas when restricted by the airways and airspaces.

129

Xe also provides

measurements of lung structure, but 3He ADC measurements have been more extensively
reported. An increased ADC value reflects a greater mean square displacement of the gas
molecule which is consistent with an increased measure of lung microstructure.
In healthy volunteers, diffusion weighted 3He MRI has been used to demonstrate that
structural changes occur with an annual increase in ADC of 0.0015cm2/s for subjects
between the ages of 20 and 70 years.149 The limited work that has used 3He ADC to
evaluate asthma has revealed to be inconsistent. Some work has shown that 3He ADC
values are elevated in asthma (suggesting gas-trapping),150 while others have reported no
differences in ADC values between asthmatics and healthy volunteers.151,152 In terms of
evaluating treatment response, 3He ADC values are elevated after bronchoconstriction
(suggesting

gas-trapping)

and

decreased

following

bronchodilator.153 In patients with COPD, 3He and
compared to age matched healthy volunteers.154

129

the

administration

of

a

Xe ADC values are elevated

Previous work has revealed the

association of 3He ADC measurements with pulmonary function test measurements,155
histology,156 age,149 smoking history,149 and gas-trapping.148

3

He ADC has also been

evaluated pre- and post-bronchodilator administration and the newly ventilated regions of
the lung did not have elevated ADC compared to the regions participating in ventilation
before bronchodilator administration.157
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Hyperpolarized noble gas MRI has yet to find wide-ranging acceptance in the clinic.
Advances in CT, limited availability of the necessary hardware for polarizing and imaging
hyperpolarized noble gases, and the identification of clinical applications that will benefit
from this have made clinical translation difficult. With this, there has been growing
motivation for the development and implementation of non-contrast enhanced pulmonary
MRI to overcome the challenges of ionization radiation and resource accessibility.

1.6.2

Non-Contrast Enhanced 1H Magnetic Resonance Imaging

As mentioned above, the lung is more challenging to image using conventional proton (1H)
MR pulse sequences than MRI of most other organs due the combined effects of low proton
density, magnetic susceptibility, and to a lesser extent because of the effects of cardiac and
respiratory motion.158,159 Because the alveolar ducts and sacs make up most of the lung
volume and are air-filled, there is very little lung tissue and consequently the mass density
of the lung is lower than any other organ in the body, and is approximately 0.15g/mL.159
Since MR signal is proportional to the proton density of the tissue, the resulting signal from
the lung is much lower than all other body tissues.
The lung parenchyma also has a short transverse magnetization relaxation time (arising
from natural interactions at the atomic or molecular levels), known as T2. This is the time
it takes the excited protons to lose phase coherence due to the interaction between spins
resulting in a reduction in transverse magnetization. The decay of the MR signal due to T2
is because of the natural interactions of spins at the atomic and molecular levels within the
tissue. The resulting T2* at 3T, which is the sum of T2 and the relaxation due to the field
inhomogeneities across a voxel (γΔB0), of the lung is also short (i.e. 0.4-0.9ms):160,161
Equation 1-2
1
1
= + 𝛥𝐵0 𝛾
𝑇2 ∗ 𝑇2
Taken together, these MR properties of the lung result in a much faster MR signal decay
for the lung parenchyma in comparison to other tissues. In addition to the short T2, another
problem for MRI of the lung relates to the fact that air and tissue have very different
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magnetic susceptibilities. The adult human lung is composed of approximately 480 million
alveoli and it is the co-distribution of airspaces/tissue/gas/blood that leads to local magnetic
field inhomogeneities158,159 that are problematic for high spatial resolution MRI. The
differences in the magnetic susceptibilities between different materials (i.e. air and alveolar
wall tissue) lead to variations in the local magnetic field and this leads to faster spin
dephasing (i.e. shorter T2*). With an increased voxel size, there is a greater number of airtissue interfaces and this may result in a greater T2* decay. A larger voxel size is also
susceptible to the main magnetic field inhomogeneities. Furthermore, since the local
magnetic field determines the angular speed of magnetic spin rotation, the magnetic field
inhomogeneity at the interface causes the spins to precess at different angular velocities
and this leads to an increased dephasing of the measureable magnetization. The dephasing
effect leads to a signal loss or field inhomogeneity artifacts which further degrade the 1H
signal and distort the image. Consequently, as shown in Figure 1-13, the lungs appear as
black holes with no information that can be obtained about lung structure. Furthermore,
the lungs of health and disease in these cases are indistinguishable.

Figure 1-13 Representative coronal centre slice of healthy young never-smoker and
patients with obstructive lung disease.
Due to low 1H and tissue density within the lung there is no signal inside the lung and thus
structural abnormalities are not visually apparent. Coronal 1H MRI acquired using the
whole-body RF coil and 1H fast-spoiled, gradient-recalled echo sequence using a partial
echo (16s total data acquisition, repetition time (TR)/echo time (TE)/flip angle =
4.7ms/1.2ms/30°, field-of-view (FOV)=40×40cm, bandwidth=24.4 kHz, matrix=128×80,
15-17 slices, 15mm slice thickness, 0 gap).
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Making this situation even more complex is the respiratory motion that occurs during tidal
breathing because the change in lung volume causes blurring of pulmonary structures. To
overcome this limitation, the lung can be imaged under rapid breath hold conditions or
using prospective or retrospective respiratory gating. The periodic motion of the heart also
causes motion artifacts in MR images making the visualization of the lung parenchyma
near the heart more complex.
Several techniques have been proposed to overcome these challenges and have been
discussed above (i.e. hyperpolarized noble gas MRI). It should be noted, however, that
these techniques require a certain amount of additional hardware such as special RF coils
tuned to the Larmor frequency of the gas being imaged and hardware to prepare the
hyperpolarized gases. Alternative methods that are based on the visualization of the
enhanced proton signal of the lung tissue have been developed and will be discussed.
Ultra-Short Echo Time MRI
Although hampered by low signal-intensity due to low 1H density and the multitude of lung
air-tissue interfaces, 1H MRI of the lung can be performed on every scanner without
additional hardware (such as a polarizer or an MR system with multi-nuclear imaging
capabilities). To maximize the potential to provide high spatial resolution quantitative
images of lung parenchyma in MR images, pulse sequences need to provide maximal signal
and minimal degradation in the presence of susceptibility dephasing. This can be achieved
by minimizing the echo time (TE) which is the time between excitation and acquisition of
the signal.159 With recent technical advancements, MRI using ultra-short echo time (UTE)
acquisition methods have emerged. These methods were first proposed as a way to address
the inherent challenges of pulmonary imaging stemming from low tissue and 1H density.162
UTE MRI combines fast RF excitation pulses and efficient k-space sampling trajectories
to minimize MR signal decay and motion artefacts.162 The length of TE, however, depends
on how quickly the RF electronics (hardware) can switch from transmit to receive.163
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Figure 1-14 Conventional two-dimensional UTE pulse sequence diagram.
The half radiofrequency (RF) pulses are applied with a negative slice-selection gradient
(Gz) in the first half and a positive gradient in the second half. The RF pulse is truncated
and followed by a radial acquisition which is when Gx and Gy are applied. These gradients
ramp up to a plateau during data acquisition.
Briefly, as shown in Figure 1-14, a typical two-dimensional UTE sequence starts with a
half-sinc pulse RF excitation followed by a centre out radial acquisition, where the free
induction decay will be acquired. To remove the out-of-slice signal and correct the phase
resulting from the half-pulse excitation, a second excitation will be implemented
simultaneously with the inverted slice select gradient. This acquisition will be added to the
first acquisition to remove the phase variation across the slice and out-of-slice signal.
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Figure 1-15 shows UTE MR images of a healthy never-smoker and patients with
obstructive lung disease. There are visually apparent regions of low signal-intensity in the
patients with obstructive lung disease which may reflect regions of low tissue density due
to gas-trapping or emphysema. As can be seen when comparing Figure 1-14 and Figure
1-15, UTE MRI methods result in higher pulmonary signal intensities than clinically
available MR methods. The biomarkers stemming from UTE MRI include mean whole
lung T2*, mean whole lung signal-intensity, and threshold based indices quantifying
volumes of low signal-intensity164 which have been all used to evaluate lung parenchyma.
It should be noted that the resulting MR signal is not only influenced by T1, T2*, and proton
density, but also hardware factors such as the positioning of the RF coils, which introduce
inter-scan variability. Because of this, it is difficult to ascertain the physiological meaning
of 1H MR signal-intensity and thus translate across multiple sites.
Thus far, in asthma, limited work has been done using UTE MR methods. However,
conventional and clinically available 1H MRI pulse sequences have been used to monitor
inflammatory responses to allergen challenges in animal models165 and asthmatics.166 With
recent advancements in pulmonary 1H MRI, the first studies employing UTE methods
imaged mice and reported that the MR signal and T2* of the lung parenchyma were higher
at end-expiratory phase than at end-inspiratory phase.167 This work also reported that these
values were reduced in the mouse model of emphysematous lungs compared to normal
mouse lungs at end-expiratory phase suggesting that higher signal-intensity and T2* values
are related to increased lung density.

More recently, UTE MRI measurements,

implemented in a mouse model of emphysematous lungs, were correlated with histology
measurements of the mean chord length of the alveoli.168 These results are consistent with
the notion that smoking exposure results in alveolar enlargement and increases the airtissue ratio and susceptibility driven local field inhomogeneity.
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Figure 1-15 Representative coronal centre slices of healthy young never-smoker and
patients with obstructive lung disease acquired using UTE MRI.
Regions of low signal-intensity are visually obvious in the obstructive lung disease subjects
compared to the healthy never-smoker. Images of healthy volunteer and COPD subject
acquired using a 2D UTE MR method using a 32-channel torso coil (GEHC) (13s
acquisition time, TR/TE/flip angle=13.0ms/0.05ms/10°, FOV=40×40cm, matrix 256×511,
NEX=2, 15mm slice thickness). Image of asthmatic acquired using a 3D UTE MR method
using a 32-channel torso coil (GEHC) (15s acquisition time, TE/TR/flip
angle=0.03ms/3.5ms/5°, FOV=40×40cm, matrix=200×200, NEX=1, and reconstructed to
a 10mm slice thickness).
Fourier Decomposition MRI
Fourier decomposition (FD) MRI has also been proposed for non-contrast enhanced
functional lung MRI to obtain regional ventilation and perfusion information about the
lung.

This approach exploits fast MRI acquisition of the lung with respiratory motion

compensation using non-rigid image registration. Spectral analysis of the images allows
for identification of peaks of the respiratory and cardiac frequencies; these peaks are related
to 1H density change caused by compression and expansion of the lung parenchyma and
pulmonary blood flow.169,170 Ventilation and perfusion maps of the lung can then be
created using this information. Currently, FD techniques utilize a short echo dynamic
steady state free precession lung image acquisition.170

The limited work that has

investigated the use of FDMRI in patients with asthma has shown similar information to
hyperpolarized noble gas MRI after a bronchoconstriction challenge.171 The first study to
have used FDMRI to quantify pulmonary abnormalities in subjects with COPD
demonstrated that the FDMRI derived ventilation measurements were associated with
noble gas MRI ventilation abnormalities and CT derived measurements of emphysema.172
Although FDMRI requires sophisticated post-processing methods, it is a promising method
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for serial lung function measurements without the dependence of inhaled gases.

Non-

contrast enhanced 1H MR methods such as UTE and FDMRI open up the opportunity for
structural and functional lung imaging on clinically available MR systems for longitudinal
monitoring of subjects with obstructive lung disease.

1.7

Thesis Hypotheses and Objectives

Pulmonary function tests are clinically used for the diagnosis, monitoring, and evaluation
of response to therapy in patients with obstructive lung disease. These measurements,
while important, conceal the regional contributions of underlying pathologies.
Accordingly, a necessary goal of obstructive lung disease research is to develop ways to
identify patients with specific underlying pathological phenotypes to further personalize
medicine with the hopes to improve patient care and outcomes. Imaging methods such as
thoracic CT and MRI have the potential to provide regional and quantitative biomarkers of
obstructive lung disease. Before identifying patients with specific underlying pathological
phenotypes, it is important to understand the physiological and clinical consequences of
MR-derived measurements. Thus, the overarching objective of this thesis was to develop
and evaluate lung structure and function measurements using multi-nuclear pulmonary
MRI in older never-smokers and obstructive lung disease to provide an understanding of
the physiological and clinical etiology of these MR-derived measurements. In Chapter 2,
an understanding of healthy aging was first developed using hyperpolarized noble gas MRI.
Following this, a non-contrast enhanced UTE MR method was developed and its
reproducibility was evaluated. This method was then used to evaluate patients with COPD
(Chapter 3) and asthma (Chapter 4) to determine the physiological and clinical
consequences of UTE-derived measurements. The objectives and hypotheses specific to
each chapter are described below.
In Chapter 2, our objective was to determine the physiological consequences and potential
relevance of ventilation abnormalities in older never-smokers. We evaluated the response
of bronchodilation (i.e. deep inspiration and salbutamol) on these defects and the
relationship of ventilation defects with occupational exposures, pulmonary function, and
exercise capacity. Based on previous work in young healthy volunteers where ventilation
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defects resolved after deep inspiration, we hypothesized that in older never-smokers,
narrowed or collapsed airways were responsible for persistent ventilation defects, and these
would be responsive to and improve following deep inspiration.
In Chapter 3, our objective was to develop a UTE MR method, evaluate its reproducibility,
and use this method to evaluate pulmonary abnormalities in COPD patients with and
without bronchiectasis. We also evaluated the relationship between UTE-derived
measurements with CT scan measurements and pulmonary function tests to better
understand the underlying determinants of signal-intensity measurements in COPD and
bronchiectasis. We hypothesized that pulmonary UTE MRI signal-intensity would have
high short-term reproducibility and be related to CT radiodensity and pulmonary function
test measurements in COPD patients with and without bronchiectasis.
In Chapter 4, our objective was to determine the underlying structural and clinical
determinants of UTE-derived signal-intensity measurements in asthma by evaluating wellestablished clinical and emerging imaging (hyperpolarized noble gas MRI and CT)
measurements in asthmatics.

These patients shared some airway and inflammatory

features common in COPD and bronchiectasis.

We hypothesized that UTE-derived

biomarkers that merge information acquired at different lung volumes could be generated
to capture evidence of regional ventilation heterogeneity and these measurements would
be related to gas-trapping and/or airway flow obstruction in patients with asthma.
In Chapter 5, an overview and summary of the important findings and conclusions of
Chapters 2-4 is provided. The study specific and general limitations of these studies will
be discussed and some potential solutions. The thesis concludes with an outline of future
studies that can build on the work presented in this thesis.
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CHAPTER 2

2

PULMONARY VENTILATION DEFECTS IN OLDER
NEVER-SMOKERS

To better understand the physiological consequences and potential relevance of 3He MRI
ventilation defects in aging, we evaluated 3He MRI ventilation defects in older neversmokers before and after bronchodilation administration. To identify the potential
determinants of ventilation defects, we also evaluated dyspnea, pulmonary function, and
exercise test measurements.
The contents of this chapter were previously published in the Journal of Applied
Physiology: K Sheikh, GA Paulin, S Svenningsen, M Kirby, NAM Paterson, DG
McCormack, and G Parraga. Pulmonary Ventilation Defects in Older Never-Smokers. J
Appl Physiol 2014; 117(3):297-306. Permission to reproduce this article was granted by
The American Physiological Society and is provided in Appendix A.

2.1

Introduction

Pulmonary aging is concomitant with changes in elastic recoil,1-3 chest wall compliance,1,3
and respiratory muscle strength.4,5 In concert with these physiological changes, functional
residual capacity (FRC), residual volume (RV), and airways resistance (Raw) also
increase,4 whereas the forced expiratory volume in one second (FEV1), forced vital
capacity (FVC)6 and inspiratory capacity (IC) decrease.7
Healthy older adults may experience breathlessness during everyday activities8-12 and this
is related to mortality risk.8,9,12 In addition, in older adults, cardiopulmonary exercise test
(CPET) measurements13 correlate more strongly with overall health status than do
measurements of resting lung function.14-16 Moreover, CPET measurements show that in
“normal” healthy aging, there is lower exercise-related oxygen uptake (VO2) as well as
greater minute ventilation (VE), and increased respiratory exchange ratio (RER).17-19
Recent studies have also shown that during exercise, significant ventilatory impairment is
possible without increased dyspnea or premature exercise limitation.20
The role of occupational and second-hand tobacco smoke exposure is important to
acknowledge and understand in both normal and accelerated lung aging. In this context,
the Burden of Obstructive Lung Disease (BOLD) study21 showed that in never-smokers,
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the prevalence of airflow limitation consistent with chronic obstructive pulmonary disease
(COPD) was as high as 30%. The BOLD study also revealed the critical relationships in
never-smokers between airflow limitation and age, history of occupational exposure and
childhood respiratory disease.22
3

He ventilation magnetic resonance imaging (MRI) provides high resolution, non-invasive

measurements of lung function,23,24 and identifies those regions of the lung that participate
in ventilation and those that do not.24,25 In healthy young subjects, a single inhalation of
hyperpolarized 3He gas results in homogeneous lung filling, but in older never-smokers,
characteristic “focal” ventilation defects are observed, corresponding to poorly ventilated
lung regions.23,25 In older never-smokers, ventilation defects are commonly observed on
the lung periphery and the dependent lung regions, and this is in contrast with COPD and
asthma, where numerous and large defects are heterogeneously distributed throughout the
lung.23,24,26
The finding of spatially and temporally-persistent 3He MRI ventilation defects in older
never-smokers with normal spirometry23,25 raises questions about the physiological
meaning of ventilation defects in all subjects. For example, as previously shown, 3He MRI
ventilation abnormalities induced by methacholine challenge in young healthy volunteers
were reversed by deep inspiration (DI).27 In young asthmatics, salbutamol inhalation
reduced ventilation defects observed with 3He MRI after methacholine challenge,28 but the
effect of DI was not investigated. Airway resistance measurements determined that
asthmatic subjects cannot maximally dilate their airways and that the dilation that does
occur after DI constricts back to baseline much faster than in healthy subjects.29 This
suggested that in asthma, ventilation defects were related to salbutamol-responsive airway
abnormalities, whereas in healthy volunteers, ventilation defects may reflect “normal”
airway smooth muscle behaviour that is reversible using DI.
We hypothesized that in older never-smokers, narrowed or collapsed airways were
responsible for the persistent ventilation defects observed and these would be responsive
to, and improve following DI. To test this hypothesis, we evaluated the effect of both DI
and salbutamol on 3He ventilation defects in a relatively large group of older never-smokers
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with no history of respiratory disease. We also evaluated the relationship of ventilation
defects with occupational exposures, pulmonary function and cardiopulmonary exercise
test measurements.

2.2
2.2.1

Materials and Methods
Study Subjects and Logistics

All subjects provided written informed consent to a study protocol approved by a local
research ethics board and Health Canada. Subjects were enrolled between the ages of 60
and 90 years with a smoking history of < 0.5 pack-years and no history of chronic
respiratory or cardiovascular disease. After providing consent, all subjects made a single
2-3 hour visit and underwent the following evaluations in the same order: 1) Burden of
Obstructive Lung Disease (BOLD) occupational questionnaire,5 2) spirometry, 3)
plethysmography and the diffusing capacity of carbon monoxide (DLCO), 4) CPET
including dyspnea score, and, 5) MRI. Pulmonary function tests were completed in
approximately 45 minutes followed by CPET that was completed in 10-15 minutes. MRI
was performed following CPET and for subjects who did not have ventilation defects and
those with defects that responded to DI, MRI was completed within 10-15 minutes. For
subjects who were administered salbutamol, MRI was performed 25-30 minutes post
salbutamol inhalation.

2.2.2

Questionnaires

All subjects completed the BOLD occupational questionnaire21 with exposures defined as
previously described22 including: 1) organic dust (farming; flour, feed or grain milling and
cotton or jute processing), 2) inorganic dust (working with asbestos; hard-rock mining;
coal mining; sandblasting and foundry or steel milling), and, 3) irritant gases (welding;
firefighting; chemical or plastics manufacturing). We also directly queried subjects about
spousal and/or life-partner smoking history and recorded potential household 2nd handsmoke exposure.
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2.2.3

Pulmonary Function and Cardiopulmonary Exercise Tests

Spirometry was performed using an ndd EasyOne spirometer (ndd Medizintechnik, Zurich)
according to American Thoracic Society (ATS) guidelines. Body plethysmography was
performed for the measurement of lung volumes and DLCO was measured using the gas
analyser (Medgraphics Corporation, St. Paul, MN). Inspiratory capacity (IC), defined as
the volume change recorded at the mouth when taking a slow full inspiration from a
position of passive end-expiration, was measured using body plethysmography31 as was
airways resistance (Raw), defined as the pressure difference per unit flow. Post-DI
pulmonary function tests were not performed but for subjects administered salbutamol,
FEV1 and FVC were recorded 35-40 minutes post-inhalation and upon completion of MRI.
After completion of pulmonary function tests, all subjects performed CPET using a cycle
ergometer (MedGraphics Ultima PFX, MedGraphics Corporation) according to ATS
guidelines 14 with a two minute warm-up with no resistance, followed by a 20 watt
incremental increase in work rate. Subjects were required to pedal at a frequency of 60
rpm with increasing work rate until the ventilatory anaerobic threshold was reached.
Ventilatory anaerobic threshold was defined as the time when CO2 production increased
disproportionately in relation to O2 consumption. The ventilatory anaerobic threshold was
determined by onboard software for the CPET unit which used an iterative regression and
analysis of slope. Subjects continued exercise until fatigue was reported. Oxygen uptake
(VO2), respiratory exchange ratio (RER), work rate (i.e. power) as well as minute
ventilation (VE) were measured at rest, at the ventilatory anaerobic threshold, and when
maximum pulmonary O2 uptake was reached. The time taken to reach VO2max was also
recorded. CPET measurements including VO2, power, and VE were adjusted for age, sex,
and height using percent predicted values previously reported.17,18,30 Borg dyspnea and leg
discomfort scales were used before and after exercise.

2.2.4

Image Acquisition

MRI was performed after completion of all pulmonary function and cardiopulmonary
exercise tests on a 3.0 Tesla MR750 (General Electric Health Care (GEHC), Milwaukee,
WI) system as previously described23 using a whole-body gradient set with maximum
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gradient amplitude of 1.94 G/cm and a single-channel rigid elliptical transmit/receive chest
coil (Rapid Biomedical GmbH, Germany). For both 1H and 3He MRI, subjects were
instructed to inhale a gas mixture from a 1.0-liter Tedlar bag (Jensen Inert Products, Coral
Springs, FL) from FRC, and image acquisition was performed during a 16 second breathhold. Coronal (anatomical) 1H MRI was performed using the whole-body RF coil and 1H
fast-spoiled, gradient-recalled echo sequence using a partial echo (16s total data
acquisition, repetition time (TR)/echo time (TE)/flip angle = 4.7ms/1.2ms/30°, field-ofview (FOV)=40×40cm, bandwidth=24.4 kHz, matrix=128×80, 15-17 slices, 15mm slice
thickness, 0 gap), as previously described.23

3

He MRI static ventilation images were

acquired using a fast gradient-echo method using a partial echo (14s total data acquisition;
TR/TE/flip angle = 4.3ms/1.4ms/7°, FOV = 40×40cm, bandwidth=48.8 kHz, matrix=
128×80, 15-17 slices, 15mm slice thickness, 0 gap).
Immediately after image acquisition, at the scanner while the subject was still in position,
3

He static ventilation images were qualitatively evaluated for ventilation abnormalities by

a single trained observer. If 3He gas was homogeneously distributed throughout the lung
and there were no visible ventilation defects, the subjects were classified as belonging to
the no defect group and the session was deemed complete. In contrast, if 3He gas was
heterogeneously distributed throughout the lung and/or there were visually obvious
ventilation defects, the subject was classified as having ventilation defect(s). Upon
qualitative inspection, subjects with visually obvious ventilation defects were instructed to
perform DI. They were instructed to sit up whilst remaining on the scanner bed and take
four deep breaths in through their nose and out through their mouth. Imaging was
performed immediately following DI. If defects persisted following DI, the subject inhaled
four puffs (400 µg) of salbutamol while seated upright, and 25 minutes later imaging was
performed on a final occasion.

2.2.5

Image Analysis

Based on visual inspection at the scanner, subjects were classified as: 1) no defects—those
subjects without visually obvious ventilation defects, 2) subjects with ventilation defects
that responded to DI or salbutamol, and, 3) subjects with ventilation defects that did not
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respond to DI or salbutamol. 3He MRI semi-automated segmentation was performed, as
previously described,31 to generate ventilation defect percent (VDP) – the ventilation defect
volume (VDV) normalized to 1H MRI thoracic cavity volume (TCV). Briefly, 3He static
ventilation images were segmented using a k-means approach that classified voxel intensity
values into five clusters ranging from signal void (cluster 1[C1] or VDV) and hypo-intense
(cluster 2 [C2]) to hyper-intense signal (cluster 5 [C5]), therefore, generating a gas
distribution cluster-map. For delineation of the ventilation defect boundaries, a seeded
region-growing algorithm was used to segment the 1H MRI thoracic cavity for registration
to the cluster-map, as previously described.31
Ventilation heterogeneity was estimated according to a previously described method27
using the coefficient of variation (COV). A local COV, rather than a global COV, was
generated27 to ensure local ventilation heterogeneity was not ignored. Briefly, for each
voxel in a region of interest (ROI) a local ventilation heterogeneity value was calculated
by computing the COV of the signal intensity in a 5×5 voxel neighbourhood which
corresponded to a 244 mm2 area centred on that voxel. To ensure that the 5×5 voxel
neighbourhood did not include voxels that were outside of the lungs, a signal-to-noise
threshold of five was established. For example, any voxels that were in a neighbourhood
with an overall signal-to-noise ratio of less than five were excluded from the COV
computation. COV of the lung was calculated for each subject as in Equation 2-1:
Equation 2-1
2

√∑𝑖=𝑁 𝜎𝑖
𝑖=1 𝑁
𝐶𝑂𝑉 =
∑𝑖=𝑁
𝑖=1 𝜇𝑖
𝑁

where 𝜎𝑖 is the standard deviation of the signal intensity of the 5×5 voxel neighbourhood,
𝜇𝑖 is the mean signal intensity of the 5×5 voxel neighbourhood, and 𝑁 is the number of
ventilation ROIs in the lung. The ventilated lung ROI was defined as gas distribution
cluster-map clusters C2-C5.
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We also measured regional differences in VDP for the centre nine 15mm thick slices using
several different measurements as shown in Figure 2-1. The VDP gradient in the posterioranterior direction was defined as the slope of the line that described the change in VDP
from the most posterior slice in centimeters over the nine central slices (with a slice
thickness of 15mm each). The centre nine slices were used to ensure the static ventilation
slices across subjects had adequate signal-to-noise ratios (i.e. SNR>10) for VDP
calculations as well as to maintain an equal number of slices among all subjects. To
calculate the gradient in the superior-inferior (SI) direction, the centre nine coronal slices
were reformatted into 15mm axial slices. The VDP SI gradient was defined as the slope
of the line that described the change in VDP over the axial superior-inferior slices. In
addition, the VDP difference between the most posterior and anterior slices (VDP ∆PA)
was calculated as was the VDP difference between the most superior and inferior slices
(VDP ∆SI) of the central nine slices. The ventilation defect percent located on the
peripheral boundary of the lung (relative peripheral VDP) was estimated as the ratio of the
ventilation defect volume for the outermost 10 voxels of each slice (not including boundary
voxels defined as SNR <2) to the 1H MRI thoracic cavity volume. The proportion of
ventilation defects located on the peripheral boundary was quantified as the ratio of
peripheral lung VDV to whole lung VDV (i.e. VDVPer/VDVWL).

Figure 2-1 Schematic for regional evaluation of 3He MRI ventilation-defect percent (VDP)
The central coronal static ventilation image slices (9 × 15 mm) were evaluated. The lung
was also divided into 15-mm slices in the axial direction. The VDP ΔSI was defined as the
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difference between the most superior slice and the most inferior slice. The VDP ΔPA was
defined as the difference between the most posterior slice and the most anterior slice.

2.2.6

Statistical Analysis

Analysis of variance (ANOVA), multivariate regression and post-hoc analysis using the
Holm Bonferroni correction 32 were performed using SPSS 20.0 (IBM, Armonk, NY).
Paired sample t-tests were performed to determine the differences in VDP ΔPA and VDP
ΔSI using SPSS 20.0. We used the NHANES III reference standards33 for percent
predicted values. Univariate relationships were determined using regression (r2) and
Pearson correlation coefficients (r) for all subjects with GraphPad Prism V.6.00 (GraphPad
Software Inc, La Jolla, CA). Stepwise multivariate regression was used to identify the
predictors of VDP.

The variables considered for modelling were chosen based on

statistically significant univariate relationships with VDP.

Results were considered

statistically significant when the probability of making a Type I error was less than 5%
(p<0.05).

2.3
2.3.1

Results
Subject Data

As summarized in Table 2-1 (and a detailed subject listing in Table 2-2), 52 never-smokers
(71±6 years) completed all measurements during a single visit. In total there were 13/52
(25%) subjects without 3He MRI ventilation defects and 39/52 (75%) with ventilation
defects. Of those subjects with ventilation defects, six (6/39, 15%) showed a VDP response
(i.e. visually obvious and quantitative decrease in VDP) to DI (n=4) or salbutamol (n=2).
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Table 2-1 Baseline subject demographic and other measurements.

No Defects
(n=13)
Demographics
Age yrs (±SD)
Male n
BMI kg/m2 (±SD)
Occupational Exposures
Organic Dust n
Inorganic Dust n
Irritant Gases n
Pulmonary Function
FEV1 %pred (±SD)
FVC %pred (±SD)
FEV1/FVC % (±SD)
FRC %pred (±SD)
IC %pred (±SD)
RV/TLC % (±SD)
DLCO %pred (±SD)
Raw %pred (±SD)
CPET
VO2max %pred (±SD)
RER (±SD)
Power %pred (±SD)
VEmax %pred (±SD)
Post Exercise Dyspnea (±SD)
Post Exercise Leg discomfort
(±SD)
Time to VO2max s (±SD)
MRI
VDP % (±SD)
3

He COV (±SD)

VDP ∆PA % (±SD)
PA VDP Gradient %/cm (±SD)
VDP ∆SI % (±SD)
SI VDP Gradient %/cm (±SD)
Relative Peripheral VDP % (±SD)
VDVPer/VDVWL % (±SD)

Ventilation Defects
(n = 39)
No
Imaging
Imaging
Response
Response
(n=6)
(n=33)

Significance
of Difference
(p-value)*
ND-IR-NIR

71 (8)
6
26 (4)

72 (4)
3
27 (3)

71 (6)
12
26 (3)

3
0
0

1
2
0

4
2
1

113 (11)
107 (15)
80 (5)
105 (24)
112 (20)
41 (7)
96 (7)
71 (25)

93 (29)
96 (26)
71 (4) **
114 (15)
94 (26)
43 (15)
75 (13)
100 (82)

106 (20)
103 (17)
77 (5)
107 (17)
106 (19)
41 (7)
92 (19)
72 (31)

0.09
0.40
0.004
0.60
0.20
0.50
0.07
0.20

83 (18)
1.17 (0.15)
126 (38)
50 (17)
2.1 (1.4)

86 (11)
1.19 (0.11)
118 (9)
54 (19)
2.0 (1.0)

87 (19)
1.21 (0.12)
121 (31)
51 (16)
2.3 (1.6)

0.80
0.90
0.70
0.90
0.80

11.5 (2.4)

11.0 (3.7)

10.9 (3.3)

0.90

478 (89)

532 (111)

494 (82)

0.50

1.6 (0.7)

5.8 (3.8) **
0.24 (0.04)
**
11.2 (13.5)
**
-0.69 (0.93)
**
-3.4 (9.6)
0.26 (0.72)
3.3 (1.8) **
68 (13)

2.6 (1.2)

<0.001

0.21 (0.02)

0.001

1.5 (4.0)

0.001

-0.05 (0.21)

<0.001

-2.8 (2.3)
0.21 (0.17)
1.9 (0.8)
78 (10)

0.67
0.67
0.001
0.05

0.19 (0.01)
0.7 (2.7)
-0.02
(0.17)
-1.9 (1.3)
0.14 (0.1)
1.3 (0.6)
80 (10)
68

0.90
0.90

Imaging response refers to subjects with change in VDP after DI or salbutamol. No
Imaging Response refers to subjects with no VDP change after salbutamol; IR=imaging
response; NIR=imaging non-responders; NR=non responders. *Significance of difference
(p<.05) determined using multivariate analysis of variance. **Post-hoc analysis conducted
using Holm-Bonferroni demonstrating significant difference between groups.
SD=standard deviation; BMI=body mass index; FEV1=forced expiratory in 1 s;
FVC=forced vital capacity; FRC=functional residual capacity; IC=inspiratory capacity;
TLC=total lung capacity; DLCO=diffusing capacity of carbon monoxide; Raw=airways
resistance; RV=residual volume; VO2max=maximal oxygen capacity; RER=respiratory
exchange ratio at VO2max; VEmax=minute ventilation at VO2max;VCO2=volume of carbon
dioxide at VO2max; Time to VO2max is time taken to reach VO2max during CPET;
VDP=ventilation defect percent; 3He COV=ventilation coefficient of variation; PA
∆VDP=change in posterior and anterior VDP; SI ∆VDP=change in superior and inferior
VDP; VDVPer=ventilation defect volume in the periphery of the lung; VDVWL=ventilation
defect volume in the whole lung.
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Table 2-2 Subject listing and demographics, pulmonary function tests, cardiopulmonary exercise testing, and imaging measurements
RER

Power
%pred

VE
%pred

Post
Dyspnea

Post
Exertion

VDP
%

3
He
COV

130
81

VO2
max
%pred
103
86

1.22
1.39

159
123

64
56

3
4

11
12

1.37
2.39

0.200
0.206

52

181

66

1.14

109

38

2

11

9.17

0.274

116
153
90

84
62
99

87
113
67

1.27
1.25
1.25

96
136
85

56
83
43

3
0.5
2

13
7
11

4.70
1.34
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F
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Figure 2-2 3He MRI for four representative subjects
3
He MRI ventilation (in blue) co-registered with anatomical 1H MRI (grey-scale) of the
centre coronal slice. Subject 64 (S64) is a 69 year old male: FEV1=130%,
FEV1/FVC=78%, slice number shown: 7. Subject 19 (S19) is a 67 year old male:
FEV1=131%, FEV1/FVC=75%, slice number shown: 8. Subject 20 (S20) is a 78 year old
male: FEV1=101%, FEV1/FVC=68%, slice number shown: 9. Subject 15 (S15) is a 65
year old female: FEV1=91%, FEV1/FVC=81%, slice number shown: 8. Yellow arrows
identify the position of ventilation defects. DI = Deep Inspiration.
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Figure 2-2 shows 3He MRI coronal slices at baseline, post-DI, and post-salbutamol for
four representative subjects. For the subject shown without ventilation defects, there was
homogeneous signal intensity over the entire lung with no obvious ventilation defects in
the centre MR slice or any of the anterior to posterior slices. For two representative
subjects that showed an imaging response to DI or salbutamol, there were ventilation
defects peripherally located in the central and posterior slices that resolved (arrows) in
response to DI or bronchodilation. For the representative subject with ventilation defects
that did not appear to respond to DI or salbutamol, a number of small peripheral ventilation
defects (arrows) remained spatially persistent post-DI and 25 minutes after salbutamol
inhalation.
For the three comparator groups (Table 2-1) there was no significant difference for age,
sex or BMI. However, there was a significant difference for FEV1/FVC (p=0.004), VDP,
3

He COV, VDP ∆PA and PA gradient (p<0.001) as well as relative peripheral VDP

(p=0.001). There was no significant difference for any CPET or other pulmonary function
measurements for the three subgroups.

Post-hoc analysis showed that the imaging

responder group had significantly lower FEV1/FVC and significantly higher VDP, 3He
COV, PA ∆VDP, and relative peripheral VDP than the no defect and no imaging response
groups. Figure 2-3 shows scatter plots for VDP, relative peripheral VDP, VDP ∆PA, VDP
∆SI, PA VDP gradient, SI VDP gradient and 3He COV.
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Figure 2-3 Scatter plots of MRI metrics
Plots showing all MRI metrics for three subgroups (non-imaging responders, imaging
responders, and no defects). A) VDP and relative peripheral VDP, B) VDP ∆PA and VDP
∆SI, C) PA and SI gradients, and, D) 3He COV. Error bars are the standard deviation of
the mean.
Table 2-2 shows that 13 subjects reported significant exposure, 10 of whom (77%) had
ventilation defects. Of those 10 subjects, three showed an imaging response to DI or
salbutamol. Table 2-2 also shows that eight never-smokers had spirometry evidence of
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airway obstruction34 (GOLD Unclassified (U) (n=2), GOLD 1 (n=4), GOLD 2 (n=2)). Five
of these eight subjects reported second-hand smoke or occupational exposures and two
subjects responded to salbutamol. In addition, 10 never-smokers had 0.70≤ FEV1/FVC
≤0.73, where the 0.73 threshold was used to compensate for the variability in FEV1 and
FVC.35,36 The eight never-smokers with spirometry evidence of COPD had significantly
greater VDP (5.5±3.1%, p<0.001) than the never smokers with (VDP=2.5±1.2%) or
without (VDP=1.6±0.7%) ventilation defects. When the subjects with spirometry evidence
of COPD (n=8) were removed in a sub analysis, only VDP remained significantly different
across all three subgroups (p=0.03). Post-hoc analysis showed that the no imaging
response group had greater baseline VDP than the no defect group, but was not
significantly different from the imaging response group.

2.3.2

Pre- and Post-DI/Salbutamol Analysis

Table 2-3 shows a subject listing for pre- and post-salbutamol FEV1, VDP, and 3He COV
for all subjects administered salbutamol (n=35). Three subgroups were identified for those
subjects administered salbutamol: imaging-responders, FEV1-responders, and nonresponders. Twenty-eight of 35 subjects did not show an imaging response or an FEV1
response to salbutamol.

There were five subjects who responded to salbutamol

(ΔFEV1>200ml), but did not have an imaging (VDP or cluster 1) response to salbutamol.
In addition, for these five subjects, there was no significant change in any of ventilation
clusters 2-5 or any combination of ventilation clusters (i.e. C1+C2) post-salbutamol. It is
worth noting that one of the five FEV1-responders reported 30 years of occupational
exposure working in the steel mill industry (S63) while two were lifelong farmers (S25 and
S59). Finally, for those subjects administered salbutamol, there were no relationships for
the change in FEV1 post-salbutamol with change in VDP (r2=0.04, p=0.50) or change in
3

He COV (r2=0.08, p=0.10).
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Table 2-3 Subject Listing for FEV1, VDP and 3He COV for all subjects administered
salbutamol (n=35)
Subject

Pre-Salbutamol
Age
(yrs)

001
002#
003
004
005
006
007
012
015
016
017*
018
020*
021
022#
023
025#
031
032
033
036
041
044
045
046
047
052
054
056
057
059#
060
061
063#
065
Imaging Responders*
Mean (SD) n=2
FEV1 Responders#
Mean (SD) n=5
Non-responders
Mean (SD) n=28

74
68
76
69
77
66
65
71
65
67
69
61
78
74
81
68
66
71
69
80
78
71
65
77
73
63
68
65
61
78
79
77
74
67
69
74
(6)
74
(7)
71
(5)

Post-Salbutamol
3

FEV1
(L)

FEV1
(%pred)

VDP
(%)

He
COV

FEV1
(L)

FEV1
%pred

VDP
(%)

3
He
COV

1.68
2.52
1.30
3.33
3.36
3.30
2.01
2.78
2.38
3.80
1.24
3.06
2.76
2.32
2.18
1.96
3.54
3.14
2.75
2.86
2.88
2.19
2.24
2.44
2.06
2.52
2.55
2.42
3.12
2.23
2.53
2.36
1.53
2.46
2.57
2.0
(1.1)
2.7
(0.5)
2.5
(0.6)

89
101
70
94
133
88
86
84
91
120
59
111
101
82
123
93
95
103
106
89
106
89
95
116
102
114
122
102
108
114
116
120
72
72
109
80
(30)
102
(20)
100
(16)

1.35
2.34
9.17
4.49
1.32
2.87
1.43
3.76
2.61
2.22
10.6
5.26
7.49
5.65
2.92
1.57
3.01
2.17
1.79
4.42
2.73
3.49
1.79
1.46
2.35
2.61
1.83
2.24
2.10
1.58
2.83
1.26
3.15
4.00
1.59
9.0
(2.2)
3.1
(0.5)
2.8
(1.7)

0.20
0.21
0.27
0.24
0.20
0.23
0.20
0.23
0.20
0.21
0.29
0.22
0.24
0.26
0.22
0.22
0.23
0.22
0.22
0.22
0.21
0.22
0.19
0.19
0.22
0.20
0.20
0.19
0.21
0.21
0.22
0.20
0.23
0.23
0.19
0.27
(0.04)
0.22
(0.01)
0.21
(0.02)

1.70
2.72
1.34
3.31
3.06
3.29
2.08
2.66
2.52
3.88
1.35
3.14
3.02
2.41
2.43
2.09
3.78
3.15
2.82
2.76
3.06
2.31
2.14
2.31
1.90
2.53
2.63
2.49
3.19
2.27
2.73
2.37
1.59
2.94
2.70
2.2
(1.2)
3.0
(0.5)
2.5
(0.6)

91
109
72
94
122
88
89
81
96
123
64
114
110
85
137
99
102
103
109
86
112
94
90
109
94
116
125
105
110
116
125
121
75
86
114
87
(33)
112
(20)
101
(15)

0.84
1.65
8.15
4.02
1.55
2.73
2.11
2.87
2.29
1.65
7.91
5.62
3.47
3.25
5.37
1.25
2.33
1.93
1.56
6.13
1.92
3.38
1.84
2.02
2.14
3.09
1.58
3.33
1.90
1.29
2.90
1.55
5.21
3.72
1.79
5.7
(3.0)
3.3
(1.3)
2.7
(1.7)

0.20
0.20
0.28
0.24
0.21
0.22
0.22
0.23
0.21
0.22
0.27
0.24
0.24
0.25
0.23
0.21
0.22
0.22
0.21
0.23
0.20
0.22
0.22
0.21
0.22
0.20
0.19
0.20
0.21
0.21
0.22
0.20
0.24
0.22
0.20
0.26
(0.02)
0.22
(0.01)
0.22
(0.02)

Δ
FEV1
(L)
0.02
0.20
0.04
-0.02
-0.30
-0.01
0.07
-0.12
0.14
0.08
0.11
0.08
0.26
0.09
0.25
0.13
0.24
0.01
0.07
-0.10
0.18
0.12
-0.10
-0.13
-0.16
0.01
0.08
0.07
0.07
0.04
0.20
0.01
0.06
0.48
0.13
0.2
(0.1)
0.3
(0.1)
0.00
(0.1)

Δ
FEV1
%pred
2
8
2
0
-11
0
3
-3
5
3
5
3
9
3
14
6
7
0
3
-3
6
5
-5
-7
-8
2
3
3
2
2
9
1
3
14
5
7.0
(2.8)
10.0
(3.8)
1.0
(4.4)

Δ
VDP
%
-0.51
-0.69
-1.02
-0.47
0.23
-0.14
0.68
-0.90
-0.33
-0.57
-2.70
0.36
-4.02
-2.40
2.45
-0.32
-0.68
-0.24
-0.24
1.71
-0.81
-0.11
0.05
0.55
-0.21
0.48
-0.25
1.08
-0.20
-0.28
0.07
0.29
2.03
-0.28
0.20
-3.4
(0.9)
0.2
(1.3)
-0.04
(0.8)

Table 2-4 shows VDP and 3He COV measurements for all three time points for imaging
responders (DI or salbutamol responders).

There were no statistically significant

differences in 3He COV or VDP across time points for the imaging responders.
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Table 2-4 VDP and 3He COV measurements for imaging responders
Baseline
Post-DI
Post-Salbutamol
Imaging Responders (n=6)
VDP % (±SD)
5.8 (3.8)
4.7 (2.6)
5.7 (3.1)
3
He COV (±SD)
0.24 (0.04)
0.24 (0.04)
0.25 (0.02)
DI Responders (n=4)
VDP % (±SD)
4.2 (3.5)
3.5 (2.3)
-3
He COV (±SD)
0.23 (0.04)
0.23 (0.04)
-Salbutamol-Responders (n=2)
VDP % (±SD)
9.0 (2.2)
7.0 (1.0)
5.7 (3.1)
3
He COV (±SD)
0.26 (0.04)
0.25 (0.03)
0.25 (0.02)

2.3.3

Relationships between Imaging and other Measurements

Table 2-5 shows the results of a forward stepwise multivariate regression model using 3He
VDP as the dependent variable and all significant pulmonary function test measurements
(obtained from the univariate analysis) as the independent variables. FEV1%pred, IC%pred,
and Raw%pred were shown to predict 45% of the variability in VDP (p=0.001), with
FEV1%pred making the greatest contribution. The univariate relationships are shown in
Figure 2-4 including FEV1%pred (r2=0.29, p<0.0001), Raw%pred (r2=0.29, p<0.0001), and
IC%pred (r2=0.17, p=0.003). There were no statistically significant relationships for VDP
with CPET, dyspnea, or occupational exposure measurements. It is important to note that
three subjects had VDP ≥ 3SD of the mean and when these data were removed from the
regression analysis, FEV1%pred (r2=0.13, p=0.009) and IC%pred (r2=0.17, p=0.003) was
significantly related to VDP, and Raw%pred was not.
Table 2-5 Univariate and Multivariate relationships for
function measurements
Parameters
Univariate Relationship VDP
r2 (p value)
FEV1 %pred
0.29 (<0.001)
Raw %pred
0.29 (<0.001)
IC %pred
0.17 (0.003)
FEV1/FVC %
0.17 (0.002)
FVC %pred
0.24 (<0.002)
RV/TLC %
0.15 (0.005)
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3

He MRI VDP with pulmonary

Multivariate Model VDP
β, r2, ∆r2 (p-value)
-0.541, 0.292, 0.292 (<0.001)
0.359, 0.391, 0.099 (<0.001)
-0.265, 0.449, 0.058 (<0.001)
-0.147, 0.449, 0 (0.23)
0.114, 0.449, 0 (0.68)
0.105, 0.449, 0 (0.44)

Figure 2-4 Univariate Relationships for 3He MRI VDP
Univariate correlations for VDP with: A) FEV1 %pred for all subjects (r2=0.29, r=-0.54,
p<0.0001), B) Raw %pred for all subjects (r2=0.29, r=0.54, p<0.0001), and, C) IC %pred for
all subjects (r2=0.17, r=-0.41, p=0.003). Grey circles show the subjects with VDP >3SD of
78

the mean. Grey regression line shows the alternate regression line that resulted from when
these subjects were excluded.

2.4

Discussion

To better understand the determinants and physiological consequences of ventilation
defects in older never-smokers, we evaluated pulmonary function and CPET
measurements, as well as occupational/second-hand smoke exposure in 52 older adults.
We made a number of key observations including: 1) three quarters of older never-smokers
had ventilation defects, the majority of whom showed no VDP response to either DI or
salbutamol, 2) ventilation heterogeneity and VDP were significantly greater, and
FEV1/FVC was significantly lower (p<0.05) for subjects with ventilation-defects
responsive to DI/salbutamol compared to subjects without ventilation defects and subjects
with ventilation-defects with no response to DI/salbutamol and, 3) in a multivariate model,
FEV1, IC and Raw explained nearly 50% of the variability in 3He VDP in these older neversmokers.

2.4.1

Ventilation Abnormalities in Older Never-Smokers

In the 39 subjects with visually obvious ventilation defects, VDP was modest and lower
than previously reported in COPD and asthma subjects; furthermore, only four subjects
showed a change in VDP in response to DI. This is consistent with previous findings that
showed that the bronchodilatory effects of DI decrease with age,37 which may explain the
low number of DI responders in this study. Similar to previous observations in COPD38
and asthma,26,28 two subjects showed an imaging response to salbutamol and this supports
previous findings that reversible airflow limitation may be underappreciated in the elderly.
Unexpectedly, the majority of older never-smokers with visually obvious ventilation
defects (n=33/39, 85%) did not respond to DI or salbutamol. This is consistent with the
notion that in older never-smokers, small ventilation defects are related to irreversible
airway narrowing or collapse, loss of elastic recoil and/or small peripheral regions that are
slow filling.
The majority of defects were observed along the periphery of the lung suggesting that
terminal airway closure or narrowing may be a “normal” age-related pulmonary finding.
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Relative peripheral VDP, 3He COV, VDP ∆PA, and VDP PA gradient were significantly
greater in the imaging responders compared to the non-responder and no defect groups.
Together these findings suggest that subjects who responded to DI or salbutamol also had
greater ventilation heterogeneity (or patchiness) and greater posterior/peripheral
ventilation defects. The difference in ventilation heterogeneity between groups may reflect
differences in lung filling related to airway lumen morphology, but this is yet to be
determined. Other potential mechanisms for ventilation heterogeneity have been suggested
including the loss of parenchymal tethering forces due to alveolar collapse that alters
airway diameters, differences in regional lung expansion due to diaphragm and ribcage
motions, or gravity-dependent differences in lung expansion contributing to airway
constriction in the gravity-dependent regions.39 Nevertheless, in these older never-smokers
there appears to be a small, yet irreversible VDP component. Finally, as might be expected
based on the BOLD study,22 eight subjects showed spirometry evidence of COPD and
another ten subjects exhibited 0.70<FEV1/FVC≤0.73 (0.73 accounts for FEV1 and FVC
variability of 2-3%).35,36 Therefore, here, the proportion of subjects with undiagnosed
airflow limitation was 35%, which is in agreement with the results of the BOLD study.22
It is interesting to note that when the eight subjects with spirometry evidence of COPD
were removed from the analysis, FEV1/FVC was no longer different across the three subgroups, however, VDP remained different. For five subjects with an FEV1 response to
salbutamol > 200ml, there were no significant changes in VDP, 3He COV or any of the
ventilation clusters (C2-C5) post-salbutamol. The discrepancy between FEV1 response
and 3He MRI response may have been due to the effort-dependence of spirometry. It is
also important to note that all ventilation defects were peripherally located, near the distal
airways, and this may also explain why salbutamol did not influence the size or magnitude
of these ventilation defects.

2.4.2

Relationships: Ventilation Defects with Exercise Capacity and
Dyspnea

In this study, the range of dyspnea scores and magnitude of ventilation defects observed
were small as compared with recent findings in COPD and asthmatic subjects.24,26,28,38 For
these reasons, we were not surprised that there were no differences in CPET or dyspnea
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measurements between subjects with and without ventilation defects. Further supporting
this finding, O’Donnell and colleagues have shown that it is possible to have substantial
ventilatory impairment during exercise without a corresponding effect on dyspnea.20 This
is consistent with the notion that in healthy subjects, cardiovascular, and not respiratory
factors provide the dominant contributions to exercise limitation.40,41 Furthermore, unlike
previous work,7 there were no relationships between dyspnea and other pulmonary function
or CPET measurements which could be due to the limited range of dyspnea scores reported.
Subjects with ventilation defects had normal lung function and exercise capacity
measurements for their age. 6,7,42

2.4.3

Relationships: Ventilation Defects with Pulmonary Function and
Volumes

There were significant but weak univariate relationships for VDP with FEV1%pred, IC%pred
and Raw%pred, although the relationship between VDP and Raw%pred was dominated by
three subjects with relatively large VDP values (S3, S17, and S21). S21 had occupational
and environmental exposures, and both S3 and S17 had spirometry evidence of GOLD II
COPD. In a multivariate regression model, IC%pred, Raw%pred, and FEV1%pred all provided
significant contributions to VDP, with FEV1%pred being the strongest predictor. The
negative correlation of IC%pred with VDP is concordant with previous results in COPD exsmokers which showed that abnormal IC is a marker of expiratory flow-limitation and a
predictor of dynamic hyperinflation during exercise.43

An increase in dynamic

hyperinflation results in an increased elastic load on the inspiratory muscles, thus
increasing the work and cost of breathing. This mechanical constraint can predispose
individuals to fatigue and it has been shown that dynamic hyperinflation contributes to
perceived exertional dyspnea in subjects with COPD.43-45 It is also interesting to note that
resting IC can predict the peak symptom-limited VO2 in patients with expiratory flowlimitation at rest.45

2.4.4

Limitations

We recognize a number of limitations that restrict the general applicability of our results.
First, subjects were classified by viewing the grayscale images while the patients were still
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in the scanner. Offline, once the ventilation images were co-registered to the anatomical
1

H images, in two cases, previously classified ventilation defects could be directly related

to anatomical bony structures and were unlikely to be ventilation abnormalities. As a
result, two subjects who were classified at the scanner as having ventilation defects, did
not appear to have these once a full analysis was completed, although both completed DI
and salbutamol inhalation. One subject had ventilation defects that responded to DI (but
not salbutamol) whereas the other subject had no ventilation defects and did not respond
to DI or salbutamol. We did not remove these subjects from the analysis and their inclusion
did not alter the final overall results. It should also be noted that since all subjects were
imaged approximately 30 minutes after completion of CPET, ventilation defects and
ventilation heterogeneity may have been influenced by exercise. Previous studies have
shown that during exercise athletes experience ventilation-perfusion mismatch and
diffusion limitation.46

Other studies have evaluated the progression of ventilation-

perfusion mismatch after exercise and showed that some subjects don’t recover fully from
ventilation-perfusion mismatch until 20 minutes post-exercise.47 Because of the time delay
between imaging and CPET and the fact that in this study, VDP did not correlate with any
CPET measurements, it is unlikely that prior exercise influenced the presence or absence
of 3He MRI ventilation defects.

2.4.5

Conclusions

In summary, we evaluated hyperpolarized 3He MRI ventilation defects—a surrogate
measurement of airway function—in the first, large imaging study of healthy older neversmokers with no history of chronic heart or lung disease. While a minority of subjects
reported occupational exposures, most subjects had visually obvious ventilation defects
that did not change after DI or salbutamol administration suggesting that terminal airway
closure or narrowing may be a normal age-related lung finding. While there were no
differences in CPET or conventional pulmonary function measurements between subjects
with and without ventilation defects, FEV1%pred in combination with IC%pred and Raw%pred
predicted VDP in a multivariate regression model. Taken together, these findings provide
a better understanding of the nature of ventilation defects in healthy older never-smokers.
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CHAPTER 3

3

ULTRA-SHORT
ECHO
TIME
PULMONARY
MAGNETIC RESONANCE IMAGING: EVALUATION
AND REPRODUCIBILITY IN COPD SUBJECTS WITH
AND WITHOUT BRONCHIECTASIS

To better understand the potential for ultra-short echo time MRI to provide quantitative
COPD endpoints, we evaluated the reproducibility and consequences of signal-intensity in
COPD subjects with and without bronchiectasis. We compared UTE MR measurements
with CT measurements of radiodensity and pulmonary function test measurements.
The contents of this chapter were previously published in the Journal of Magnetic
Resonance Imaging: W Ma, K Sheikh, S Svenningsen, D Pike, F Guo, R Etemad-Rezai, J
Leipsic, HO Coxson, DG McCormack, and G Parraga. J Magn Reson Imaging 2015;
41(5):1465-1474. Permission to reproduce this article was granted by John Wiley & Sons
and is provided in Appendix A.

3.1

Introduction

Computed tomography (CT) provides the main anatomical/morphological measurements
for research and clinical investigations in patients with chronic obstructive pulmonary
disease (COPD). Large multi-centre studies such as ECLIPSE,1 COPDGene2 and MESA3
have highlighted the quantitative information that CT provides including structure-function
phenotypes related to airway (including airway thickening and bronchiectasis) and
parenchymal abnormalities that are regionally and heterogeneously distributed in
obstructive lung disease.4 Cumulative radiation exposure related to thoracic CT imaging
remains a concern5 and limits CT use in serial and longitudinal studies.
MRI using short and ultra-short echo time (UTE) acquisition methods, was first proposed
as a way to address the inherent challenges of pulmonary imaging stemming from low
tissue and proton density.6 UTE MRI combines fast radiofrequency (RF) excitation pulses
and efficient k-space sampling trajectories to minimize MR signal decay and motion
artifacts.6 Pulmonary UTE methods have been used to estimate pulmonary emphysema in
COPD patients7 lobar fissures and airways in pulmonary fibrosis8 as well as inflammation
and peribronchial abnormalities in animal models of asthma.9
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Before UTE measurements can be used in longitudinal clinical studies of respiratory
disease or for monitoring treatment effects, it is critical to understand the inherent
variability that can be attributed to image acquisition methods, including those related to
the scanner (e.g. field strength and coils used) and subject compliance (e.g. breath-hold,
motion, and position). We hypothesized that rapid, single breath-hold UTE MRI could be
optimized to reproducibly quantify abnormalities in COPD and that both low density
parenchymal abnormalities and high density abnormalities such as airway thickening and
mucous plugs could be quantified.

Therefore, our objective was to evaluate rapid

pulmonary MRI using UTE methods with comparison to quantitative CT scan
measurements and pulmonary function tests of subjects with COPD.

3.2
3.2.1

Materials and Methods
Study Logistics

All subjects and healthy volunteers provided written informed consent to a protocol
approved by a local research ethics board and Health Canada; the study was compliant with
the Personal Information Protection and Electronic Documents Act (PIPEDA, Canada).
MRI was performed 10 minutes after completion of spirometry and plethysmography that
were performed using a MedGraphics Elite Series plethysmograph (MedGraphics, St. Paul,
Minnesota, USA). For seven subjects with COPD, (n=3 with emphysema; n=4 with
emphysema and bronchiectasis) there was a three-week follow-up visit to determine UTE
signal intensity and 3He apparent diffusion coefficients (ADC) reproducibility. 3He ADC
reproducibility analysis was conducted as an internal control of reproducibility
comparisons with the 1H UTE measurements.
CT evidence of bronchiectasis was established by an experienced chest radiologist with
>20 years experience (RER) and defined by an enlarged bronchial diameter, the failure of
larger airways to taper while progressing to the lung periphery, bronchial wall thickening,
mucous in the dilated airways, and tree-in-bud nodularity.10 All subjects had a clinical
diagnosis of COPD with CT evidence of emphysema or both emphysema and
bronchiectasis and were categorized according to the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) grades.11
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3.2.2

Pulse Sequence

A research prototype two-dimensional pulse sequence (Figure 3-1) with interleaved halfpulse excitation and 2D radial k-space trajectories was used.6 There was no dephasing lobe
after the slice-select gradient and two half-sinc excitations were required per slice to
remove inter-slice cross-talk.

To decrease acquisition time, we adapted a compressed

sensing algorithm that was previously described.12

Figure 3-1 Pulse sequence diagram for 2D UTE with interleaved half-pulse excitation and
2D radial k-space trajectories
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3.2.3

Image Acquisition

MRI was performed on a whole body 3T MR750 (General Electric Health Care [GEHC],
Milwaukee, Wisconsin). To ensure that the same location was imaged at baseline and
follow-up, we used the same fiducial landmarks and values for each of the three plane
localizer scans performed. Briefly, using the sternum and spinal cord fiducials in the
anterior-posterior direction, the scan space was divided into slices with slice
thickness=15mm. In this manner, the same centre slice could be imaged which was
typically the fifth coronal slice from the posterior direction and the slice that allowed for
visualization of the carina. Centre slice 1H UTE MRI was obtained in the coronal plane
using a 32-channel torso coil and the single channel body coil for comparison (GEHC) (13s
acquisition time, repetition time (TR) /echo time (TE)/flip angle=13.0ms/0.05ms/10°,
field-of-view (FOV)=40×40cm, matrix 256×511, number of excitations (NEX)=2, 15mm
slice thickness) at a lung volume of functional residual capacity (FRC)+1L.

For

comparison, coronal 1H MRI was performed with a 32-channel torso coil using a fastspoiled, gradient-recalled echo (FGRE) sequence (16s acquisition time, TR/TE/flip
angle=4.7ms/1.2ms/30°, FOV=40×40cm, matrix 256×128, NEX=1, 14 slices, 15mm slice
thickness). Diffusion-weighted hyperpolarized 3He MRI was performed using a fast
gradient-echo sequence with centric k-space sampling as previously described.13

In

healthy volunteers, UTE MRI was acquired in the coronal plane at four different lung
volumes (23s acquisition time, TR/TE/flip angle=13.0ms/0.05ms/10°, FOV=40×40cm,
matrix 256×439, NEX=4, 15mm slice thickness): full expiration (FE), FRC, FRC+1L, and
full inhalation (FI). Thoracic CT was acquired in all COPD patients at FRC+1L, within 30
minutes of MRI, using a 64-slice Lightspeed VCT scanner (GEHC) using a detector
configuration of 64×0.625mm, 120kVp, 100 effective mA, tube rotation time of 500ms,
and a pitch of 1.0.

3.2.4

Image Analysis

We adapted definitions of the normalized contrast-to-noise ratio (𝐶𝑅 ) and the apparent
signal-to-noise ratio (𝑆𝑅 ) as previously described8 where 𝑆𝐼𝑙𝑢𝑛𝑔 is the mean signal intensity
of the lung, 𝑆𝐼𝑎𝑖𝑟 is the signal intensity of air outside of the subject, 𝑆𝐼𝑙𝑖𝑣𝑒𝑟 is the mean
signal intensity of the liver, 𝑆𝐼𝑣𝑒𝑠𝑠𝑒𝑙 is the mean signal intensity of the aorta:
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Equation 3-1
𝐶𝑅 =

𝑆𝐼𝑙𝑢𝑛𝑔 −𝑆𝐼𝑎𝑖𝑟
𝑆𝐼𝑣𝑒𝑠𝑠𝑒𝑙

.

Equation 3-2
𝑆𝑅 =
Absolute

1

𝑆𝐼𝑙𝑢𝑛𝑔
𝑆𝐼𝑎𝑖𝑟

.

H signal intensity was normalized to the liver in the same images

(𝑆𝐼 ⁄𝑆𝐼𝑙𝑖𝑣𝑒𝑟 × 100%) to account for potential inter-scan variability in RF amplification and
coil positioning. The 1H SI coefficient of variation (COV) was calculated as the ratio of
the standard deviation of the lung parenchyma signal intensity to the mean of the lung
parenchyma signal intensity. The 15th percentile of the signal intensity histogram (SI15)
was compared with CT threshold measurements.
For healthy volunteers, manually segmented FRC+1L images were registered to the other
three lung volumes as previously described.14

3

He MRI apparent diffusion coefficient

(ADC) maps were generated using software, as previously described.13 For CT image
analysis, Pulmonary Workstation 2.0 (VIDA Diagnostics Inc., Iowa City, IA) was used to
quantify tissue attenuation in Hounsfield units (HU) based on the relative area of the
density histogram≤-950 HU (RA950), 15th percentile of the density histogram (HU15), mean
radio-density, wall area percent (WA%), and lumen area (LA) for the segmental and
subsegmental airways.15 Signal intensity and CT density histograms were generated by
combining all the pixel values of the corresponding subgroup or lung volume together.
Histograms were normalized to the area beneath the curve.

3.2.5

Statistics

Independent t-tests, the Shapiro-Wilk test for normality, analysis of variance (ANOVA)
and post-hoc analysis using the Holm-Bonferroni correction were performed using IBM
SPSS Statistics 21.0 (SPSS Inc., Chicago, IL, USA). The data was normal and therefore
parametric tests were used.

Univariate relationships were determined using linear

regression (r2) and Pearson correlation coefficients (r) using Prism GraphPad version 6.00
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(GraphPad Software, San Diego, CA). To evaluate three-week reproducibility, a repeated
measures analysis of variance (ANOVA) was used for UTE signal intensity and ADC using
IBM SPSS Statistics 21.0 (SPSS Inc., Chicago, IL, USA). Linear regression and Pearson
correlation coefficients (r) were used to determine 3-week correlations and the relationship
between UTE signal intensity and SR using GraphPad Prism version 6.00 (GraphPad
Software Inc, San Diego, CA). The COV which is the ratio of the standard deviation of all
measurements and the mean of repeated measurements was used to evaluate repeat imaging
reproducibility. A two-way mixed model intra-class correlation coefficient (ICC) analysis
for absolute agreement was also used to determine reproducibility. Fisher z-transformation
was used to determine the significance of difference between Pearson correlation
coefficients. Results were considered significant when the probability of making a Type I
error was less than 5% (p<0.05).

3.3
3.3.1

Results
Subject Demographics

Twenty subjects were evaluated including five healthy volunteers and 15 subjects (60±39
pack-years) with a clinical diagnosis of COPD, based on symptoms and GOLD criteria.
For eight COPD subjects, there was qualitative CT evidence of emphysema only, whereas
in seven COPD subjects, there was both emphysema and bronchiectasis. Table 3-1 shows
subject demographics and pulmonary function measurements for healthy volunteers, all
COPD subjects and stratified into COPD subjects with emphysema, and subjects with both
emphysema and bronchiectasis.

3.3.2

Relationship between Lung Density and Signal Intensity

Figure 3-2 shows the centre coronal slice for a healthy 22yr male using a conventional
FGRE sequence and two different UTE imaging schemes.

The normalized lung

parenchyma signal intensity increased from 6% to 27% using 32-channel UTE MRI with
compressed sensing. The bar graphs in the right panel show the significant improvements
in signal intensity (p<0.001), SR (p=0.002), and CR (p<0.001) for the 32-channel UTE
sequence as compared to the single-channel UTE and 32-channel FGRE approaches.
Figure 3-3 shows UTE images acquired for a representative healthy volunteer at four
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different lung volumes and shows the qualitative differences in parenchymal signal
intensity at full expiration compared to full inspiration. Figure 3-3 also shows the strong
and significant relationships of nominal lung mass-density with signal intensity using MRIderived (r2=0.98, r=0.99, p=0.007) and plethysmography-derived (r2=0.89, r=0.94, p=0.06)
lung volumes for all healthy volunteers. The relationship for signal intensity with MRI and
plethysmography-derived volumes was not significantly different.

The frequency

distribution of mean signal intensity for all four lung volumes is also shown in Figure 33C, and shows a shift towards lower densities and narrowed distribution at higher lung
volumes.
Table 3-1 Subject demographic and pulmonary function test measurements
Healthy
Mean (±SD)

(n=5)

Age yrs

22(1)

COPD
(n=15)
Emphysema
Emphysema
+Bronchiectasis
(n=8)
(n=7)
67 (9)

65(8)

GOLD Grade
(n=15)
GOLD
GOLD
GOLD I
II
III+IV
(n=3)
(n=6)
(n=6)
70 (9)

66 (8)

63 (9)

Significant Difference
H/E/E+B

I/II/III+IV

p

p

<0.001

0.6

Male Sex n

5

5

3

2

3

3

BMI kg/m2

26(1)

28(4)

26(4)

28 (4)

29 (3)

25 (5)

0.5

0.2

FEV1 %pred

101(14)

62(24)

54(19)

89 (8)

65 (9)

37 (8)

0.003

<0.001

FVC %pred

99(14)

93(15)

82(26)

104 (7)

94 (22)

74 (17)

0.3

0.08

FEV1/FVC %

85(3)

51(17)

49(12)

64 (11)

53 (11)

39 (10)

<0.001

0.02

TLC %pred

103(11)

123(11)

111(17)

118 (4)

109 (17)

126 (13)

0.05

0.4

RV %pred

117(1)

174(52)

151(44)

142 (15)

129 (27)

208 (38)

0.1

0.002

FRC %pred

101(16)

137(31)

134(36)

116 (13)

114 (24)

168 (15)

0.1

0.001

DLCO %pred

132(18)

59(30)

58(19)

70 (38)

54 (4)

57 (32)

<0.001

0.7

Significance of difference (p<0.05) determined using an analysis of variance. H=healthy
volunteer; E=CT evidence of emphysema only, E+B: CT evidence of emphysema and
bronchiectasis; SD=standard deviation; BMI=body mass index; FEV1=forced expiratory
in 1s; %pred=percent predicted; FVC=forced vital capacity; FRC=functional residual
capacity; TLC=total lung capacity; RV=residual volume; DLCO=diffusing capacity of lung
for carbon monoxide.
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Figure 3-2 1H MRI of healthy volunteers
Top panel: 32-channel FGRE MRI with mean normalized 1H SI=6%, SR=1. Middle panel:
single-channel UTE MRI with normalized mean 1H SI=11%, SR=3. Bottom panel: 32channel UTE MRI using compressed sensing (CS) with mean normalized 1H SI=27%,
SR=7. Right panel shows bar graphs with mean 1H SI (normalized 1H signal intensity), 1H
SR (apparent signal-to-noise ratio), and 1H CR (normalized contrast-to-noise ratio) for all
healthy volunteers (n=3 for signal channel UTE 1H measurements). Significant differences
between FGRE, signal-channel UTE, and 32-channel UTE MRI measurements shown by
asterisks. *p<0.01, **p<0.001.

95

Figure 3-3 Centre coronal slice MRI of a representative healthy volunteer
A) UTE MR images of a 21 yr old male (FEV1=89%pred, FEV1/FVC=88%,
DLCO=141%pred) at full expiration (FE), functional residual capacity (FRC), FRC+1L, and,
full inspiration (FI) (from left to right); B) Normalized UTE signal intensity compared to
lung mass-density derived from FGRE volumes in black (y=5.3x103x+6, r2=0.98, r=0.99,
p=0.007) and with lung mass-density derived from plethysmography volumes in grey
(y=3.2x103x+12, r2=0.89, r=0.94, p=0.06); C) Normalized UTE signal intensity histograms
for mean of all healthy volunteers at four different lung volumes.

3.3.3

Reproducibility

Seven subjects with COPD (emphysema, n=3; emphysema with bronchiectasis, n=4)
underwent a three-week follow-up visit. Table 2 shows 1H and 3He MRI measurements at
baseline and follow-up for seven subjects with COPD including COV, Pearson correlation
coefficients, and ICC for 3-week re-scan measurements.

3

He ADC measurements were

used as an internal control for reproducibility comparisons with the 1H UTE measurements.
There was no significant difference between baseline and 3-week 1H UTE signal intensity
(Δ1H SI=0±2%, p=0.9), 1H SI SD (∆1H SI SD=0±1%, p=0.2), 1H SI COV (∆1H SI
COV=2±4%, p=0.2), or 1H SI15 (Δ1H SI15=0±1%, p=0.6).
measurements of

1

The COV for repeated

H signal intensity and SI15 was 4% and 8%, respectively.

Reproducibility is also shown in Figure 3-4 for a subject with emphysema and
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bronchiectasis (Figure 3-4A) and for a subject with emphysema only (Figure 3-4B). The
corresponding histograms are shown for the baseline and three-week histograms for UTE
signal intensity and ADC maps. Figures 3-4C-4E show strong linear relationships for
baseline and three-week normalized 1H signal intensity (r2=0.85, p=0.003), SI15 (r2=0.67,
p=0.02), and SR (r2=0.74, p=0.01), respectively. Figure 3-4F shows the strong linear
relationship for baseline and three-week ADC measurements (r2=0.95, p=0.002). There
was no significant difference between 1H signal intensity and 3He ADC Pearson correlation
coefficients (p=0.3). Finally, there was no significant correlation between 1H signal
intensity and SR (r2=0.08, p=0.5).
Table 3-2 Baseline and 3-week 1H and 3He measurements and reproducibility analysis
1

Measurements
Baseline (±SD)
3-Week (±SD)
Reproducibility
COV (%)
Pearson r
ICC

H SI
(%)

1

H SI SD
(%)

COPD (n=7)*
H SI COV 1H SI15
(%)
(%)

1

1

H SR

1

H CR

ADC
(cm2/s)

27(4)
27(4)

3(2)
3(1)

27(6)
29(5)

19(3)
19(2)

7(5)
7(7)

0.19(0.05)
0.17(0.07)

0.42(0.14)
0.42(0.12)

4
0.87
0.87

13
0.84
0.80

4
0.85
0.84

8
0.82
0.81

36
0.85
0.79

9
0.09
0.08

6
0.97
0.96

*Including emphysema (n=3) and emphysema with bronchiectasis subjects (n=4). 1H
SI=normalized centre slice signal intensity, 1H SI SD=standard deviation of the centre slice
signal intensity, 1H SI COV=centre slice signal intensity coefficient of variation, 1H
SI15=15th percentile of the frequency distribution histogram of UTE signal intensities; 1H
SR=centre slice apparent signal-to-noise ratio, 1H CR=centre slice normalized contrast-tonoise ratio, ADC=apparent diffusion coefficient, COV=coefficient of variation, ICC=intraclass correlation coefficient.
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Figure 3-4 Baseline and 3-week images for two representative COPD subjects
Baseline CT, baseline and 3-week UTE MRI signal intensity maps and 3He ADC maps
with corresponding histograms. A) S20 is a 61 yr male with emphysema and
bronchiectasis; B) S27 is a 51 yr male with emphysema. Shown below are linear
regressions of inter-scan reproducibility for C) normalized 1H signal intensity (r2=0.85,
r=0.87, p=0.003), D) SI15 (r2=0.67, r=0.82, p=0.02), E) SR (r2=0.74, r=0.85, p=0.01), and,
F) ADC (r2=0.95, r=0.97, p=0.002).

3.3.4

Quantitative Analysis

Table 3-3 shows imaging measurements for healthy volunteers, COPD subjects with
emphysema, and COPD subjects with both emphysema with bronchiectasis. Independent
t-tests showed significant signal intensity differences (p<0.05) for healthy volunteers as
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compared to subjects with emphysema and subjects with both emphysema with
bronchiectasis. Healthy volunteers had significantly greater 1H signal intensity and 1H CR
than subjects with emphysema and subjects with both emphysema with bronchiectasis.
Healthy volunteers also had significantly greater 1H SI15 than the COPD subjects with
emphysema, but this was not significantly different than subjects with both emphysema
and bronchiectasis.
Table 3-3 Imaging measurements for all subjects

Healthy

COPD
(n=15)
Emphysema
Emphysem
+Bronchiectasi
a
s
(n=8)
(n=7)

GOLD Grade
(n=15)

Significant
Difference

GOLD I

GOLD II

GOLD
III+IV

H/E/E
+B

I/II/III+
IV

(n=3)

(n=6)

(n=6)

p

p

Mean (±SD)

(n=5)

1

H SI %

29(2)

23(3)*

24(4)*

27 (3)

23 (5)

22 (3)

0.07

0.3

1

H SI15 %

21(1)

18(3)*

18(4)

18 (4)

19 (4)

17 (2)

0.09

0.6

1

H SR

5.17(1.99)

4.82(2.02)

3.04(1.57)

6.12 (2.17)

3.55 (1.59)

3.37 (1.80)

0.1

0.1

1

H CR

0.22(0.03)

0.17(0.03)*

0.13(0.04)*

0.19 (0.03)

0.15 (0.04)

0.14 (0.03)

0.001

0.1

0.20(0.01)

0.46(0.14)

0.41(0.11)

0.39 (0.17)

0.41 (0.10)

0.48 (0.13)

0.003

0.4

--

-855(35)

-849(43)

-831(26)

-839(47)

-874(27)

0.8

0.2

ADC cm2/s
Radiodensity
HU
RA950 %

--

17(15)

11(9)

9 (12)

11 (9)

19 (15)

0.3

0.4

HU15% HU

--

-942(37)

-927(41)

-921 (42)

-923 (47)

-950 (28)

0.5

0.3

WA %

--

60(4)

59(4)

63 (3)

58 (4)

60 (4)

0.7

0.1

LA mm2
LA/BSA
mm2/m2
Pi10 mm

--

21(4)

27(14)

18 (6)

30 (13)

20 (4)

0.2

0.2

--

11(3)

15(6)

10 (3)

16 (6)

12 (3)

0.1

0.6

--

4.23(0.15)

4.22(0.11)

4.31 (0.20)

4.24 (0.10)

4.17 (0.11)

0.9

0.3

Significance of difference (p<0.05) determined using an analysis of variance. H=healthy
volunteer; E=CT evidence of emphysema only, E+B: CT evidence of emphysema and
bronchiectasis; SD=standard deviation; SI=normalized 1H signal intensity; SI15=15th
percentile of the frequency distribution histogram of UTE signal intensities; S R=apparent
signal-to-noise ratio; CR=normalized contrast-to-noise ratio; ADC=apparent diffusion
coefficients; RA950=relative area of the lung with attenuation values < -950 HU;
HU15%=15th percentile of the frequency distribution histogram in HU; LA=lumen area;
BSA=body surface area; Pi10=airway wall thickness at an internal perimeter of 10mm.
*Independent t-test shows significant difference between healthy volunteers (p<0.05).
Figure 3-5 shows the MRI signal intensity maps, CT images and frequency distribution
for MRI signal intensity and CT radio-density for two representative subjects with
emphysema and two representative subjects with both emphysema and bronchiectasis. The
UTE signal intensity maps show regions of emphysema in blue and regions of
inflammation, mucous, and other regions of increased lung density in yellow. For the UTE
signal intensity and CT radio-density there is evidence of regionally consistent
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identification of corresponding abnormalities. As shown in the signal intensity frequency
distributions in Figure 3-5, there was a bi-modal distribution in S24 and with increasing
COPD grade, the signal intensity distributions shifted towards lower signal intensities.
This trend was also observed in the radio-density frequency distributions, where with
increasing COPD grade, there was a shift towards the lower radio-densities.

Figure 3-5 MRI and CT of COPD patients
Normalized UTE signal intensity maps, CT images with relative area (RA) emphysema
mask for 15th percentile of the HU (HU15, in blue), MRI signal intensity histograms, and
CT radio-density histograms. S24 is a 59 yr female with emphysema and bronchiectasis,
FEV1=67%pred, FEV1/FVC=71%, DLCO=54%pred; S17 is a 77 yr male with emphysema and
bronchiectasis and FEV1=79%pred, FEV1/FVC=42%, DLCO=50%pred; S31 is a 75 yr female
with GOLD III and FEV1=46%pred, FEV1/FVC=39%, DLCO=29%pred; S27 is a 51 yr male
with GOLD IV and FEV1=28%pred, FEV1/FVC=22%, DLCO=32%pred.

3.3.5

Correlations with Pulmonary Function Measurements and CT

Table 3-4 summarizes the significant correlations for MRI signal intensity and pulmonary
measurements for all COPD subjects. For all subjects, there were significant correlations
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for signal intensity with RA950 (r2=0.50, p=0.005), FEV1/FVC (r2=0.35, p=0.02), DLCO
(r2=0.25, p=0.05), and mean radio-density (r2=0.85, p<0.001). There was a significant but
very modest correlation for SI15 and HU15 (r2=0.38, p=0.01). For subjects with only
emphysema, significant relationships were observed for signal intensity with RA950
(r2=0.90, p=0.002), HU15 (r2=0.83, p=0.005), and mean radio-density (r2=0.90, p=0.001).
For subjects with both emphysema and bronchiectasis, there were significant relationships
were observed for signal intensity and RV (r2=0.59, p=0.04), HU15 (r2=0.76, p=0.01), Pi10
(r2=0.62, p=0.04) and mean radio-density (r2=0.85, p=0.04).
Table 3-4 UTE signal intensity correlations with 3He MRI ADC, CT and pulmonary
function test measurements
COPD

GOLD Grade

(n=15)

(n=15)

Emphysema

FEV1 %pred
FEV1/FVC %
FRC %pred
TLC %pred
RV %pred
DLCO %pred
ADC cm2/s
Radiodensity HU
RA950 %
HU15% HU
WA %
LA mm2
LA/BSA mm2/m2
Pi10 mm

(n=8)
r
p
0.50
NS
NS
0.50
NS
-0.04
NS
0.31
NS
0.19
0.62
NS
-0.41
NS
0.95
0.001
-0.94
0.002
0.91
0.005
0.45
NS
-0.60
NS
-0.70
0.05
0.38
NS

Emphysema+
Bronchiectasis
(n=7)
r
p
0.57
NS
0.70
NS
-0.64
NS
-0.75
NS
-0.77
0.04
0.32
NS
-0.61
NS
0.92
0.004
-0.60
NS
0.87
0.01
-0.09
NS
0.20
NS
-0.02
NS
0.79
0.04

GOLD I

GOLD II

(n=3)
r
p
NS
0.78
NS
0.91
NS
-0.44
NS
0.99
NS
0.49
0.67
NS
-0.76
NS
0.99
0.04
-0.93
NS
0.87
NS
0.51
NS
-0.75
NS
-0.87
NS
0.19
NS

(n=6)
r
p
0.39
NS
0.61
NS
-0.46 NS
-0.57 NS
-0.58 NS
0.09
NS
-0.30 NS
0.93 0.02
-0.49 NS
0.84
NS
0.19
NS
0.12
NS
0.04
NS
0.41
NS

GOLD
III+IV
(n=6)
r
p
NS
0.30
NS
0.37
-0.56 NS
-0.16 NS
NS
0.31
0.85 0.03
-0.51 NS
0.82 0.04
-0.76 NS
0.86 0.03
-0.19 NS
-0.01 NS
-0.57 NS
0.90 0.01

r=Pearson correlation coefficient (p<0.05). FEV1=forced expiratory in 1s; %pred=percent
predicted; FVC=forced vital capacity; FRC=functional residual capacity; TLC=total lung
capacity; RV=residual volume; DLCO=diffusing capacity of lung for carbon monoxide;
ADC=apparent diffusion coefficient; RA950=relative area of the lung with attenuation
values<-950 HU; HU15%=15th percentile of the frequency distribution histogram in HU;
LA=lumen area; BSA=body surface area; Pi10=airway wall thickness at an internal
perimeter of 10mm

101

3.4

Discussion

In recognition of some of the limitations of CT for longitudinal and serial evaluations of
COPD, we are developing rapid pulmonary MRI methods to provide quantitative
measurements of tissue density and airway abnormalities. By utilizing compressed sensing
and parallel imaging in combination with an ultra-short echo time, we showed: 1)
significantly improved CR, SR, and signal intensity, 2) a significant and strong relationship
for MR signal intensity and tissue density, 3) high three-week reproducibility for UTE
signal intensity measurements, and, 4) spatial correlations for signal intensity with CTidentified regions of emphysema, inflammation, and mucous plugging and quantitative
correlations with pulmonary function and CT measurements.
First, there was significantly improved signal intensity, SR, and CR using the 32-channel
UTE approach as compared to the single channel UTE and 32-channel FGRE approaches.
The improved signal intensity and SR was not surprising because of the geometry and
number of elements in the 32-channel compared to the body coil. Improvements in signal
intensity, SR, and CR using the 32-channel UTE sequence were also expected because of
the shorter echo-time and radial sampling. Furthermore, for the UTE sequence, data
acquisition began at the centre of k-space and extended radially, oversampling the centre
of k-space and as a result, there was improved contrast at lower frequencies.
Second, in healthy volunteers, pulmonary signal intensity was strongly related to the
inverse of lung volume and because total lung mass was constant, this reduced to a strong
linear relationship for signal intensity and nominal lung density. Therefore, similar to
CT,16 signal intensity directly reflected lung density, which suggests that UTE signal
intensity can be used to quantify parenchymal tissue destruction and inflammation. UTE
signal intensity histograms shifted towards lower intensity values at higher lung volumes
which is consistent with CT studies,16 and this is important, given that CT is universally
recognized as the clinical non-invasive gold standard for lung density measurements. The
increased heterogeneity at full expiration may be explained by the changing vascular
portion at different lung volumes.16 UTE signal intensity maps showed similar regional
information for both emphysema and inflammation/mucous deposition and these
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preliminary qualitative results suggest that 1H MRI may provide a way to characterize the
heterogeneous pathological processes of COPD and offer an alternative to CT
measurements.
We reported high UTE signal intensity reproducibility for three-week re-scan for COPD
subjects which was consistent with high Pearson correlation coefficients, low COV and
high ICC. To further understand the relationship of reproducibility with image quality, we
investigated whether differences in SR would influence UTE signal intensity, but did not
find a significant relationship between them. This suggests that noise did not influence the
UTE signal intensity measurements. Moreover, these results suggest that 2D UTE MRI
provides a reproducible technique to monitor treatment response in longitudinal studies.
We reported significant and moderate correlations for UTE signal intensity with pulmonary
function, and CT measurements for COPD subjects. These correlations are consistent with
lung tissue destruction in emphysema leading to lung mass and density loss.

It is

interesting to note that in subjects with emphysema only, in addition to significant
relationships between RA950, HU15, and mean radio-density there was a significant
correlation with lumen area normalized to body surface area. It is also interesting to note
that in subjects with both emphysema and bronchiectasis, there was a positive relationship
between Pi10 and signal intensity, consistent with the notion that in bronchiectasis subjects,
thickened airways resulted in increased signal intensity.
Although this study provides promising preliminary results, several limitations must be
acknowledged. First, our analysis ignored the effect of pulmonary perfusion at different
lung volumes in healthy volunteers. As lung perfusion is dictated by the relationship
between alveolar, pulmonary arterial, and pulmonary venous pressures - all of which vary
at different lung volumes, it is expected that different lung volumes will change perfusion
and subsequently change the UTE signal. Several potential mechanisms may explain
pulmonary perfusion changes at different lung volumes (hypoxic vasoconstriction of the
alveolar vessels, vessel branching pattern change, and the cavity pressure change) and its
impact on UTE signal intensity. Second, it is important to note that the impact of effective
transverse decay time T2* on signal intensity at different lung volumes was ignored in
103

healthy volunteers for two reasons: 1) in human lungs, T2* variability was significantly
smaller than other factors affecting SI across different lung volumes17 2) the echo-time of
50µs was significantly smaller than the parenchymal T2* (500-800µs),7,17 which
minimized the T2* weighting effect. Also, unlike CT, MRI signal intensity is influenced
by hardware factors such as RF amplifications and the positioning of the RF coils, which
introduce inter-scan variability.

While we corrected for absolute signal intensity

quantification by normalizing acquired images to the liver, this is influenced by the
precision of liver measurements. In this regard, we note that the liver has minimal motion
during the image acquisition and is relatively homogeneous despite inter-subject signal
variability. Finally, we acknowledge that the histopathological relationship between MRI
signal intensity and CT radio-density measurements has not yet been established. The
quantification of emphysema using CT uses different threshold type analyses has been
compared with histology,18 this has not yet been undertaken with parenchymal MRI signal
intensity. The comparison of mean MRI signal intensity to CT RA950 and HU15 is likely
a conservative estimate of any direct relationships. For this reason, the comparison of
MRI-derived SI15 with CT-derived HU15 is likely a better estimate of the direct
relationships of MRI signal intensity and CT radio-density measurements.
Future studies will investigate three-dimensional UTE acquisition. The three-dimensional
UTE method would allow for more efficient RF excitation, isotropic spatial resolution, and
reduced sensitivity to motion artifacts compared to 2D UTE.19
In summary, we developed a 2D UTE MRI method to generate rapid measurements of
pulmonary signal intensity that are strongly related to tissue density and in subjects with
COPD is related to pulmonary function and CT measurements.
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CHAPTER 4

4

THREE DIMENSIONAL ULTRA-SHORT ECHO TIME
MAGNETIC RESONANCE IMAGING OF ASTHMA

To determine the underlying structural and clinical determinants of MRI signal-intensity
in patients with asthma we generated novel ultra-short echo time (UTE) MRI biomarkers
in asthmatics and directly compared these with structural CT and other clinical
measurements.
The contents of this chapter have been submitted to the Journal of Magnetic Resonance in
Medicine: K Sheikh, F Guo, DPI Capaldi, A Ouriadov, RL Eddy, S Svenningsen, and G
Parraga. Accepted for publication in J Magn Reson Imaging 2016 (in press).

4.1

Introduction

Asthma is a chronic inflammatory disease involving both the large and small airways.1,2
Complex airway abnormalities including airway smooth muscle remodeling3,4 and
inflammation4 are thought to be the source of shortness of breath, wheeze and chest
tightness. These are also associated with gas-trapping5 and ventilation/perfusion
abnormalities.6

Currently, asthma is diagnosed and monitored based on spirometry

measurements of airflow made at the mouth.7 These measurements tend to over-estimate
large airway constriction, under-estimate small airways disease8 and cannot provide
regional information.
Lung structural and functional abnormalities have also been measured in patients with
asthma using chest computed tomography (CT),9 single photon emission computed
tomography,10 positron emission tomography11 and magnetic resonance imaging (MRI)
using inhaled gases.12,13 Because asthma often spans the lifetime of individual patients,
the risk of cumulative radiation exposure certainly limits the use of x-ray based imaging
for longitudinal and treatment response evaluations, especially in children.14
A number of research teams have pioneered the use of inhaled gas MRI in asthmatics;12,15,16
this previous work showed that ventilation abnormalities were heterogeneously
distributed,17,18 reproducible,19 related to asthma severity12 and asthma control.17 Recently,
zero echo time and ultra-short echo time (UTE) MRI have emerged as methods to minimize
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MRI signal decay for the quantification of lung proton density.20-26 Previous UTE asthma
studies showed the inflammatory response to allergen challenge in animal models27 and
patients.28 This previous work demonstrated the potential and feasibility of 1H MRI
methods for measuring the therapeutic efficacy of new asthma treatments. Recent work
also estimated regional ventilation deficits in asthmatics based on the change in signalintensity measured at different lung volumes using conventional 1H MR methods and echotimes.29

However, it is well-understood that MRI signal-intensity is influenced by

hardware factors such as RF amplification and RF coil positioning, which can introduce
inter-scan variability. Because of this, it is difficult to ascertain the physiological meaning
of

1

H MR signal-intensity changes especially in asthma where the underlying

pathophysiology is complex.
In an effort to better understand pulmonary MRI measurements, two-dimensional UTE
MRI was recently evaluated in participants with COPD and bronchiectasis,30 patients that
share some of the airway and inflammatory features common in asthmatics.31 Based on
some of this previous work, we hypothesized that UTE-derived biomarkers could be
generated across different lung volumes to capture evidence of ventilation abnormalities in
patients with asthma and these measurements would be related to pulmonary function test
measurements of gas-trapping and/or airflow obstruction. Therefore, the objective of this
proof-of-concept study was to generate novel UTE MRI biomarkers in asthmatics in whom
CT structural and other clinical measurements could be directly compared.

4.2
4.2.1

Materials and Methods
Study Logistics

All participants provided written informed consent to a study protocol approved by a local
research ethics board and compliant with the Health Insurance Portability and
Accountability Act (HIPAA, USA). Healthy volunteers underwent pulmonary function
tests and UTE MRI only. All subjects with a diagnosis of asthma underwent pre- and postsalbutamol pulmonary function tests, hyperpolarized noble gas MRI, UTE MRI and postsalbutamol thoracic CT. Methacholine challenge (MCh) was restricted to asthmatics
according to ATS guidelines32 with testing halted at the PC20 which is the provocative
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concentration resulting in a 20% decrease in forced expiratory volume in 1 second, or
FEV1.
Spirometry was used to measure FEV1, forced vital capacity (FVC), and their ratio
(FEV1/FVC) according to American Thoracic Society (ATS) guidelines (MedGraphics
Elite Series Plethysmograph, MedGraphics Corporation, St. Paul, Minnesota, USA).33
Body plethysmography was also performed to measure lung volumes such as residual
volume (RV), functional residual capacity (FRC), and total lung capacity (TLC).

4.2.2

Image Acquisition

MRI was acquired in the coronal plane using a whole body 3 Tesla Discovery MR750
(General Electric Health Care [GEHC], Milwaukee, WI, USA) system with broadband
imaging capability. MRI was acquired pre- and post-salbutamol for all asthmatics and at
PC20 in those asthmatics who underwent the methacholine challenge. UTE MRI was
obtained using a 32-channel torso coil (GEHC) and 3D cones UTE sequence (GEHC).
Whole lung UTE images were acquired in the coronal plane with the following parameters
in breath-hold: 15s acquisition time, echo time (TE)/repetition time (TR)/flip
angle=0.03ms/3.5ms/5°, field-of-view (FOV)=40×40cm, bandwidth (BW)=125kHz,
matrix=200×200, number of excitations (NEX)=1, and reconstructed to a 10mm slice
thickness. UTE MR images were acquired at four lung volumes including full expiration,
FRC, FRC plus one liter, and full inspiration and this was completed in 5-10 minutes.
Subjects were coached to achieve full expiration and full inspiration. FRC was achieved
at the end of passive expiration and FRC+1L was achieved by the inhalation of a 1L bag
of N2. The B1 field was mapped using a dual angle 3D Look-Locker pulse sequence (40s
total

data

acquisition,

TE/TR=0.3ms/1200ms,

α/2α=5°/10°,

FOV=48×48cm,

BW=62.5kHz, matrix=32×32, 32 slices, 15mm slice thickness, 0 gap) using the 3T GE
phantom model 2360049 (GEHC).34
Polarization of 3He or

129

Xe gas was achieved using commercial polarizer systems

(Polarean, Durham, NC, USA). Hyperpolarized 3He was diluted with medical-grade N2
gas (Spectra Gases, New Jersey, USA) and

129

Xe was diluted with 4He and administered

in 1.0-L Tedlar® bags (Jensen Inert Products, Florida, USA). Subjects were instructed to
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inhale a gas mixture from the bag from FRC and image acquisition was performed under
breath‐hold conditions.35 1H MRI was acquired with subjects in breath-hold using a wholebody radiofrequency coil and a 1H fast spoiled gradient-recalled echo (FGRE) sequence
with a partial echo (12s total data acquisition, TR/TE/flip angle=4.7ms/1.2ms/30°,
FOV=40×40cm, BW=24.4kHz, matrix=128×80, number of slices=16, 15mm slice
thickness, 0 gap), as previously described.35 3He static ventilation MRI was acquired using
a 2D multi-slice fast gradient‐recalled echo sequence with a partial echo (total data
acquisition time=10s, TR/TE/flip-angle=3.8ms/1.0ms/7°, FOV=40×40cm, BW=48.8kHz,
matrix=128×80, NEX=1, number of slices=16, slice thickness=15mm) during breathhold.35

129

Xe static ventilation MRI was also acquired in three subjects using methods

previously described.36
Thoracic CT was acquired post-salbutamol with subjects at inspiration (lung volume of
FRC+1L) breath-hold (FRC+1L to allow for CT to MRI comparison) using a multidetector, 64-slice Lightspeed VCT scanner (GEHC, Milwaukee, WI) (64×0.625mm
collimation, 120 kVp, 100 mA, tube rotation time=500ms, pitch=0.98).37 All subjects were
coached prior to scanning with a practice bag; subjects were instructed to breath in and out
through their nose and after a passive expiration the N2 gas was inhaled through the mouth
from a 1 litre bag. A spiral acquisition was used and images were reconstructed using a
Standard reconstruction algorithm and reconstructed slice thickness of 1.25mm.37

4.2.3

Image Analysis

A B1 map was first applied to all UTE MR images to correct for flip angle inhomogeneities,
which were then subsequently segmented using a multi-regional segmentation approach,
previously described.38,39 Briefly, a single observer (F.G.) placed seeds on the left lung,
right lung and the background.

These seeds were used to generate the probability

distribution of signal intensities, which was used to generate the cost for assigning a
corresponding label to a voxel. The segmentation optimization problem was solved using
primal-dual analysis and convex optimization techniques, resulting in the segmented lung.
The mean UTE MRI signal-intensity for the whole lung was determined and normalized to
the mean liver signal-intensity, as previously described.30 To determine signal-intensity
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differences across the four different lung volumes, the images acquired at full-expiration,
FRC, and full-inspiration were segmented and the extracted lung was registered to the lung
acquired at FRC+1L (to ensure consistency with the noble gas and CT acquisitions) using
an affine followed by a deformable registration approach provide by NiftyReg.40 Figure
4-1 shows a schematic that summarizes how dynamic proton-density maps were generated.
Dynamic proton-density maps reflect the change from full inspiration to full expiration of
UTE signal intensity for each lung voxel in the map. Each dynamic proton-density map
required 15 minutes to generate (including the segmentation and registration time).
Briefly, UTE MRI was acquired at four different lung volumes, and the magnitude of the
slope of the line that described the signal intensity change across lung volumes was
calculated on a voxel-by-voxel basis to generate the dynamic proton-density map. UTE
images were qualitatively evaluated based on visual evidence of diminished signalintensity at baseline, PC20, and post-salbutamol. Dynamic proton-density maps with
mainly warmer colours (e.g. orange, red) were classified as having diminished differences
between full inspiration and full expiration signal-intensity. Dynamic proton-density maps
with mainly cool colours (e.g. blue, green) were classified as having greater differences
between full inspiration and full expiration signal-intensity.
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Figure 4-1 Schematic for generating Dynamic Proton-Density Maps
A) Volume-time plot that shows lung volumes at which MRI was acquired: full expiration,
passive expiration (functional residual capacity [FRC]), FRC+1L, and full inspiration, B)
Centre slice UTE images in greyscale at four lung volumes with corresponding segmented
and registered images. Yellow box represents region-of-interest (ROI) and, C) Plot of ROI
signal-intensity versus lung volume, where the slope of the line represents the dynamic
proton-density value for each ROI or voxel that is used to generate a dynamic protondensity map.
Static ventilation images were segmented and co-registered with 1H FGRE MRI using
custom software generated using MATLAB R2014a (Mathworks, Natick, Massachusetts,
USA).41 Ventilation abnormalities were quantified using the ventilation defect percent
(VDP) which represents the volume of ventilation defects (VDV) normalized to the
thoracic cavity volume. Briefly, static ventilation images were segmented by a single
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observer (K.S.) using a k-means approach that classified voxel intensity values into five
clusters ranging from signal void (cluster 1[C1] or VDV) and hypo-intense (cluster 2 [C2])
to hyper-intense signal (cluster 5 [C5]) to generate a gas distribution cluster-map. For
delineation of the ventilation defect boundaries, a seeded region-growing algorithm was
used to segment the 1H FGRE MRI thoracic cavity for registration to the cluster-map, as
previously described.41 Hyperpolarized noble gas images were qualitatively evaluated
based on visual evidence of ventilation defects defined as any lung region of diminished
signal-intensity but not including those areas of signal loss associated with the pulmonary
vascular structures, heart, hilum, and mediastinum.

Homogeneous distribution of

hyperpolarized noble gas was defined as static ventilation images without focal areas of
diminished signal-intensity. When ventilation defects were visibly improved (signalintensity was greater) after the administration of salbutamol, they were deemed
qualitatively diminished or improved.
Pulmonary Workstation 2.0 (VIDA Diagnostics Inc., Coralville, Iowa, USA) was used to
segment whole lung and pulmonary lobes from the CT images. As previously described,30
mean CT radio-density was determined using the CT pulmonary mask generated using
VIDA. A threshold of -856HU5 was not used to evaluate gas-trapping because images
were not acquired at full expiration and instead, mean CT radio-density was used for direct
comparison with mean UTE values across the entire lung and for individual lobes. Using
the CT pulmonary lobe masks, CT radio-density, UTE signal-intensity and VDP (by
registering CT to hyperpolarized noble gas MRI42) were determined for each pulmonary
lobe. CT images were qualitatively evaluated and decreased lung density was described as
a pulmonary hyperlucency or regions of hypoattenuation (i.e. low radio-density).

4.2.4

Statistics

Data were tested for normality using the Shapiro-Wilk normality test using SPSS 23.0
(IBM, Armonk, NY, USA) and parametric tests were performed when the data satisfied
normal distribution. Univariate relationships were evaluated using linear regressions (r2)
and Pearson correlations (r), and Spearman correlations (rs) (adjusted with HolmBonferroni correction). One-way analysis of variance (ANOVA) with a Holm-Bonferroni
correction for multiple comparisons was used to compare measurements between healthy
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volunteers and asthmatics. Repeated measures ANOVA was performed to evaluate the
difference between baseline, PC20, and post-salbutamol measurements. All statistical tests
were performed using SPSS 23.0 (IBM, Armonk, NY).

Results were considered

significant when the probability of making a Type I error was less than 5% (p<.05).

4.3
4.3.1

Results
Study Subjects

Thirty subjects were evaluated including 13 healthy volunteers (7M/6F, 25±5 years) with
no history of chronic or acute respiratory disease and 17 asthmatics (7M/10F, 47±11 years).
Fourteen asthmatics were clinically diagnosed with severe, uncontrolled disease, while
three patients had mild-to-moderate asthma. Table 4-1 shows subject demographics and
pulmonary function test measurements for all participants pre-salbutamol.

Healthy

volunteers were significantly younger and reported significantly greater FEV1 and
FEV1/FVC as well as significantly lower RV/TLC than the asthmatics (p<.001).
Table 4-1 Participant demographics
Healthy
Significance of
Asthma
Volunteers
Difference
n=17
p-value
Mean (±SD)
n=13
Male n
7
7
-Age yrs
25 (5)
47 (11)
<.001
BMI kg/m2
24 (4)
28 (5)
.09
FEV1 %pred
102 (11)
69 (23)
<.001
FVC %pred
102 (11)
89 (17)
.1
FEV1/FVC %
85 (6)
78 (17)
<.001
RV %pred
128 (29)
148 (43)
.7
TLC %pred
110 (12)
110 (11)
~1
RV/TLC %
28 (5)
42 (11)
.002
FRC %pred
112 (14)
116 (25)
~1
IC %pred
104 (17)
103 (22)
.9
*Significance of difference (p<.05) was determined using a one-way ANOVA with HolmBonferroni correction to correct for multiple comparisons. SD=standard deviation;
BMI=body mass index; FEV1=forced expiratory in 1s; FVC=forced vital capacity;
TLC=total lung capacity; RV=residual volume, FRC=functional residual capacity;
IC=inspiratory capacity.
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4.3.2

UTE Signal Intensity and Dynamic Proton-density maps

Figure 4-2 shows multi-volume UTE MRI and dynamic proton-density maps for a
representative healthy volunteer and an asthmatic participant as well as the normalized
signal-intensity values for the two subgroups at each lung volume. For the healthy
volunteer, there was qualitative evidence of homogeneously distributed low signalintensity at all lung volumes and a homogeneous dynamic proton-density map that
reflected an approximate 10%/L difference in mean signal-intensity across lung volumes
(with greater signal-intensity at smaller lung volumes). For the representative asthmatic
subject, there was qualitative evidence of low signal-intensity regions at all lung volumes,
and a greater regional variability in the dynamic proton-density map reflecting regional
heterogeneity in signal-intensity differences across the four lung volumes. The dynamic
proton-density map for the asthma patient was not only more heterogeneous but also
reflected smaller differences in signal-intensity. Quantitatively, there were significant
differences between the healthy and asthmatic subgroup for signal-intensity at full
expiration (healthy volunteers: 58±7%, asthmatics: 43±10%, p<.001) and FRC (healthy
volunteers: 50±7%, asthmatics: 40±8%, p=.003). Whole lung dynamic proton-density
measurements were also significantly different (p<.001) for healthy volunteers
(7.4±2.0%/L) and asthmatics (4.5±1.9%/L).
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Figure 4-2 UTE MRI for Healthy Volunteers and Asthmatics
Coronal UTE MRI at full expiration, FRC, FRC+1L, and full inspiration with
corresponding dynamic proton-density maps for a representative healthy volunteer and
asthmatic. The far right panel shows normalized signal intensity and dynamic proton116

density values for the healthy volunteer and asthmatic subgroups. P-value determined using
a one-way ANOVA with Holm-Bonferroni correction for multiple comparisons (*:p<.05,
**:p<.01).
For participants with asthma, we also evaluated qualitative and quantitative relationships
for UTE signal-intensity and dynamic proton-density maps with biomarkers derived from
CT, 3He MRI and pulmonary function tests. As shown in Figure 4-3, for subject S19, there
was a homogeneous distribution of hyperpolarized 3He gas and there were no visually
obvious CT low attenuating regions or lucency. For asthmatic subject S27, there were
ventilation defects in the lower lobes which corresponded to regional CT lucency and
smaller signal-intensity/volume differences in the dynamic proton-density maps. In a
similar manner for asthmatic subject S15, ventilation defects corresponded to regional CT
lucency and small signal-intensity changes in the dynamic proton-density maps.
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Figure 4-3 Pulmonary MRI and CT for Participants with Asthma
Coronal centre slice 3He MRI, CT, UTE MRI at full expiration and full inspiration and
dynamic proton-density maps for three representative asthmatic subjects. S19: 39 year old
female, FEV1=71%pred, RV/TLC=45%, mean whole lung CT radio-density=-792HU, full
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expiration/full inspiration signal-intensity=46%/31%, VDP=2%, whole lung mean
dynamic proton-density=5.06%/L; S27: 60 year old female, FEV1=52%pred,
RV/TLC=54%, mean whole lung CT radio-density=-814HU, full expiration/full
inspiration signal-intensity=34%/23%, VDP=10% whole lung mean dynamic protondensity=4.80%/L; S15: 57 year old male, FEV1=36%pred, RV/TLC=48%, mean whole lung
CT radio-density=-865HU, full expiration/full inspiration signal-intensity=31%/20%,
VDP=32%, whole lung mean dynamic proton-density=2.65%/L.
Quantitative results for asthmatics are provided in Figure 4-4 shows significant
quantitative whole lung relationships for lung tissue CT radio-density with UTE signalintensity at full expiration (r2=0.67, r=0.82, p=.004) and FRC+1L (r2=0.69, r=0.83,
p=.006). There were similar findings for lobar relationships between CT radio-density and
MRI signal-intensity at full expiration (r2=0.30, r=0.55, p=.003) and FRC+1L (r2=0.48,
r=0.69, p=.004). Whole lung dynamic proton-density was also correlated with whole lung
CT radio-density (r2=0.51, r=0.71, p=.01) and lobar results were very similar (r2=0.66,
r=0.81, p=.003). Finally, there were significant whole lung relationships for UTE signalintensity at full expiration with VDP (r2=0.45, r=-0.67, p=.006) and as well for UTE signal
intensity at FRC+1L with VDP (r2=0.31, r=-0.56, p=.03). The relationship of whole lung
dynamic proton-density with whole lung VDP was on the threshold of significance
(r2=0.26, r=-0.51, p=.05) while lobar signal-intensity at FRC+1L (r2=0.13, rs=-0.33, p=.02)
and lobar dynamic proton-density (r2=0.14, rs=-0.47, p=.01) were both related to lobar
VDP. We note that in this evaluation, data for three subjects were based on
VDP measurements. Because previous work demonstrated
greater than 3He VDP

43

129

129

Xe MRI

Xe VDP was significantly

in asthmatics, we evaluated all correlations without

129

Xe VDP

data and the relationships remained significant. Previous work showed that lung inflation
volume and CT lung density

44-47

are strongly related and that UTE signal-intensity also

scales with lung volume 30, which is exactly what the dynamic proton-density maps show.
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Figure 4-4 Relationships for UTE MRI Signal intensity and imaging measurements in
asthmatics
Linear correlations for A) whole lung radio-density with whole lung UTE signal intensity
(SI) at full expiration (r2=0.67, r=0.82, p=.004) and FRC+1L (r2=0.69, r=0.83, p=.006), B)
lobar radio-density and lobar UTE signal intensity at full expiration (r2=0.30, r=0.55,
p=.003) and FRC+1L (r2=0.48, r=0.69, p=.004), C) whole lung VDP with whole lung UTE
signal intensity at full expiration (r2=0.45, r=-0.67, p=.006) and FRC+1L (r2=0.31, r=-0.56,
p=.03), D) lobar VDP with lobar UTE signal intensity at FRC+1L (r2=0.13, rs=-0.33,
p=.02), E) whole lung radio-density and whole lung dynamic proton-density (r2=0.51,
r=0.71, p=.01), F) lobar radio-density and lobar dynamic proton-density (r2=0.66, r=0.81,
p=.003), and G) lobar VDP with lobar dynamic proton-density (r2=0.14, rs=-0.47, p=.01).
Associations with pulmonary function test measurements and lung volumes are shown in
Figure 4-5 for all subjects by subgroup.

In healthy volunteers, FEV1 %pred was

significantly correlated with whole lung UTE signal-intensity at full expiration (r2=0.50,
r=0.71, p=.03), while for the asthmatic subgroup, there were significant relationships for
FEV1 %pred (r2=0.50, r=0.71, p=.006), FEV1/FVC (r2=0.53, r=0.73, p=.002) and RV/TLC
(r2=0.32, r=-0.57, p=.02) with whole lung signal-intensity. In asthma patients only, mean
whole lung dynamic proton-density was related to FEV1 %pred (r2=0.37, r=0.61, p=.02),
FEV1/FVC (r2=0.56, r=0.75, p=.003), and RV %pred (r2=0.38, r=-0.62, p=.02). Based on
previous work,47 we performed linear regression analysis while controlling for TLC and
the relationships for UTE and pulmonary function test measurements remained significant.

120

Figure 4-5 Relationships for UTE MRI and pulmonary function measurements
Signal intensity (SI) at full expiration associations with A) FEV1 (Healthy: r2=0.50, r=0.71,
p=.03; Asthma: r2=0.50, r=0.71, p=.006), B) FEV1/FVC (Healthy: r2=0.14, r=0.37, p=.2;
Asthma: r2=0.53, r=0.73, p=.002), C) RV/TLC (Healthy: r2=0.25, r=0.50, p=.2; Asthma:
r2=0.32, r=-0.57, p=.02).
Dynamic proton-density associations with D) FEV1 (Healthy: r2=0.45, r=0.67, p=.4;
Asthma: r2=0.37, r=0.61, p=.02), E) FEV1/FVC (Healthy: r2=0.31, r=0.56, p=.2; Asthma:
r2=0.56, r=0.75, p=.003) F) RV (Healthy: r2=0.06, r=-0.24, p=.4; Asthma: r2=0.38, r=-0.62,
p=.02).

4.3.3

Response to Bronchoconstriction and Bronchodilation

Because of the quantitative relationships observed in Figures 4-4 and 4-5, we also
qualitatively investigated the potential for UTE MRI biomarkers to reflect well-understood
changes in asthma lung function that occur during methacholine challenge and after
bronchodilator inhalation. We note that based on international guidelines,32 the vast
majority of asthmatics in this study were too severe to undertake a methacholine challenge
and therefore results were limited to three subjects in whom methacholine challenge and
therapy withholding could be safely undertaken.

Table 4-2 summarizes pulmonary

function test and imaging results from the bronchodilator and bronchoconstrictor
challenge. There were significant differences in FEV1 and RV/TLC pre- and post121

salbutamol in all asthmatics.

There were no significant differences in imaging

measurements in those subjects who only underwent tests pre- and post-salbutamol (n=14).
In the three subjects that underwent the methacholine challenge, there were significant
differences in signal-intensity at full expiration (p=.03).
Table 4-2 Pre- and post-salbutamol pulmonary function test and imaging measurements
for all asthmatics.
Baseline
Mean (±SD)
FEV1 %pred
FEV1/FVC %
RV %pred
RV/TLC %
VDP %
Full Expiration Signal-Intensity %
Dynamic Proton Density %/L

FEV1 %pred
FEV1/FVC %
RV %pred
RV/TLC %
VDP %
Full Expiration Signal-Intensity %
Dynamic Proton Density %/L

n=14
64 (22)
58 (15)
157 (41)
44 (11)
10 (10)
42 (10)
4.4 (2.1)
Baseline

PC20

n=3
92 (13)
74 (5)
103 (12)
33 (4)
4 (2)
49 (6)
4.8 (0.6)

n=3
9 (6)
40 (3)
3.6 (0.2)

PostSalbutamol
n=14
72 (21)
63 (16)
139 (29)
40 (8)
8 (8)
42 (8)
4.3 (2.2)
PostSalbutamol
n=3
100 (15)
80 (9)
76 (6)
25 (3)
4 (3)
48 (7)
5.1 (1.6)

Significant
Difference*
p-value
<.001
.001
.05
.03
.1
.9
.8

.04
.1
.03
.008
.3
.03
.2

*Significance of difference (p<.05) was determined using a repeated measures ANOVA.
Figure 4-6 shows the results of a methacholine challenge and pre-to-post-salbutamol
changes in two different representative asthmatics. At PC20, for participant S14, MRI
signal-intensity was qualitatively diminished and there were numerous

3

He MRI

ventilation defects, most of which resolved post-salbutamol. In addition, dynamic protondensity maps reflected diminished differences between full inspiration and full expiration
signal-intensity as represented by the regions of warm colours.

After salbutamol

administration, the lung signal-intensity was visually higher than at PC20 and the dynamic
proton-density maps reflected greater differences between full inspiration and full
expiration as represented by the regions of cool colours. These images were visually
similar to what was observed in the healthy volunteers. For the individual patient S28 who
was evaluated pre- and post-salbutamol, MRI signal-intensity was increased post122

salbutamol and there was a concomitant reduction in 3He MRI ventilation defects.
Concomitant with these post-salbutamol changes, dynamic proton-density maps showed
that the difference between full inspiration and full expiration signal-intensity was greater
and this is represented by the regions of cool colours.
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Figure 4-6 Asthma Response to Bronchodilator
MRI at baseline, PC20, and post-salbutamol. For all subjects that underwent MCh (n=3),
the mean VDP was: pre-/post-MCh=4±2%/9±6%, mean full expiration UTE signalintensity was: pre-/post-MCh=49±6%/40±3%, and UTE dynamic proton-density was: pre/post-MCh=4.8±0.5%/L/3.6±0.2%/L. S14: Asthmatic subject is 45 year old female with
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pre-/post-salbutamol FEV1=103%pred/114%pred, RV/TLC=29%/23%. Baseline UTE at full
expiration signal-intensity/VDP/Dynamic proton-density=56%/2%/4.8%/L, post-MCh
UTE at full expiration signal-intensity/VDP/Dynamic proton-density=43%/16%/3.7%/L,
post-salbutamol UTE at full expiration signal-intensity/VDP/Dynamic protondensity=55%/2%/6.4%/L. For subjects that underwent pre-/post-salbutamol only (n=14),
the mean VDP pre-/post-Salbutamol was 10±10%/8±8%, the mean full expiration UTE
signal-intensity pre-/post-Salbutamol was 42±10%/42±8%, and the mean dynamic protondensity pre-/post-Salbutamol was 4.4±2.0/4.3±2.2%/L. S28: Asthmatic subject is 47 year
old female with pre-/post-salbutamol FEV1=55%pred/74%pred, RV/TLC=50%/43%.
Baseline
UTE
at
full
expiration
signal-intensity/VDP/Dynamic
protondensity=46%/4%/6.7%/L, post-salbutamol UTE at full expiration signalintensity/VDP/Dynamic proton-density=48%/3%/7.6%/L.

4.4

Discussion

Inhaled gas MRI biomarkers of asthma lung function have been developed over the past
decade and have disrupted our understanding about the regional heterogeneity of lung
functional abnormalities in asthmatics. While it has not been straightforward to replicate
these findings using conventional 1H MRI, we sought to establish such an approach by
developing multi-volume UTE lung biomarkers. Therefore, in this proof-of-concept study
in 30 participants, we investigated the potential of 3D UTE MRI as a practical way to
measure and understand regional asthma lung function and observed: 1) UTE dynamic
proton-density and signal-intensity measurements at full expiration and FRC were greater
in healthy volunteers as compared to asthmatics, 2) in asthmatics, UTE biomarkers were
significantly correlated with pulmonary function, CT radio-density and MRI VDP, and, 3)
subsequent to methacholine inhalation, there were qualitative changes in signal-intensity
and dynamic proton-density that resolved post-salbutamol.
First, we observed significantly greater normalized signal-intensity measurements in
healthy volunteers as compared to asthmatics. These findings were similar to previously
published work using CT that showed significantly lower radio-density in asthmatics than
in healthy volunteers.48 Diminished signal-intensity in the asthmatic lung may reflect gastrapping which is certainly plausible given that in these patients there is often premature
closure of peripheral airways toward the end of full expiration. In asthmatic lungs, small
airways also close at higher lung volumes than in healthy subjects -a result of increased
smooth muscle tone, edema, and or inflammation of the airway walls. In addition to
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diminished signal-intensity, there was also diminished dynamic proton-density in the
asthmatic subgroup. This was consistent with previous work using conventional 1H MR
that showed there was a larger change in signal-intensity across lung volumes in healthy
volunteers than in asthmatics29 which may be reflective of reduced lung compliance or
decreased compressibility due to gas-trapping in asthmatics.
Second, in the participants with asthma, we observed moderate-to-strong correlations for
UTE measurements with pulmonary function and CT measurements. Signal-intensity at
full expiration and dynamic proton-density were both significantly correlated with FEV1
and FEV1/FVC suggesting relationships with airflow obstruction. Signal-intensity at full
expiration was also correlated with RV/TLC which is consistent with the notion that gastrapping is responsible for signal-intensity differences in asthmatics. Similar findings were
previously reported using CT, where gas-trapping score was related to pulmonary function
tests.49
Whole lung and regional UTE signal-intensity and dynamic proton-density measurements
were also related to whole lung and regional CT radio-density. These findings are in
agreement with previous work in COPD patients.30 Similar to previous work in asthmatics
in which focal lucency was spatially correlated with 3He MRI ventilation defects,16 here
we also observed significant correlations for regional VDP and regional UTE
measurements. These relationships were weak-to-modest, perhaps reflective of asthma
heterogeneity and the relatively small sample size or that UTE measurements necessarily
include signal from the vasculature.
Finally, we also observed visually obvious changes in UTE images after methacholine and
salbutamol administration. To provide context, these results are similar to previous work
using diffusion-weighted 3He MRI to evaluate gas-trapping post-MCh.50 This previous
work demonstrated larger apparent diffusion coefficients (ADC) post-methacholine,
suggesting an increase in airspace size or gas-trapping. Here, using UTE methods, the
decrease in signal-intensity at PC20 suggests an increase in airspace size due to retained air
(i.e. gas-trapping) resulting in lower proton density per voxel. These results hold promise
for future studies attempting to evaluate treatment response in patients with asthma because
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these regions of low signal-intensity and low magnitude of dynamic proton-density may
provide potential targets for therapy.
Although this study provides promising preliminary results, we must point out a number
of study limitations. We acknowledge that CT was not acquired at full expiration and this
limited our ability to ascertain the etiology of CT lucency. Therefore, while we observed
a relationship for UTE signal-intensity and CT radio-density, this was not in itself
definitive for regional gas-trapping. However, signal-intensity at full expiration and
dynamic proton-density measurements were related to RV and to RV/TLC (both reflective
of gas-trapping) and to MRI ventilation defects. Previous studies have demonstrated the
relationship of expiratory CT lucency and 3He MRI ventilation abnormalities which is also
supportive of a relationship between gas-trapping and ventilation defects in asthma.16
There was a significant age difference between healthy volunteers and asthmatics which
may have biased some of the results. We should also stress that for three asthmatics, only
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Xe MRI was performed, which based on previous work, would be expected to be greater

than 3He VDP.43 Importantly however, when these data were removed from the analysis,
the correlations with VDP were not significantly different which may also be attributed to
a small sample size.

Finally, it should be noted that three subjects underwent the

methacholine challenge. Although there were significant differences in signal-intensity at
full expiration, caution must be taken when extrapolating these results to a larger sample
size.
In conclusion, we developed UTE MRI signal-intensity and dynamic proton-density
biomarkers of asthma that were related to pulmonary function and hyperpolarized noble
gas MR measurements of ventilation defects. These MRI measurements made using
conventional equipment suggested that UTE MRI may reflect ventilation heterogeneity
and/or gas-trapping in asthmatics, making this approach amenable for clinical use.
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CHAPTER 5

5

CONCLUSIONS AND FUTURE DIRECTIONS

In this final chapter, an overview and summary are provided in addition to the important
findings and conclusions of Chapters 2-4. The study specific limitations and general
limitations are also provided with some potential solutions. Finally, based on these
findings, an outline is provided for future pulmonary MRI studies.

5.1

Overview and Research Questions

Obstructive lung diseases, including COPD and asthma, affect over six million Canadians.
By 2030, it is projected that the current economic burden will double if no further
improvements (including drug development) are made in dealing with obstructive lung
disease.1 Despite decades of research, therapies that modify obstructive lung disease
progression and control are lacking.2,3 This is in part because the diagnosis and monitoring
of these patients and their response to therapy are currently made using airflow
measurements. These measurements, while important, cannot account for inter-subject
variability or be used to regionally evaluate pathologies. One goal of obstructive lung
disease research is to develop ways to identify patients with specific underlying
pathological phenotypes with the hope that this will improve patient care and outcomes.
In this regard, imaging methods such as thoracic CT and MRI have the potential to provide
regional and quantitative biomarkers of obstructive lung disease. As the first step to
identify patients with specific underlying pathological phenotypes, it is important to
understand the physiological and clinical consequences of these imaging derived
measurements.
In response to the need for a better understanding of imaging-derived biomarkers, studies
have evaluated the clinical significance of hyperpolarized noble gas MR biomarkers in
obstructive lung disease.4-6 Work using hyperpolarized noble gas MRI in aging has shown
that with increasing age there is a relationship with increased ventilation defects7 and
increased lung microstructure measured using 3He ADC.8 But this work did not ascertain
the clinical consequences of these biomarkers in older never-smokers. This understanding
is important to appreciate the pulmonary consequences associated with obstructive lung
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disease. Furthermore, hyperpolarized noble gas MRI has yet to find acceptance in the
clinic. Dose limiting advances in CT, limited availability of the necessary hardware for
polarizing and imaging hyperpolarized noble gases, and the identification of clinical
applications that will benefit from this have made clinical translation difficult. With this
in mind, there has been growing motivation for the development and implementation of
non-contrast enhanced pulmonary MRI to overcome the challenges of ionizing radiation
and resource accessibility.
Non-contrast enhanced pulmonary UTE MRI has been proposed as a way to address the
inherent challenges of pulmonary imaging that stem from low tissue and 1H density without
the use of specialized equipment or personnel. Recent studies using pulmonary UTE MRI
have quantified parenchymal signal-intensity as a function of lung volume or gravity
dependence in healthy volunteers.9 In mouse models, UTE MRI has been used to evaluate
inflammation and peribronchial abnormalities in animal models of asthma.10 Studies have
also used UTE MRI to produce T2* maps in murine models11 and healthy volunteers,12 and
have shown that this biomarker is related to smoking history in COPD.13 Previous work
using this technique provides a strong foundation for its use in obstructive lung disease
research and patient care; however, a major drawback is that the reproducibility and clinical
and physiological meaning of UTE-derived measurements in obstructive lung disease are
poorly understood. Thus, a clear understanding of UTE-derived biomarkers (including
reproducibility and clinical meaning) is necessary prior to widespread clinical translation.
The overarching objective of this thesis was to develop and evaluate lung structure and
function measurements using multi-nuclear MRI in aging and obstructive lung disease to
provide an understanding of the physiological and clinical consequences of these MRderived measurements. The specific research questions addressed were: 1) What are the
physiological and clinical consequences of MR-derived biomarkers in normal aging?
(CHAPTER 2); 2) Can non-contrast enhanced UTE MRI measurements be developed to
have high reproducibility (comparable to that of 3He derived measurements), and are these
measurements related to pulmonary function tests and CT measurements of emphysema in
obstructive lung disease (i.e. COPD)? (CHAPTER 3); and, 3) Can we extend the method
in Chapter 3 and merge different lung volume information to capture evidence of gas133

trapping and ventilation heterogeneity in patients with obstructive lung disease (i.e.
asthma)? (CHAPTER 4)

5.2

Summary and Conclusions

In Chapter 2 we determined the physiological consequences and potential relevance of
ventilation abnormalities in older never-smokers. We also evaluated the relationship of
ventilation defects with occupational exposures, pulmonary function, and exercise
capacity. We found that majority of older never-smokers (39/52) had ventilation defects
and 33 of these subjects had ventilation defects that did not resolve after bronchodilation.
The six older never-smokers that did respond to bronchodilation had significantly worse
baseline pulmonary function test measurements. However, most of these older neversmokers had normal pulmonary function test measurements, but with peripheral ventilation
defects that were not reversible by bronchodilation. Ventilation defects were related to
pulmonary function tests, however, dyspnea and exercise capacity were not. This study
builds the foundation of pulmonary abnormalities observed with aging. Obstructive lung
disease, such as COPD, tends to occur in elderly individuals and thus it will be important
in future studies to quantify lung function using MRI to differentiate between normal aging
and both aging and obstructive lung disease in this elderly diseased population.
We then developed and evaluated reproducibility of a non-contrast enhanced UTE MR
method in patients with COPD in Chapter 3. We tested the hypothesis that the signalintensity derived from UTE MRI has high short-term reproducibility in COPD and is
related to CT radio-density and pulmonary function test measurements.

In healthy

subjects, signal-intensity correlated with the inverse of lung volume (r=0.99, p=.007). The
coefficient of variation for 3-week repeated measurements was 4%. There were significant
correlations for signal-intensity with RA950 (r=-0.71, p=.005), FEV1/FVC (r=0.59, p=.02),
and for SI15 with HU15 (r=0.62, p=.01). We developed a UTE MRI method to generate
measurements of pulmonary signal-intensity that are strongly related to tissue density and
in subjects with COPD are related to pulmonary function and CT measurements.
In Chapter 4 of this thesis, we developed and utilized UTE MRI biomarkers of asthma lung
function. The mean signal-intensity at four lung volumes (full expiration, FRC, FRC+1L,
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and full inspiration) was quantified. The difference in MRI signal-intensity across four
lung volumes was also determined on a voxel-by-voxel basis to generate dynamic protondensity maps. The mean whole lung signal-intensity at full expiration and magnitude of
the dynamic proton density maps were significantly greater (p=.001) in healthy volunteers
than asthmatics.

Mean signal-intensity at full expiration (p<.01), FRC (p<.05) and

dynamic proton-density (p<.01) were greater in healthy-volunteers compared to
asthmatics. In asthmatics, UTE signal-intensity at full expiration and dynamic protondensity were correlated with FEV1/FVC (signal-intensity r=0.73/p=.002; dynamic protondensity r=0.75/p=.003), RV/TLC (signal-intensity r=-0.57/p=.02) or RV (dynamic protondensity r=-0.62/p=.02), CT radio-density (signal-intensity r=0.83/p=.006; dynamic protondensity r=0.71/p=.01) and lobar VDP (signal-intensity rs=-0.33/p=.02; dynamic protondensity rs=-0.47/p=.01). This work demonstrated that in patients with asthma, UTE MR
signal-intensity measurements were correlated with pulmonary function test measurements
of gas-trapping and airflow obstruction, provided information about regional ventilation
deficits and provided similar information as CT. Taken together, UTE MR measurements
may provide a surrogate measurement for ventilation heterogeneity and/or gas-trapping in
patients with asthma.
In summary, we have provided: 1) evidence that in a majority of older never-smokers there
are age-related changes in pulmonary ventilation that are not reversible by bronchodilation
and are related to pulmonary function test measurements, but not dyspnea or exercise
capacity; 2) a new and reproducible non-contrast enhanced MR method to evaluate
pulmonary abnormalities in patients with obstructive lung disease; and, 3) evidence that
the measurements derived from non-contrast enhanced MR are related to tissue density
measurements (evaluated using CT) and pulmonary function test measurements.

5.3

Limitations

In this section the most significant limitations from Chapters 2-4 will be discussed. It
should be noted that the study specific limitations are also presented in the Discussion
section of each respective Chapter.

135

5.3.1

Study Specific Limitations

Pulmonary ventilation defects in older never-smokers (Chapter 2)
In Chapter 2, we sought to better understand the physiological consequences and potential
relevance of 3He MRI ventilation defects in older never-smokers. We did not acquire CT
images which limited our understanding of age-related airway changes and their
relationship to ventilation defects. Our results, therefore, could not be directly compared
to more established CT measurements, such as the percentage of low attenuation pixels as
a measurement of the extent of senile emphysema or WA% as a measurement of airway
wall thickness. A direct comparison of CT and hyperpolarized 3He MRI measurements in
the same subjects would allow for a better understanding of the etiology of the ventilation
defects observed in older never-smokers.
Another limitation of this study was that subjects were classified by viewing the gray-scale
images, while the patients were still in the scanner. In two cases, once the ventilation
images were co-registered to the anatomical 1H images, offline, previously classified
ventilation defects could be directly related to anatomical bony structures and were
unlikely to be ventilation abnormalities. As a result, the two subjects, who were classified
at the scanner as having ventilation defects did not appear to have these once a full analysis
was completed.

Ideally, all subjects should have undergone deep inspiration and

salbutamol administration and image analysis should have been used to evaluate
bronchodilator response.
Finally, 129Xe and UTE MRI were not acquired in the older never-smokers. The high cost
of 3He gas has restricted translation of this imaging method beyond specialized MRI
centres. As previously discussed, this shortage is forcing the noble gas MRI community
to transition to 129Xe gas, a less expensive and more readily available contrast agent, and
non-contrast enhanced methods such as UTE MRI. One can hypothesize that ventilation
defects may be more prominent and obvious using
shown the increased sensitivity of
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Xe MRI since previous work has

Xe gas compared to 3He gas in OLD.14,15 One can

also hypothesize that UTE MR signal-intensity measurements would be lower in older
individuals than younger individuals due to increased resting lung volumes in older
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subjects. Regardless, future studies should aim to image older never-smokers using 129Xe
and UTE MRI to better understand the age-related changes in these imaging measurements.
Ultra-short echo-time pulmonary MRI: evaluation and reproducibility in COPD subjects
with and without bronchiectasis (Chapter 3)
In the study presented in Chapter 3, a reproducible UTE MRI method was developed and
an understanding of the physiological determinants of UTE signal-intensity in patients with
COPD was determined. First, we acquired single slice images rather than whole-lung
images. This limited our understanding of this measurement in the anterior and posterior
regions of the lung.
Second, it is important to note that the impact of effective transverse decay time T 2* on
signal-intensity at different lung volumes was ignored in healthy volunteers for two
reasons: 1) in human lungs, T2* variability was significantly smaller than other factors
affecting signal-intensity across different lung volumes 2) the echo-time of 0.05ms was
significantly smaller than the parenchymal T2* (0.5-0.8ms), which minimized T2*
weighting. Also, unlike CT, MRI signal-intensity is influenced by hardware factors such
as the positioning of the RF coils, which introduce inter-scan variability. While we
corrected for absolute signal intensity quantification by normalizing acquired images to the
liver, this is influenced by the precision of liver measurements. In this regard, we note that
the liver has minimal motion during the image acquisition and is relatively homogeneous
despite inter-subject signal variability.
Finally, we acknowledge that the histopathological relationship between UTE MRI signalintensity and CT radio-density measurements has not yet been established.

The

quantification of emphysema using CT uses different threshold type analyses has been
compared and validated with histology, yet this has not been undertaken with parenchymal
MRI signal intensity.

The comparison of mean MRI signal-intensity to CT RA950 and

HU15 is likely a conservative estimate of any direct relationships. For this reason, the
comparison of MRI-derived SI15 with CT-derived HU15 is likely a better estimate of the
direct relationships of MRI signal-intensity and CT radio-density measurements.
Ultra-short Echo Time Magnetic Resonance Imaging Biomarkers of Asthma (Chapter 4)
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In Chapter 4 we developed a whole lung breath-hold UTE MRI protocol and evaluated
asthmatics and healthy volunteers. There was a significant age difference between healthy
volunteers and asthmatics which may have biased our results.
Another limitation of this study was that CT was not acquired at full expiration. Chest CT
at full expiration allows for the evaluation of gas-trapping. The extent of the gas-trapping
can be evaluated using a threshold type measurements (i.e. the relative area under -856HU,
RA856).16 Unfortunately, this threshold is only appropriate when CT is acquired at a lung
volume of full expiration and this limited our understanding of regional gas-trapping.
Consequently, the mean whole lung radio-density was used for direct comparison with
mean whole lung signal-intensity.

It should be noted that not only does the mean

measurement not capture the extent of low signal-intensity, but the lack of expiratory CT
limits our understanding of regional gas-trapping and our ability to ascertain the etiology
of CT lucency. Although we can comment on the relationship of UTE signal-intensity and
CT radio-density, it is difficult to conclude that the signal-intensity at full expiration was
reflective of regional gas-trapping. We can conclude, however, that signal-intensity at full
expiration and dynamic proton-density measurements are related to pulmonary function
test measurements of gas-trapping such as residual volume and the ratio of residual volume
to total lung capacity. It is also important to note that UTE signal-intensity measurements
were related to hyperpolarized noble gas ventilation defects.

Previous studies have

demonstrated the relationship of CT lucency and 3He MRI which suggest the relationship
between gas-trapping and ventilation defects in asthma.17
Finally, for three asthmatics, only
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Xe MRI was performed, which based on previous

work, would be expected to be greater than 3He VDP.14 Importantly, however, when these
data were removed from the analysis, the correlations with VDP were not significantly
different. It should also be noted that three subjects underwent the methacholine challenge.
Although there were significant differences in signal-intensity at full expiration, caution
must be taken when extrapolating these results to a larger sample size.
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5.3.2

General Limitations

In Chapters 2-4, we used mean whole lung measurements of ventilation defects and signalintensity to evaluate the extent of pulmonary abnormalities. Mean measurements tend to
disregard the heterogeneity of lung disease. Threshold based measurements, such as VDP
and SI15, also do not capture the heterogeneity of obstructive lung disease. Moreover, these
measurements ignore the regions of signal hyper-intensity since VDP is dependent on the
noble gas signal that is of the lowest intensity and SI15 is dependent on the low signalintensity. Limitations with single threshold methods also include the over or underestimation of the disease, where a lower threshold differentiates more severe diseased
regions18 disregarding regions of mild disease and a higher threshold identifies regions of
mild disease.19 As a result, methods that diverge from single threshold measurements (e.g.
principal component analysis and texture analysis) have emerged20-22 to evaluate lung
disease. Automated evaluation of the CT density histogram using principal component
analysis21 has been used to generate a principal component score based on each frequency–
HU pair.21 The strength of this approach relates to the fact that a broad frequency
distribution of pixel intensities across a wide range of Hounsfield unit values is evaluated
to generate a single score. This measurement is strongly related to pulmonary function
tests and expert radiologist emphysema scores.21 In future studies, it will be important to
investigate pulmonary MR measurements that incorporate all signal-intensities to evaluate
obstructive lung disease.
An important limitation of this work is that we still do not understand the etiology of MR
ventilation defects in aging or UTE signal-intensity in obstructive lung disease. To truly
understand the cause of the MR-derived biomarkers presented in this thesis it is important
to determine the relationship between MRI measurements and histology and inflammatory
markers. Although it can be speculated that these pulmonary imaging abnormalities are
related to airway narrowing or wall thickening in older never-smokers, and emphysema or
gas-trapping in patients with obstructive lung disease, it is difficult to ascertain the cause
without histological specimen or other clinical biomarkers. Studies in mouse models of
asthma10,23 and emphysema11 have demonstrated the relationship between histology and
1

H MR-derived measurements.

Studies have also shown differences in eosinophil
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percentages of bronchoalveolar lavage fluid that correspond to proton MR measurements
in patients with asthma that have undergone an allergy challenge.24 However, future
studies still need to investigate the etiology of MR-derived biomarkers for us to fully
understand what these measurements represent in patients with obstructive lung disease.
Another important limitation to this work is the limited availability of 3He gas. It should
be noted that Chapters 2-4 used 3He MRI to evaluate static ventilation and/or apparent
diffusion coefficients. The high cost of 3He gas has restricted translation of this imaging
method beyond specialized MRI centres. As previously discussed, this shortage is forcing
the noble gas MRI community to transition to 129Xe gas, a less expensive and more readily
available inhaled gas. Studies have shown increased sensitivity to ventilation defects in
COPD and asthma using 129Xe MRI.14,15 If Chapters 2 and 4 were to be done using 129Xe,
one may hypothesize that the extent of ventilation defects may be of greater magnitude
than the values reported. Regardless of this speculation, future

129

Xe MRI studies are

required to validate the results presented here using 3He MRI. Moreover, future research
and potential clinical applications of noble gas MRI will most definitely utilize 129Xe gas.
Finally, for clinical translation of the presented methods it is important to understand their
reproducibility and feasibility across a number of centres and in a clinically relevant
population. As stated before, MR measurements are influenced by hardware factors such
as RF amplifications and the positioning of the RF coils, which introduce inter-scan
variability. An important application for the MR methods presented is pediatric imaging
(e.g. survivors of preterm birth and those with bronchopulmonary dysplasia) and those
subjects who require longitudinal monitoring (e.g. those with hereditary disorders such as
alpha-1 antitrypsin deficiency). These populations are vulnerable to the radiation burden
associated with CT based methods. To better understand these biomarkers in pediatric
populations, one might want to image a younger cohort. Thus, future studies should aim
to evaluate these MR methods across several sites and in a pediatric cohort.
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5.4

Future Directions

5.4.1

Ultra-short echo time MRI Measurements of Tissue Density using
Principal Component Analysis

In Chapters 3 and 4, we evaluated obstructive lung disease using mean signal-intensity of
the UTE images. Pulmonary emphysema has been quantified using mean signal-intensity
and T2* measurements enabled by UTE MRI.25 Previous work also showed the utility of
a single MRI signal-intensity threshold based on thoracic CT emphysema thresholds.26
Thoracic CT threshold-based emphysema measurements are correlated to pulmonary
function tests, 27 and both microscopic and macroscopic measurements of emphysema,28,29
but there is no consensus regarding an optimal threshold. Recent work has used principal
component analysis (PCA) of CT radio-density histograms to assess emphysema. This
method uses a broad frequency distribution of pixel intensities across a wide range of
density values to produce a single score and measurements derived from this method have
been shown to correlate with pulmonary function tests and expert radiologist emphysema
scores.21
We have performed preliminary analysis in a small proof-of-concept study in which PCA
was used to evaluate the UTE signal-intensity histograms to generate principal components
based on each frequency-signal intensity pair. We wanted to evaluate and compare the
performance of the UTE signal-intensity PCA score with CT measurements.
Frequency histograms of MR signal-intensity and CT radio-density (Hounsfield Units,
HU) were generated and PCA was performed on the relative area under the histogram curve
for each signal-intensity and HU value. Principal components (PC) were generated based
on the variation between input variables. The first two PCs with the highest eigenvalues
were selected and the density histogram principal component score (DHPCS) and signalintensity histogram principal component score (SHPCS) were determined, as previously
described:21
Equation 5-1

𝑆𝐻 𝑃𝐶 𝑆 = ∑50
0 𝑅𝐴𝑖 𝑃𝐶𝑖
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Where RA is the relative area under the histogram curve for each signal-intensity value
and PC is the principal component value calculated from PCA analysis.
In this preliminary work in 10 COPD ex-smokers (68±8yrs) with CT evidence of
emphysema, UTE signal-intensity histogram PC scores were determined. Figure 5-1
shows mean signal-intensity, CT radio-density histograms and corresponding principal
components. SHPCS was significantly correlated with DHPCS (r2=0.49, p=.02). As shown
in Figure 5-2, SHPCS significantly correlated with RA950 (r2=0.43, p=.04) and FEV1/FVC
(r2=0.50, p=.02), but not HU15 (r2=0.34, p=.08), DLCO (r2=0.08, p=.5) or six minute walk
distance (6MWD) (r2=0.14, p=.3). SI15 was not significantly correlated with RA950
(r2=0.05, p=.5), HU15 (r2=0.08, p=.4), FEV1/FVC (r2=0.09, p=.4), DLCO (r2=0.0004, p=.9)
or 6MWD (r2=0.34, p=.06). We speculate that in a larger population of COPD subjects,
PCA can be used to derive a UTE MRI score that is related to CT measurements of
emphysema and gas-trapping. Accordingly, the next steps require a similar but larger-scale
validation study of UTE PCA in COPD.

Figure 5-1 UTE signal-intensity and CT radio-density histograms and corresponding
principal components generated by PCA with sum of the first and second principal
components.
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Figure 5-2 Relationships between UTE PCA score (SHPCS-defined as the summation of
the relative frequency multiplied by the principal component value) and CT and pulmonary
function test measurements.

5.4.2

The Etiology of Ultra-short echo time MRI Signal-Intensity

In this thesis, we demonstrated that UTE MR measurements are reproducible and related
to CT measurements of tissue density. However, unlike CT measurements, MRI signalintensity is dependent on four parameters that include the proton density, T1 relaxation, T2
relaxation, and flow. Briefly, proton density is the concentration of protons in the tissue in
the form of water, fats, or proteins (i.e. macromolecules), T1 and T2 define the way the
protons revert back to their resting states after excitation, and flow effects are due to the
loss of signal due to arterial blood flow. UTE measurements of signal-intensity have the
potential to be novel biomarkers of tissue density (e.g. parenchymal loss due to emphysema
or regions of inflammation) in longitudinal studies of lung disease. But before this goal
can be achieved, the etiology of regions of low UTE signal-intensity and high signalintensity need to be determined.
To determine the etiology of UTE signal-intensity, there are various potential studies that
could be performed. The most concrete evidence would be provided by histological
evidence to determine the underlying pathology leading to regions of either high or low
signal-intensity. Previous work in mouse models of asthma10,23 and emphysema11 have
demonstrated the relationship between histology and 1H MR-derived measurements. To
evaluate the cause of these regions of low signal-intensity, a study following a similar
protocol, but with a human population undergoing lung transplantation should be
considered. Sampling the areas within the regions of low signal-intensity would allow for
the evaluation of the parenchyma in the region of the low signal-intensity to determine
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whether or not bullae or gas-trapping were present that may have contributed to the region
of low signal. The area of the lungs that precede the ventilation defect should also be
sampled to determine what lead to these regions of low signal.
In patients with asthma who have undergone an allergy challenge, studies have shown
differences in eosinophil percentages of bronchoalveolar lavage fluid that correspond to
increased regions of high signal-intensity.24 Similar work could be done to evaluate the
etiology of high signal-intensity regions where inflammation biomarkers are acquired to
determine whether or not the high signal-intensity corresponds to inflammation, edema, or
other pathologies that can potentially increase tissue density.

5.4.3

Ultra-short echo time MRI of Emphysema in Adults with Alpha-1Antitrypsin Deficiency

Alpha-1-Antitrypsin Deficiency (AATD) is a hereditary disorder caused by a mutation in
the SERPINA1 gene, which leads to a dysregulation in neutrophil elastase.30 This disease
affects approximately 1/5000 North Americans.31,32 One of the hallmark findings of this
chronic and progressive disease is panlobular emphysema which is mainly located in the
lower lobes of the lung. This under-recognized genetic condition increases the risk of
COPD.33 Similar to smoking-related emphysema, AATD related emphysema has no cure.
Therapies do exist, however, to slow the progression of alveolar destruction (e.g.
exogenous alpha-1 antitrypsin augmentation therapy).
Current tools available to longitudinally monitor and evaluate therapy response in AATD
include pulmonary function tests and imaging methods such as thoracic CT. However,
pulmonary function tests do not provide regional information. Studies have shown the CT
is more sensitive at monitoring emphysema progression in patients with AATD.34-36 CT
has also been used to monitor therapy response from augmentation therapy.37
Unfortunately, x-ray based imaging methods pose radiation concerns especially in these
patients where serial monitoring is important. Hyperpolarized noble gas MRI offers highly
reproducible measurements of lung microstructure and may serve as a sensitive tool to
evaluate disease progression. However, the translation of this method to clinic is limited
due to advances in CT and limited availability of the necessary hardware for polarizing and
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imaging hyperpolarized noble gases. UTE MRI provides a non-contrast enhanced and nonionizing alternative to pulmonary imaging with reproducible measurements of tissue
density (Chapter 3). UTE MR-derived measurements may serve as sensitive biomarkers
to evaluate disease progression and response to potential AATD therapies.
Figure 5-3 shows coronal CT, UTE MR, and hyperpolarized noble gas images of three
AATD patients with decreasing lung function. The signal intensity in the UTE images
becomes visually lower from S1 to S3. In S2 (smoking history<0.5 pack-years) there are
regions of visually obvious low signal intensity in the lower lobes of the UTE images that
spatially correspond to the regions of ventilation defects and low radiodensity. Similarly,
in S3 (smoking history=43 pack years), there are regions of low signal-intensity that
visually correspond to regions of low radiodensity and ventilation defects. In this case,
these regions are apparent in both the upper and lower lobes indicative of perhaps
panlobular and centrilobular emphysema.
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Figure 5-3 Pulmonary MR and CT of AATD.
Thoracic CT, UTE MRI at full expiration and FRC+1L, and 3He MR static ventilation
images shown for AATD subjects with decreasing lung function (S1: FEV1=77%pred, S2:
FEV1=55%pred, S3: FEV1=32%pred).
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Initial investigations should focus on qualitatively and quantitatively comparing CT and
UTE MR images in a larger cohort of AATD. Future work should aim to answer the
following research questions:
1) Can UTE MRI provide similar information to that of CT in patients with AATD?
2) Are there regional structural and functional relationships between UTE MRI and
hyperpolarized noble gas MRI?
3) What are the relationships between UTE MR signal-intensity measurements and
pulmonary function test measurements in patients with AATD?
4) Can UTE MRI be used to monitor treatment response in AATD?

5.4.4

From Neonatal Chronic Lung Disease to Early Onset Adult COPD:
Ultra-short echo time MRI of Bronchopulmonary Dysplasia

Bronchopulmonary dysplasia (BPD) is a chronic lung disease resulting from oxygen
therapy, mechanical-ventilation, and/or surfactant deficiency in premature infants who
require oxygen 36 weeks post-menstrual age.38 Studies in infants39 with BPD have
consistently demonstrated abnormalities in the peripheral lung, including failed
alveolarization with a decreased number of large and simplified alveoli.38 Although welldescribed in children, the long-term respiratory consequences of BPD in adults are not
well-understood, although it is hypothesized that the risk of chronic lung disease and
emphysema are increased.40 Consequently, there is growing interest in risk factors beyond
smoking given the development of emphysema and COPD in non-smokers.41 Equipped
with the knowledge of how the normal lung ages (Chapter 2) and the pulmonary MRI
abnormalities that result in obstructive lung disease (Chapters 3 and 4), we can evaluate
patients who are at risk of developing COPD with age. More importantly, we can evaluate
regional structural and functional information using MRI without the use of ionizing
radiation.
Individuals born extremely preterm, especially with BPD, share many clinical features with
COPD patients.

Prematurity-related morbidities are quite substantial and impact on
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patient’s health status such as seen in COPD patients.42 Airflow obstruction is only
partially reversible following administration of bronchodilators.43 In fact, studies have
shown that over 70% of children with BPD do not respond to bronchodilators as
demonstrated by lack of significant increase in FEV1.44 Not only is there is no cure for
BPD,45 there are no evidence-based or consensus-based guidelines for its treatment in
adults.45 Stem cell therapies aimed at regenerating damaged lung tissue are now being
developed, yet there are few tools that allow for longitudinal measures of treatment
efficacy.46 Moreover, our understanding of the morphological alterations of lung structure
in patients with BPD is limited due to the difficulty of obtaining lung tissue from living
individuals. Proton and inhaled hyperpolarized noble gas MRI provide ways to visualize
functional and structural pulmonary information.
We have performed preliminary analysis in a single young adult (a survivor of extreme
prematurity of birth) with bronchopulmonary dysplasia. She was born at 27 weeks
gestation and was mechanically ventilated and in the neonatal intensive care unit for six
weeks without surfactant therapy. She underwent pulmonary function tests, chest x-ray,
hyperpolarized 3He and UTE MRI, both pre- and post-salbutamol. As shown in Figure 54, cyst-like regions of low UTE signal-intensity were similar to previous MRI findings in
infants47 and previous CT findings in adults.48 These regions of low UTE signal-intensity
likely reflected gas-trapping and/or emphysema and have been hypothesized to be
associated with prolonged mechanical-ventilation47 often injurious to immature, surfactant
deficient lungs.49

3

He ventilation defects were clearly abnormal and irreversible and

spatially related to regions of low signal-intensity and elevated lung microstructure
measurements, reflective of enlarged airspaces.

Abnormal ADC (whole-lung mean

ADC=0.36cm2/s) were also heterogeneously distributed throughout the lung. These results
demonstrate the feasibility of pulmonary MRI in BPD patients and showed the potential
for MRI biomarkers to provide a better understanding of underlying pathophysiology
responsible for symptoms and disease worsening in BPD patients.
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Figure 5-4 Pulmonary MR Images of a young adult with BPD.
Ultra-short echo time (UTE) MR images at full expiration and full inspiration shown for
the posterior, centre, and anterior slices. Hyperpolarized 3He static ventilation (cyan)
images overlaid on FGRE anatomical images (greyscale) and ADC maps shown for
posterior to anterior slices (from left to right).
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In a study currently underway, we aim to use UTE and noble gas MRI to evaluate preterm
young adults with and without BPD. We hypothesize that young adults born preterm have
imaging abnormalities that can be used to evaluate the risk of developing COPD with age.
This knowledge will help provide opportunities for early disease interventions. The
overarching objective of this work is to characterize the structural and functional
pulmonary changes following preterm birth in young adults. This study will address the
following research questions:
1) Are there differences in UTE MR images of young adults born preterm with and
without BPD and term-born controls?
2) What are the relationships between UTE MR signal-intensity measurements and
pulmonary function test measurements in young adults born preterm with and
without BPD and term born controls?
3) Can UTE MRI be used to longitudinally evaluate young adults born preterm with
and without BPD to better understand the natural history of BPD? Are longitudinal
changes in UTE MRI measurements in young adults born preterm similar to those
young adults born at term?

5.5

Significance and Impact

Obstructive lung disease affects over six million Canadians and costs the economy $12
billion per year in direct and indirect expenditures. These diseases affect individuals of all
ages and can start from birth lasting until the end of life. Despite years of research,
obstructive lung disease continues to takes its toll on our healthcare system and economy.
More importantly, the quality of life of patients and families facing a life-long battle with
lung disease is severely burdened. For many patients, current therapies do not modify
disease progression or control requiring the need for hospitalizations or emergency
department visits which lead to days lost at school or work. Pulmonary function tests are
the gold standard for the diagnosis, monitoring, and evaluation of response to therapy in
patients with obstructive lung disease. These measurements, while important, conceal the
regional contributions of underlying pathologies.
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Accordingly, a necessary goal of

obstructive lung disease research is to develop ways to identify patients with specific
underlying pathological phenotypes to further personalize medicine with the hopes to
improve patient care and outcomes. Imaging methods such as thoracic CT and MRI have
the potential to provide regional and quantitative biomarkers of obstructive lung disease.
Until now, pulmonary MRI has focused on hyperpolarized noble gas MRI. These inhaled
gas MR methods have yet to find wide-ranging acceptance in the clinic. Advances in low
dose CT, limited availability of the necessary hardware for polarizing and imaging
hyperpolarized noble gases, and the determination of clinically-relevant applications have
made clinical translation difficult. However for clinical trials, especially those including a
placebo cohort, repeated exposure to ionizing radiation must be considered given that there
may be no clinical benefit to monitoring these subjects.
In this thesis we have evaluated pulmonary MR biomarkers in aging and disease to better
understand their physiological and clinical consequences. Not only have we provided a
basis for imaging abnormalities associated with pulmonary aging, we have introduced a
novel method for quantifying lung tissue density without the use of ionizing radiation or
inhaled gas contrast. UTE signal-intensity measurements have high reproducibility and
are related to pulmonary function test and CT measurements in obstructive lung disease.
These methods can be used on clinically available MR scanners without additional
specialized equipment or personnel and have the potential to longitudinally evaluate
emphysema/gas-trapping for exploratory research or drug-development.

151

5.6

References

(1)

Louis Theriault, G. H., Danielle Goldfarb, Carole Stonebridge, Fares Bounajm.
Cost Risk Analysis for Chronic Lung Disease in Canada. (Ottawa, Canada, 2012).

(2)

Vestbo, J. et al. Global strategy for the diagnosis, management, and prevention of
chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir
Crit Care Med 2013; 187: 347-365.

(3)

Reddel, H. K. et al. A summary of the new GINA strategy: a roadmap to asthma
control. Eur Respir J 2015; 46: 622-639.

(4)

Svenningsen, S. et al. What are ventilation defects in asthma? Thorax 2014; 69: 6371.

(5)

Svenningsen, S., Nair, P., Guo, F., McCormack, D. G. & Parraga, G. Is ventilation
heterogeneity related to asthma control? Eur Respir J 2016.

(6)

Kirby, M., Pike, D., Coxson, H. O., McCormack, D. G. & Parraga, G.
Hyperpolarized He Ventilation Defects Used to Predict Pulmonary Exacerbations
in Mild to Moderate Chronic Obstructive Pulmonary Disease. Radiology 2014;
140161.

(7)

Parraga, G., Mathew, L., Etemad-Rezai, R., McCormack, D. G. & Santyr, G. E.
Hyperpolarized 3He magnetic resonance imaging of ventilation defects in healthy
elderly volunteers: initial findings at 3.0 Tesla. Acad Radiol 2008; 15: 776-785.

(8)

Fain, S. B. et al. Detection of age-dependent changes in healthy adult lungs with
diffusion-weighted 3He MRI. Acad Radiol 2005; 12: 1385-1393.

(9)

Lederlin, M. & Cremillieux, Y. Three-dimensional assessment of lung tissue
density using a clinical ultrashort echo time at 3 tesla: A feasibility study in healthy
subjects. J Magn Reson Imaging 2013.

152

(10)

Bianchi, A., Ozier, A., Ousova, O., Raffard, G. & Cremillieux, Y. Ultrashort-TE
MRI longitudinal study and characterization of a chronic model of asthma in mice:
inflammation and bronchial remodeling assessment. NMR Biomed 2013.

(11)

Takahashi, M. et al. Ultra-short echo time (UTE) MR imaging of the lung:
comparison between normal and emphysematous lungs in mutant mice. J Magn
Reson Imaging 2010; 32: 326-333.

(12)

Togao, O., Tsuji, R., Ohno, Y., Dimitrov, I. & Takahashi, M. Ultrashort echo time
(UTE) MRI of the lung: assessment of tissue density in the lung parenchyma. Magn
Reson Med 2010; 64: 1491-1498.

(13)

Ohno, Y. et al. T2* measurements of 3-T MRI with ultrashort TEs: capabilities of
pulmonary function assessment and clinical stage classification in smokers. AJR
Am J Roentgenol 2011; 197: W279-285.

(14)

Svenningsen, S. et al. Hyperpolarized He and Xe MRI: Differences in asthma
before bronchodilation. J Magn Reson Imaging 2013.

(15)

Kirby, M. et al. Pulmonary ventilation visualized using hyperpolarized helium-3
and xenon-129 magnetic resonance imaging: differences in COPD and relationship
to emphysema. J Appl Physiol 2013; 114: 707-715.

(16)

Busacker, A. et al. A multivariate analysis of risk factors for the air-trapping
asthmatic phenotype as measured by quantitative CT analysis. Chest 2009; 135: 4856.

(17)

Fain, S. B. et al. Evaluation of structure-function relationships in asthma using
multidetector CT and hyperpolarized He-3 MRI. Acad Radiol 2008; 15: 753-762.

(18)

Muller, N. L., Staples, C. A., Miller, R. R. & Abboud, R. T. "Density mask". An
objective method to quantitate emphysema using computed tomography. Chest
1988; 94: 782-787.

153

(19)

Coxson, H. O. et al. A quantification of the lung surface area in emphysema using
computed tomography. Am J Respir Crit Care Med 1999; 159: 851-856.

(20)

Xu, Y., Sonka, M., McLennan, G., Guo, J. & Hoffman, E. A. MDCT-based 3-D
texture classification of emphysema and early smoking related lung pathologies.
IEEE Trans Med Imaging 2006; 25: 464-475.

(21)

Owrangi, A. M., Etemad-Rezai, R., McCormack, D. G., Cunningham, I. A. &
Parraga, G. Computed tomography density histogram analysis to evaluate
pulmonary emphysema in ex-smokers. Acad Radiol 2013; 20: 537-545.

(22)

Mohamed Hoesein, F. A. et al. Computed tomography-quantified emphysema
distribution is associated with lung function decline. Eur Respir J 2012; 40: 844850.

(23)

Conti, G. et al. Evaluation of lung inflammation induced by intratracheal
administration of LPS in mice: comparison between MRI and histology. MAGMA
2010; 23: 93-101.

(24)

Vogel-Claussen, J. et al. Quantification of pulmonary inflammation after segmental
allergen challenge using turbo-inversion recovery-magnitude magnetic resonance
imaging. Am J Respir Crit Care Med 2014; 189: 650-657.

(25)

Zurek, M., Boyer, L., Caramelle, P., Boczkowski, J. & Crémillieux, Y.
Longitudinal and noninvasive assessment of emphysema evolution in a murine
model using proton MRI. Magnetic Resonance in Medicine 2012; 68: 898-904.

(26)

Ma, W. et al. Ultra-short echo-time pulmonary MRI: Evaluation and
reproducibility in COPD subjects with and without bronchiectasis. J Magn Reson
Imaging 2014.

(27)

Park, K. J., Bergin, C. J. & Clausen, J. L. Quantitation of emphysema with threedimensional CT densitometry: comparison with two-dimensional analysis, visual

154

emphysema scores, and pulmonary function test results. Radiology 1999; 211: 541547.
(28)

Gevenois, P. A., de Maertelaer, V., De Vuyst, P., Zanen, J. & Yernault, J. C.
Comparison of computed density and macroscopic morphometry in pulmonary
emphysema. Am J Respir Crit Care Med 1995; 152: 653-657.

(29)

Gevenois, P. A. et al. Comparison of computed density and microscopic
morphometry in pulmonary emphysema. Am J Respir Crit Care Med 1996; 154:
187-192.

(30)

Stoller, J. K. Alpha-1 antitrypsin deficiency: An underrecognized, treatable cause
of COPD. Cleve Clin J Med 2016; 83: 507-514.

(31)

Marciniuk, D. et al. Alpha-1 antitrypsin deficiency targeted testing and
augmentation therapy: A Canadian Thoracic Society clinical practice guideline.
Can Respir J 2012; 19: 109-116.

(32)

Stoller, J. K. & Aboussouan, L. S. A review of α1-antitrypsin deficiency. American
journal of respiratory and critical care medicine 2012; 185: 246-259.

(33)

Evald, T., Dirksen, A., Keittelmann, S., Viskum, K. & Kok-Jensen, A. Decline in
pulmonary function in patients with alpha 1-antitrypsin deficiency. Lung 1990; 168
Suppl: 579-585.

(34)

Dirksen, A. et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation
therapy. Am J Respir Crit Care Med 1999; 160: 1468-1472.

(35)

Dawkins, P. A., Dowson, L. J., Guest, P. J. & Stockley, R. A. Predictors of mortality
in alpha1-antitrypsin deficiency. Thorax 2003; 58: 1020-1026.

(36)

Parr, D. G., Stoel, B. C., Stolk, J. & Stockley, R. A. Validation of computed
tomographic lung densitometry for monitoring emphysema in alpha1-antitrypsin
deficiency. Thorax 2006; 61: 485-490.
155

(37)

Chapman, K. R. et al. Intravenous augmentation treatment and lung density in
severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind,
placebo-controlled trial. Lancet 2015; 386: 360-368.

(38)

Jobe, A. H. & Bancalari, E. Bronchopulmonary dysplasia. Am J Respir Crit Care
Med 2001; 163: 1723-1729.

(39)

Husain, A. N., Siddiqui, N. H. & Stocker, J. T. Pathology of arrested acinar
development in postsurfactant bronchopulmonary dysplasia. Hum Pathol 1998; 29:
710-717.

(40)

Saigal, S. & Doyle, L. W. An overview of mortality and sequelae of preterm birth
from infancy to adulthood. The Lancet 2008; 371: 261-269.

(41)

Eisner, M. D. et al. An official American Thoracic Society public policy statement:
Novel risk factors and the global burden of chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 2010; 182: 693-718.

(42)

Zwicker, J. G. & Harris, S. R. Quality of life of formerly preterm and very low birth
weight infants from preschool age to adulthood: a systematic review. Pediatrics
2008; 121: e366-376.

(43)

Fawke, J. et al. Lung function and respiratory symptoms at 11 years in children
born extremely preterm: the EPICure study. Am J Respir Crit Care Med 2010; 182:
237-245.

(44)

Baraldi, E., Bonetto, G., Zacchello, F. & Filippone, M. Low exhaled nitric oxide in
school-age children with bronchopulmonary dysplasia and airflow limitation. Am J
Respir Crit Care Med 2005; 171: 68-72.

(45)

Kotecha, S. J. et al. Effect of bronchodilators on forced expiratory volume in 1 s in
preterm-born participants aged 5 and over: a systematic review. Neonatology 2015;
107: 231-240.

156

(46)

van Haaften, T. et al. Airway delivery of mesenchymal stem cells prevents arrested
alveolar growth in neonatal lung injury in rats. American journal of respiratory and
critical care medicine 2009; 180: 1131-1142.

(47)

Adams, E. W. et al. Magnetic resonance imaging of lung water content and
distribution in term and preterm infants. Am J Respir Crit Care Med 2002; 166:
397-402.

(48)

Howling, S. J. et al. Pulmonary sequelae of bronchopulmonary dysplasia survivors:
high-resolution CT findings. AJR Am J Roentgenol 2000; 174: 1323-1326.

(49)

Dreyfuss, D. & Saumon, G. Ventilator-induced lung injury: lessons from
experimental studies. Am J Respir Crit Care Med 1998; 157: 294-323.

157

APPENDIX
Appendix A – Permission for Reproduction of Scientific Articles

158

159

160

Appendix B – Health Science Research Ethics Board Approval Notices

161

162

163

164

165

Appendix C – Curriculum Vitae
EDUCATION
08/12-11/16

Doctor of Philosophy in Medical Biophysics (Candidate)
Department of Medical Biophysics
The University of Western Ontario, London, Ontario, Canada
Supervisor: Dr. Grace Parraga
Thesis Title: Multi-nuclear Magnetic Resonance Imaging of
Obstructive Lung Disease

08/12-11/16

Clinical Master of Science in Medical Biophysics
(CAMPEP-accredited) (Candidate)
Department of Medical Biophysics
The University of Western Ontario, London, Ontario, Canada
Supervisor: Dr. Grace Parraga

09/08-08/12

Bachelor of Science
Honours Physics and High Technology (Medical Physics)
with Co-op
Minor in Mathematics
The University of Windsor, Windsor, Ontario, Canada

POSITIONS
09/12-present

Graduate Research Assistant
Department of Medical Biophysics
The University of Western Ontario, London, Ontario, Canada
Supervisor: Dr. Grace Parraga

05/14-08/14,
09/15-12/15

Quality Assurance Internship
London Regional Cancer Program
London Health Science Centre, London, Ontario, Canada
Supervisor: Dr. Slav Yartsev

09/11-12/11

Production Engineer Co-op Student
Production Department
Tokai Rika Quality Safety Systems Company, Tecumseh, Ontario,
Canada

07/11-11/11

Student Research Assistant
Department of Physics
The University of Windsor, Windsor, Ontario, Canada
Supervisor: Dr. Steven Rehse
Project: Laser Based Identification of Bacteria using Discriminant
Function Analysis
166

01/11-04/11

Student Research Assistant
Department of Physics
TRIUMF, Vancouver, British Columbia, Canada
Supervisor: Dr. Michael Hasinoff
Project: Time Reversal Experiment with Kaon Decay

05/10-09/10

X-ray Diffraction Technician
Department of Research and Design
Proto Manufacturing, Sandcastle, Ontario, Canada

ACADEMIC AWARDS, SCHOLARSHIPS, and DISTINCTIONS
09/16

Western University Doctoral Excellence Research Award
Awarded to a full time graduate student holding a national tri-agency
(i.e. CIHR, NSERC, or SSHRC) doctoral scholarship.
Institutional
$10,000

05/16

International Society for Magnetic Resonance in Medicine Magna
Cum Laude Award
Awarded to the top 15% of written abstracts at the annual
international meeting within a major subject review category.
International

05/16

International Society for Magnetic Resonance in Medicine
Educational Stipend Award
Awarded to support the attendance of students, postdoctoral and
clinical trainees to present abstracts at the scientific meeting.
International
$475 USD

03/16

London Health Research Day Top Written Abstract in Circulatory
Category
Awarded to the top written abstract within a major subject category.
Institutional
$100

05/15-05/16

Western University Ontario Graduate Scholarship
Queen Elizabeth II Graduate Scholarship in Science and Technology
Awarded to a full time graduate student for stipend support who has
maintained an average of 80% or more and exhibits research ability,
excellent communication skills, and interpersonal and leadership
abilities.
Provincial
$15,000
167

Declined
05/15-05/17

Natural Sciences and Engineering Research Council of Canada
(NSERC)
Alexander Graham Bell Canadian Graduate Scholarship (CGS)
Doctoral
Award based on academic excellence, research ability, and
communication, interpersonal, and leadership abilities.
National
$70,000

06/15

International Society for Magnetic Resonance in Medicine
Educational Stipend Award
Awarded to support the attendance of students, postdoctoral and
clinical trainees to present abstracts at the scientific meeting.
International
$360 USD

09/13-Present

Canadian Institutes of Health Research Strategic Training Program in
Vascular Research
Institutional
$20,000

05/13-05/14

Western University Ontario Graduate Scholarship
Queen Elizabeth II Graduate Scholarship in Science and Technology
Awarded to a full time graduate student for stipend support who has
maintained an average of 80% or more and exhibits research ability,
excellent communication skills, and interpersonal and leadership
abilities.
Provincial
$15,000

09/12-09/13

Schulich Graduate Scholarship, The University of Western Ontario
Awarded to a full time graduate student for stipend support who has
maintained an average of 80% or more.
Institutional
$4,500

04/12, 01/09

Dean’s Honour Roll
Awarded to a full-time student who has maintained an 11.0 or more
out of 13.0.
Institutional

09/10

Canadian Interuniversity Sport Academic All-Canadian
Awarded to a student-athlete who has maintained an 80% average
while competing as a varsity athlete.
168

National
09/10

Recognition of Achievement Bursary
Awarded to students on OSAP assistance who have maintained an
80% or higher average
Provincial
$1000

09/10

Blue and Gold Scholarship, The University of Windsor
Awarded to a student-athlete who has excelled at his/her sport.
Institutional
$200

09/08-09/09

Outstanding Scholars Scholarship
Awarded upon admission to Windsor students who have an admission
average of 85% or more.
Institutional
$1500

09/08

Interfaculty Physics Scholarship
Awarded upon admission to the top five Honours Physics students
who have the highest admission average
Institutional
$1000

PUBLICATIONS and PRESENTATIONS
A. Refereed Journal Manuscripts (14 published, 4 submitted)
Published (14)
1. K Sheikh, F Guo, A Ouriadov, DPI Capaldi, RL Eddy, S Svenningsen, G Parraga. Ultrashort Echo Time Magnetic Resonance Imaging Biomarkers of Asthma. Submitted to
Journal of Magnetic Resonance Imaging (MS # JMRI-16-0866R1 in press).
2. F Guo, S Svenningsen, RL Eddy, DPI Capaldi, K Sheikh, J Yuan, A Fenster, G Parraga.
Anatomical Pulmonary Magnetic Resonance Imaging Segmentation for Regional
Structure-Function Measurements of Asthma. Medical Physics (MS #16-156R in press).
3. C Davis, K Sheikh, D Pike, S Svenningsen, DG McCormack, D O’Donnell, JA Neder, G
Parraga. Ventilation Heterogeneity in Never-Smokers and COPD: Comparison of
Pulmonary Functional Magnetic Resonance Imaging with the Poorly Communicating
Fraction Derived from Plethysmography. Academic Radiology. 2016 Apr;23(4):398-405.
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4. GA Paulin, A Ouriadov, E Lessard, K Sheikh, NAM Paterson, DG McCormack, G
Parraga. Non-Invasive Quantification of Alveolar Morphometry in Older Never-Smokers.
Physiological Reports 2015 Oct; 3(10): e12583.
5. K Sheikh, HO Coxson, G Parraga. This is What COPD Looks Like. Respirology 2016
Feb; 21(2):224-236. Cover of Journal.
6. K Sheikh, DPI Capaldi, DA Hoover, DA Palma, BP Yaremko, G Parraga. Magnetic
Resonance Imaging Biomarkers of Chronic Obstructive Pulmonary Disease prior to
Radiation Therapy for Non-Small Cell Lung Cancer. European Journal of Radiology
Open. 2015 May 26; 2: 81-89.
7. F Guo, J Yuan, M Rajchl, S Svenningsen, DPI Capaldi, K Sheikh, A Fenster, G Parraga.
Globally optimal joint segmentation of three-dimensional pulmonary 1H and
hyperpolarized 3He MRI with spatial consistence prior. Medical Image Analysis. 2015 Apr
17; 23(1):43-55.
8. S Svenningsen, GA Paulin, K Sheikh, F Guo, A Hasany, M Kirby, J Suggett, R EtemadRezai, G Parraga, DG McCormack. Oscillatory Positive Expiratory Pressure in Chronic
Obstructive Pulmonary Disease. Journal of Chronic Obstructive Pulmonary Disease. 2016
Feb;13(1):66-74.
9. DA Hoover, DPI Capaldi, K Sheikh, DA Palma, GB Rodrigues, R Dar, E Yu, M Landis,
B Dingle, W Kocha, MS Sanatani, MD Vincent, J Younus, S Kuruvilla, S Gaede, G
Parraga, BP Yaremko. Functional lung avoidance for individualized radiotherapy
(FLAIR): Study protocol for a randomized, double-blind clinical trial. BMC Cancer. 2014
Dec 11; 14:934.
10. DPI Capaldi, K Sheikh, F Guo, S Svenningsen, R Etemad-Rezai, HO Coxson. JA Leipsic,
DG McCormack, G Parraga. Free-breathing pulmonary 1H and hyperpolarized 3He MRI:
comparison in COPD and bronchiectasis. Academic Radiology. 2015 Mar; 22(3):320-329.
11. W Ma, K Sheikh, S Svenningsen, D Pike, F Guo, R Etemad-Rezai, J Leipsic, HO Coxson,
DG McCormack, G Parraga. Ultra-short echo-time Pulmonary MRI: Evaluation and
Reproducibility in COPD subjects with and without Bronchiectasis. Journal of Magnetic
Resonance Imaging. 2015 May; 41(3):1465-1474.
12. D Pike, M Kirby, TJ Lindenmaier, K Sheikh, CE Neron, DG Hackam, JD Spence, A
Fenster, NA Paterson, DD Sin, HO Coxson, DG McCormack, G Parraga. Pulmonary
abnormalities and carotid atherosclerosis in ex-smokers without airflow limitation.
Journal of Chronic Obstructive Pulmonary Disease. 2015 Feb; 12(1):62-70.
13. K Sheikh, GA Paulin, S Svenningsen, M Kirby, NA Paterson, DG McCormack, G Parraga.
Pulmonary ventilation defects in older never-smokers. Journal of Applied Physiology.
2014; 117(3): 297-306.
170

14. QI Mohaidat, K Sheikh, S Palchaudhuri, SJ Rehse. Pathogen identification with laserinduced breakdown spectroscopy: the effect of bacterial and biofluid specimen
contamination. Applied Optics. 2012; 51: B99-B107.
Submitted (4)
1. A Bhalla, E Lessard, D Pike, K Sheikh, DG McCormack, A Ouriadov, G Parraga. Crosssectional and Longitudinal Pulmonary Magnetic Resonance Imaging Biomarkers of Alpha1 Antitrypsin Deficiency. Submitted to Journal of Chronic Obstructive Pulmonary
Disease.
2. K Sheikh, A Ouriadov, HM Young, C Yamashita, TM Luu, SL Katz, G Parraga. MultiSpectral Pulmonary Magnetic Resonance Imaging of Bronchopulmonary Dysplasia.
Submitted to Journal of Chronic Obstructive Pulmonary Disease.
3. F Guo, S Svenningsen, M Kirby, DPI Capaldi, K Sheikh, A Fenster, G Parraga. CT-1H/3He
MRI Co-Registration for Regional Pulmonary Structure-Function Measurements of
Chronic Lung Disease. Submitted to Medical Image Analysis.
4. A Ouriadov, E Lessard, K Sheikh, A Bhalla, GA Paulin, M Kirby, G Parraga. Chronic
Obstructive Pulmonary Disease and Alpha-one Antitrypsin Deficiency: Non-invasive MRI
Biomarkers of Airspace Enlargement and Emphysema. Submitted to Radiology.
B. Published Refereed Conference Papers (1)
1. TJ Lindenmaier, K Sheikh, E Bluemke, I Gyacskov, M Mura, C Licskai, L Mielniczuk, A
Fenster, IA Cunningham, G Parraga. Three-Dimensional Segmentation of Pulmonary
Artery Volume from Thoracic Computed Tomography Imaging. Proc SPIE 2015 Vol.
8320, 9417-99.
C. Peer Reviewed Published Conference Abstracts (28)
1. K Sheikh, DPI Capaldi, DA Hoover, DA Palma, BP Yaremko, G Parraga, Pulmonary
Functional imaging Biomarkers of NSCLC to Guide and Optimize Functional Lung
Avoidance Radiotherapy. American Association of Physicists in Medicine Annual Meeting
2016 Washington, District of Columbia, July 31-August 4, 2016.
2. K Sheikh, F Guo, A Ouriadov, DPI Capaldi, S Svenningsen, M Kirby, DG McCormack,
HO Coxson, G Parraga, Ventilation Estimates in Severe Uncontrolled Asthma using 3D
Single breath-hold Ultra-short Echo Time MRI. International Society of Magnetic
Resonance in Medicine Annual Scientific Meeting 2016 Singapore, Singapore May 7-13,
2016.
3. DPI Capaldi, A Lausch, K Sheikh, F Guo, DG McCormack, G Parraga, Pulmonary
Imaging Biomarkers of COPD for Personalized Treatment and Better Outcomes.
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International Society of Magnetic Resonance in Medicine Annual Scientific Meeting 2016
Singapore, Singapore May 7-13, 2016.
4. F Guo, K Sheikh, RL Eddy, DPI Capaldi, DG McCormack, A Fenster, G Parraga, A
Segmentation Pipeline for Measuring Pulmonary Ventilation Suitable for Clinical
Workflows and Decision-making. International Society of Magnetic Resonance in
Medicine Annual Scientific Meeting 2016 Singapore, Singapore May 7-13, 2016.
5. M Fennema, N Zha, D Pike, K Sheikh, S Svenningsen, DG McCormack, G Parraga, MRI
Ventilation Texture Measurements as an Intermediate Endpoint of Asthma. International
Society of Magnetic Resonance in Medicine Annual Scientific Meeting 2016 Singapore,
Singapore May 7-13, 2016.
6. K Sheikh, F Guo, S Svenningsen, A Ouriadov, DPI Capaldi, RL Eddy, DG McCormack,
G Parraga, What does Magnetic Resonance Imaging Signal-Intensity mean in Asthma?
American Thoracic Society Annual Scientific Meeting 2016 San Francisco, California
May 13-18, 2016.
7. RL Eddy, D Pike, K Sheikh, GA Paulin, M Kirby, DG McCormack, G Parraga, Testing
the Fletcher-Peto Assumptions using Pulmonary Imaging Biomarker Longitudinal
Measurements. American Thoracic Society Annual Scientific Meeting 2016 San
Francisco, California May 13-18, 2016.
8. M Fennema, DPI Capaldi, K Sheikh, S Svenningsen, RL Eddy, C Licskai, DG
McCormack, G Parraga, The Abnormal Airways that Dominate Asthma Attack: New clues
using ventilation MRI during Exercise- and Methacholine-Challenge. American Thoracic
Society Annual Scientific Meeting 2016 San Francisco, California May 13-18, 2016.
9. DPI Capaldi, K Sheikh, S Svenningsen, M Kirby, HO Coxson, DG McCormack, G
Parraga. Measurement of Asthma Treatment Response using Free-breathing 1H
Ventilation MRI. American Thoracic Society Annual Scientific Meeting 2016 San
Francisco, California May 13-18, 2016.
10. B Yaremko, DA Palma, G Parraga, DPI Capaldi, K Sheikh, G Rodrigues, AR Dar, AV
Louie, E Yu, S Gaede, D Hoover, Functional Lung Avoidance Radiation Therapy for Stage
III Non-Small Cell Lung Cancer: A Double-Blind Randomized Phase 2 Trial. American
Society for Radiation Oncology Annual Scientific Meeting 2015 San Antonio, Texas
October 18-21, 2015.
11. K Sheikh, A Ouriadov, F Guo, DPI Capaldi, DG McCormack, G Parraga. StructureFunction Magnetic Resonance Imaging of Bronchopulmonary Dysplasia as an alternative
to pulmonary CT. International Workshop for Pulmonary Functional Imaging Edinburgh,
United Kingdom September 28-30, 2015.
12. DPI Capaldi, K Sheikh, DA Hoover, DA Palma, BP Yaremko, G Parraga. Fourierdecomposition Pulmonary Magnetic Resonance Imaging Ventilation and Perfusion
172

Defects in Non-Small Cell Lung Cancer Patients prior to Radiotherapy: Comparison with
3
He Ventilation Defects and Smoking History. International Workshop for Pulmonary
Functional Imaging Edinburgh, United Kingdom September 28-30, 2015.
13. DPI Capaldi, K Sheikh, S Svenningsen, D Pike, D McCormack, G Parraga. MRI
Measurements of Regional Ventilation Heterogeneity: Ventilation Defect Clusters.
International Society of Magnetic Resonance in Medicine Meeting 2015, Toronto, Canada
June 1-5, 2015.
14. DPI Capaldi, N Zha, D Pike, K Sheikh, D McCormack, G Parraga. 3He MRI and CT
Parametric Response Mapping of Small Airways Disease: The Battle-Ground for Ground
Truth. International Society of Magnetic Resonance in Medicine Meeting 2015, Toronto,
Canada June 1-5, 2015.
15. GA Paulin, A Ouriadov, K Sheikh, DG McCormack, G Parraga. What can multiple bvalue 3He MRI tell us about lung micro-structure in healthy elderly never-smokers?
International Society of Magnetic Resonance in Medicine Meeting 2015, Toronto, Canada
June 1-5, 2015.
16. K Sheikh, DPI Capaldi, S Svenningsen, DG McCormack, G Parraga. Ultra-short Echo
Time MRI Measurements of Emphysema using Principal Component Analysis.
International Society of Magnetic Resonance in Medicine Meeting 2015, Toronto, Canada
June 1-5, 2015.
17. GA Paulin, K Sheikh, DG McCormack, G Parraga. Differences in Pulmonary Structure
and Function in Healthy Elderly Never-smokers after Two Years. American Thoracic
Society Annual Scientific Meeting 2015, Denver, Colorado May 16-20 2015.
18. E Bluemke, S Svenningsen, K Sheikh, GA Paulin, DG McCormack, G Parraga.
Relationship of Ventilation Heterogeneity in the Conducting and Acinar Airway Zones
with 3He MRI in Elderly Never-Smokers. American Thoracic Society Annual Scientific
Meeting 2015, Denver, Colorado May 16-20 2015.
19. S Svenningsen, DPI Capaldi, E Bluemke, GA Paulin, C Davis, K Sheikh, DG McCormack,
G Parraga. Lung Clearance Index and Hyperpolarized 3He MRI Ventilation Heterogeneity
Measurements in non-CF Bronchiectasis and COPD. American Thoracic Society Annual
Scientific Meeting 2015, Denver, Colorado May 16-20 2015.
20. K Sheikh, GA Paulin, S Svenningsen, DG McCormack, JA Neder, G Parraga. How do
Exercise Responses Relate to 3He Magnetic Resonance Imaging Apparent Diffusion
Coefficients in Older Never-Smokers? American Thoracic Society Annual Scientific
Meeting 2015, Denver, Colorado May 16-20 2015.
21. DPI Capaldi, K Sheikh, GA Paulin, S Svenningsen, HO Coxson, DG McCormack, G
Parraga. Conventional non-contrast MRI of Ventilation Abnormalities in Bronchiectasis:
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New Tools and Measurements for an Old Disease. American Thoracic Society Annual
Scientific Meeting 2014, San Diego, California May 17-21 2015.
22. W Ma, K Sheikh, D Pike, S Svenningsen, HO Coxson, DG McCormack, G Parraga.
Conventional Pulmonary MRI and CT of Bronchiectasis and Emphysema: Tissue density
measurements and relationship to pulmonary function tests. American Thoracic Society
Annual Scientific Meeting 2014, San Diego, California May 17-21 2015.
23. K Sheikh, W Ma, F Guo, S Svenningsen, TM Peters, HO Coxson, DG McCormack, R
Etemad-Rezai, G Parraga. Two Dimensional Radial Pulmonary Ultra-short time 1H MRI:
Reproducibility in COPD and Bronchiectasis. International Society of Magnetic
Resonance in Medicine Meeting 2014, Milan, Italy May 10-16, 2014.
24. DPI Capaldi, F Guo, S Svenningsen, W Ma, K Sheikh, R Etemad-Rezai, J Leipsic, HO
Coxson, DG McCormack, G Parraga. Comparison of Pulmonary 1H non-contrast and
Hyperpolarized 3He MRI Ventilation Abnormalities in Bronchiectasis and COPD.
International Society of Magnetic Resonance in Medicine Meeting 2014, Milan, Italy May
10-16, 2014.
25. W Ma, K Sheikh, J Leipsic, HO Coxson, DG McCormack, R Etemad-Rezai, G Parraga.
Pulmonary Ultra-short Echo-time (UTE) Two-dimensional Radial Acquisition with
Compressed Sensing: Preliminary Quantitative Results with Comparison to Thoracic CT.
International Society of Magnetic Resonance in Medicine Meeting 2014, Milan, Italy May
10-16, 2014.
26. D Pike, M Kirby, K Sheikh, D Buchanan, C Neron, JD Spence, NAM Paterson, HO
Coxson, DG McCormack, G Parraga. Airways Disease in Asymptomatic Ex-smokers
without Airflow Limitation: Relationship to Carotid Atherosclerosis. American Thoracic
Society Annual Scientific Meeting 2013, Philadelphia, Pennsylvania May 18-22, 2013.
27. K Sheikh, S Svenningsen, M Kirby, NAM Paterson, A Wheatley, DG McCormack, G
Parraga. What is the Relationship between Hyperpolarized 3He MRI Measurements,
Airborne Toxin Exposure, and Exercise Capacity in Healthy Elderly Never-Smokers?
American Thoracic Society Annual Scientific Meeting 2013, Philadelphia, Pennsylvania
May 18-22, 2013.
28. K Sheikh, S Svenningsen, M Kirby, DG McCormack, G Parraga. Hyperpolarized 3He MRI
Ventilation Defects in Healthy Elderly Never-Smokers: Response to Deep Inspiration and
Salbutamol. American Thoracic Society Annual Scientific Meeting 2013, Philadelphia,
Pennsylvania May 18-22, 2013.
29. K Sheikh, S Svenningsen, M Kirby, DG McCormack, G Parraga. Hyperpolarized 3He
Magnetic Resonance Imaging ADC Gradients in Healthy Elderly Never-Smokers.
International Society of Magnetic Resonance in Medicine Meeting 2013, Salt Lake City,
Utah April 20-26, 2013.
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C. Peer Reviewed Oral Presentations (12)
1. K Sheikh, DPI Capaldi, DA Hoover, DA Palma, BP Yaremko, G Parraga, Pulmonary
Functional imaging Biomarkers of NSCLC to Guide and Optimize Functional Lung
Avoidance Radiotherapy. American Association of Physicists in Medicine Annual Meeting
2016 Washington, District of Columbia, (08/16).
2. K Sheikh, F Guo, A Ouriadov, DPI Capaldi, S Svenningsen, M Kirby, DG McCormack,
HO Coxson, G Parraga, Ventilation Estimates in Severe Uncontrolled Asthma using 3D
Single breath-hold Ultra-short Echo Time MRI. International Society of Magnetic
Resonance in Medicine Annual Scientific Meeting 2016 Singapore, Singapore (05/16)
3. K Sheikh, F Guo, S Svenningsen, A Ouriadov, DPI Capaldi, RL Eddy, DG McCormack,
G Parraga, What does Magnetic Resonance Imaging Signal-Intensity mean in Asthma?
American Thoracic Society Annual Scientific Meeting 2016 San Francisco, California
(05/16).
4. RL Eddy, D Pike, K Sheikh, GA Paulin, M Kirby, DG McCormack, G Parraga, Testing
the Fletcher-Peto Assumptions using Pulmonary Imaging Biomarker Longitudinal
Measurements. American Thoracic Society Annual Scientific Meeting 2016 San
Francisco, California (05/16).
5. DPI Capaldi, K Sheikh, S Svenningsen, M Kirby, HO Coxson, DG McCormack, G
Parraga. Measurement of Asthma Treatment Response using Free-breathing 1H
Ventilation MRI. American Thoracic Society Annual Scientific Meeting 2016 San
Francisco, California May (05/16).
6. K Sheikh, F Guo, S Svenningsen, A Ouriadov, DPI Capaldi, RL Eddy, DG McCormack,
G Parraga, What does Magnetic Resonance Imaging Signal-Intensity mean in Asthma?
London Health Research Day (Top 32), London, Ontario (03/16).
7. B Yaremko, DA Palma, G Parraga, DPI Capaldi, K Sheikh, G Rodrigues, AR Dar, AV
Louie, E Yu, S Gaede, D Hoover, Functional Lung Avoidance Radiation Therapy for Stage
III Non-Small Cell Lung Cancer: A Double-Blind Randomized Phase 2 Trial. American
Society for Radiation Oncology Annual Scientific Meeting 2015, San Antonio, Texas
(10/15).
8. DPI Capaldi, N Zha, D Pike, K Sheikh, D McCormack, G Parraga. 3He MRI and CT
Parametric Response Mapping of Small Airways Disease: The Battle-Ground for Ground
Truth. International Society of Magnetic Resonance in Medicine Annual Scientific
Meeting, Toronto, Canada (05/15).
9. K Sheikh, GA Paulin, S Svenningsen, DG McCormack, JA Neder, G Parraga. How do
Exercise Responses Relate to 3He Magnetic Resonance Imaging Apparent Diffusion
Coefficients in Older Never-Smokers? Imaging Network of Ontario Symposium, Toronto,
Canada (03/15).
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10. DPI Capaldi, K Sheikh, F Guo, S Svenningsen, DG McCormack, G Parraga. Fourierdecomposition Pulmonary Magnetic Resonance Imaging Ventilation Defects in Exsmokers: Relationship to Emphysema and 3He ventilation defects. Radiological Society of
North America Conference, Chicago, Illinois (12/14).
11. W Ma, K Sheikh, J Leipsic, HO Coxson, DG McCormack, R Etemad-Rezai, G Parraga.
Pulmonary Ultra-short Echo-time (UTE) Two-dimensional Radial Acquisition with
Compressed Sensing: Preliminary Quantitative Results with Comparison to Thoracic CT.
Imaging Network Ontario Symposium, Toronto, Canada (03/14).
12. K Sheikh, S Svenningsen, M Kirby, D.G. McCormack, G Parraga. Hyperpolarized 3He
MRI Ventilation Defects in Healthy Elderly Never-Smokers: Response to Deep Inspiration
and Salbutamol. Imaging Network Ontario Symposium, Toronto, Canada (02/13).
D. Peer Reviewed Poster Presentations (23)
1. DPI Capaldi, A Lausch, K Sheikh, F Guo, DG McCormack, G Parraga, Pulmonary
Imaging Biomarkers of COPD for Personalized Treatment and Better Outcomes.
International Society of Magnetic Resonance in Medicine Annual Scientific Meeting 2016
Singapore, Singapore May 7-13, 2016. (Accepted February 1, 2016)
2. F Guo, K Sheikh, RL Eddy, DPI Capaldi, DG McCormack, A Fenster, G Parraga, A
Segmentation Pipeline for Measuring Pulmonary Ventilation Suitable for Clinical
Workflows and Decision-making. International Society of Magnetic Resonance in
Medicine Annual Scientific Meeting 2016 Singapore, Singapore May 7-13, 2016.
(Accepted February 1, 2016)
3. M Fennema, DPI Capaldi, K Sheikh, S Svenningsen, RL Eddy, C Licskai, DG
McCormack, G Parraga, The Abnormal Airways that Dominate Asthma Attack: New clues
using ventilation MRI during Exercise- and Methacholine-Challenge. American Thoracic
Society Annual Scientific Meeting 2016 San Francisco, California May 13-18, 2016.
(Accepted January 20, 2016)
4. K Sheikh, A Ouriadov, F Guo, DPI Capaldi, DG McCormack, G Parraga. StructureFunction Magnetic Resonance Imaging of Bronchopulmonary Dysplasia as an alternative
to pulmonary CT. International Workshop for Pulmonary Functional Imaging Edinburgh,
United Kingdom (09/15).
5. DPI Capaldi, K Sheikh, S Svenningsen, D Pike, D McCormack, G Parraga. MRI
Measurements of Regional Ventilation Heterogeneity: Ventilation Defect Clusters.
International Society of Magnetic Resonance in Medicine 2015, Toronto, Canada (05/15).
6. GA Paulin, A Ouriadov, K Sheikh, DG McCormack, G Parraga. What can multiple bvalue 3He MRI tell us about lung micro-structure in healthy elderly never-smokers?
International Society for Magnetic Resonance in Medicine 2015, Toronto, Canada (05/15).
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7. K Sheikh, DPI Capaldi, S Svenningsen, DG McCormack, G Parraga. Ultra-short Echo
Time MRI Measurements of Emphysema using Principal Component Analysis.
International Society for Magnetic Resonance in Medicine 2015, Toronto, Canada (05/15).
8. GA Paulin, K Sheikh, DG McCormack, G Parraga. Differences in Pulmonary Structure
and Function in Healthy Elderly Never-smokers after Two Years. American Thoracic
Society Annual Scientific Meeting 2015, Denver, Colorado (05/15).
9. E Bluemke, S Svenningsen, K Sheikh, GA Paulin, DG McCormack, G Parraga.
Relationship of Ventilation Heterogeneity in the Conducting and Acinar Airway Zones
with 3He MRI in Elderly Never-Smokers. American Thoracic Society Annual Scientific
Meeting 2015, Denver, Colorado (05/15).
10. S Svenningsen, DPI Capaldi, E Bluemke, GA Paulin, C Davis, K Sheikh, DG McCormack,
G Parraga. Lung Clearance Index and Hyperpolarized 3He MRI Ventilation Heterogeneity
Measurements in non-CF Bronchiectasis and COPD. American Thoracic Society Annual
Scientific Meeting, Denver, United States of America (05/15).
11. K Sheikh, GA Paulin, S Svenningsen, DG McCormack, JA Neder, G Parraga. How do
Exercise Responses Relate to 3He Magnetic Resonance Imaging Apparent Diffusion
Coefficients in Older Never-Smokers? American Thoracic Society Annual Scientific
Meeting, Denver, United States of America (05/15).
12. K Sheikh, W Ma, F Guo, S Svenningsen, TM Peters, HO Coxson, DG McCormack, R
Etemad-Rezai, G Parraga. Two Dimensional Radial Pulmonary Ultra-short time 1H MRI:
Reproducibility in COPD and Bronchiectasis. International Society for Magnetic
Resonance in Medicine Annual Meeting 2014, Milan, Italy (05/14).
13. DPI Capaldi, F Guo, S Svenningsen, W Ma, K Sheikh, R Etemad-Rezai, J Leipsic, HO
Coxson, D.G. McCormack, G Parraga. Comparison of Pulmonary 1H non-contrast and
Hyperpolarized 3He MRI Ventilation Abnormalities in Bronchiectasis and COPD.
International Society for Magnetic Resonance in Medicine Annual Meeting 2014, Milan,
Italy (05/14).
14. W Ma, K Sheikh, J Leipsic, HO Coxson, DG McCormack, R Etemad-Rezai, G Parraga.
Pulmonary Ultra-short Echo-time (UTE) Two-dimensional Radial Acquisition with
Compressed Sensing: Preliminary Quantitative Results with Comparison to Thoracic CT.
International Society for Magnetic Resonance in Medicine Annual Meeting 2014, Milan,
Italy (05/14).
15. DPI Capaldi, K Sheikh, GA Paulin, S Svenningsen, HO Coxson, DG McCormack, G
Parraga. Conventional non-contrast MRI of Ventilation Abnormalities in Bronchiectasis:
New Tools and Measurements for an Old Disease. American Thoracic Society Annual
Scientific Meeting (05/14).
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16. W Ma, K Sheikh, D Pike, S Svenningsen, HO Coxson, DG McCormack, G Parraga.
Conventional Pulmonary MRI and CT of Bronchiectasis and Emphysema: Tissue density
measurements and relationship to pulmonary function tests. American Thoracic Society
Annual Scientific Meeting (05/14).
17. K Sheikh, S Svenningsen, M Kirby, NAM Paterson, A Wheatley, DG McCormack, G
Parraga. What is the Relationship between Hyperpolarized 3He MRI Measurements,
Airborne Toxin Exposure, and Exercise Capacity in Healthy Elderly Never-Smokers?
American Thoracic Society Annual Scientific Meeting (05/13).
18. K Sheikh, S Svenningsen, M Kirby, DG McCormack, G Parraga. Hyperpolarized 3He MRI
Ventilation Defects in Healthy Elderly Never-Smokers: Response to Deep Inspiration and
Salbutamol. American Thoracic Society Annual Scientific Meeting (05/13).
19. K Sheikh, S Svenningsen, M Kirby, DG McCormack, G Parraga. Hyperpolarized 3He
Magnetic Resonance Imaging ADC Gradients in Healthy Elderly Never-Smokers. The
International Society for Magnetic Resonance in Medicine (04/13).
20. K Sheikh, S Svenningsen, M Kirby, NAM Paterson, A Wheatley, DG McCormack, G
Parraga. Relationship between Hyperpolarized 3He MRI Measurements and Exercise
Capacity in Healthy Elderly. Imaging Network Ontario Symposium (02/13).
21. D Pike, M Kirby, K Sheikh, D Buchanan, C Neron, JD Spence, NAM Paterson, HO
Coxson, DG McCormack, G Parraga. Airways Disease in Asymptomatic Ex-smokers
without Airflow Limitation: Relationship to Carotid Atherosclerosis. American Thoracic
Society (05/13).
22. K Sheikh, A Daabous, R Putnam, SJ Rehse. Chemometric Data Analysis Strategies for
Optimizing Pathogen Discrimination and Classification Using Laser-Induced Breakdown
Spectroscopy (LIBS) Emission Spectra. Canadian Association of Physicists Congress,
Calgary, Alberta, Canada (06/12).
23. QI Mohaidat, K Sheikh, S Palchaudhuri, SJ Rehse. Laser-Based Identification of Bacteria
using Discriminant Function Analysis. Canadian Undergraduate Physics Conference,
Saskatoon, Saskatchewan, Canada (10/11).
LEADERSHIP and VOLUNTEER ACTIVITIES
02/16
05/15-5/16
09/12-present
01/12-05/12
09/11-08/12
09/10
06/09-09/09

Team Captain, Fight for Air Climb-American Lung Association
Member, Medical Biophysics Graduate Recruitment Committee
Member, Network of Imaging Students extraordinaire (NOISe)
Organizer, Science Rendezvous Windsor
Vice President, University of Windsor Physics Club
Member, Ontario University Athletics Women’s Track and Field
Championship Team
Volunteer, Women’s Enterprise of Skills and Training
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09/08-09/10
10/04-05/11
10/04-04/11

Member, University of Windsor Varsity Track and Field Team
Volunteer, Lancer Alumni
Member, Windsor Legion Track and Field Club

PROFESSIONAL MEMBERSHIPS
2015-present American Association of Physicists in Medicine
Student Member
2013-present Canadian Organization of Medical Physicists
Student Member
2013-present International Society of Magnetic Resonance in Medicine
Student Member
2013-present Canadian Thoracic Society
Student Member
2013-present American Thoracic Society
Student Member
2011-2012

Canadian Association of Physicists
Student Member
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